

Non-motor symptoms of Parkinson's disease: diagnosis

Lancet Neurology, The
5, 235-245

DOI: [10.1016/s1474-4422\(06\)70373-8](https://doi.org/10.1016/s1474-4422(06)70373-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Parkinson Disease: An Update. <i>Neurologist</i> , 2004, 10, 185-194.	0.7	29
2	B.1 The non-motor symptom complex of Parkinson's Disease: The Questionnaire and Scale Development Program. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 7.	2.2	0
3	B.2 Dopamine agonists in the treatment of non-motor symptoms of Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 7.	2.2	0
4	B.3 Risk-benefit assessment of dopamine agonists. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 7-8.	2.2	0
5	Novel pharmacological targets for the treatment of Parkinson's disease. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 845-854.	46.4	262
6	PARK8 LRRK2 parkinsonism. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 287-294.	4.2	19
7	Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. <i>Lancet Neurology</i> , The, 2006, 5, 355-363.	10.2	324
8	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. <i>Aging Health</i> , 2006, 2, 967-982.	0.3	19
9	A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 465-469.	1.9	130
10	Predicting Parkinson's disease: worthwhile but are we there yet?. <i>Practical Neurology</i> , 2006, 6, 272-277.	1.1	12
13	Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17087-17092.	7.1	190
14	REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. <i>Neurology</i> , 2007, 69, 1843-1849.	1.1	264
15	Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. <i>Brain</i> , 2007, 130, 1787-1798.	7.6	819
17	Patient-reported autonomic symptoms in Parkinson disease. <i>Neurology</i> , 2007, 69, 333-341.	1.1	274
18	A perspective on the current issues in the diagnosis of Parkinson's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2007, 68, S6-S15.	0.5	2
19	Erectile Function and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2007, 166, 1446-1450.	3.4	102
20	Cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1182-1187.	1.9	204
21	Treatment Options in the Modern Management of Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 1083.	4.5	116

#	ARTICLE	IF	CITATIONS
22	Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. Annals of Pharmacotherapy, 2007, 41, 1842-1849.	1.9	12
23	Chronic Pain in Machado-Joseph Disease. Archives of Neurology, 2007, 64, 1767.	4.5	26
24	The premotor phase of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S2-S7.	2.2	130
25	Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Research Reviews, 2007, 6, 54-63.	10.9	55
26	Current Pharmacotherapeutic Treatment Options in Parkinson's Disease. Disease-a-Month, 2007, 53, 214-222.	1.1	58
27	Trastornos del movimiento (I): conceptos generales. Clasificación de los síndromes parkinsonianos. Enfermedad de Parkinson. Medicine, 2007, 9, 4719-4729.	0.0	1
28	Non-motor Parkinsonism. Parkinsonism and Related Disorders, 2007, 13, S211-S220.	2.2	29
29	Non-motor symptoms: Identification and management. Parkinsonism and Related Disorders, 2007, 13, S450-S456.	2.2	48
30	Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opinion on Drug Delivery, 2007, 4, 111-118.	5.0	21
31	Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson's Disease. CNS Drugs, 2007, 21, 677-692.	5.9	172
32	Autosomal dominant Parkinson's disease and the route to new therapies. Expert Review of Neurotherapeutics, 2007, 7, 649-656.	2.8	2
33	Hypocretin (orexin) loss in Parkinson's disease. Brain, 2007, 130, 1577-1585.	7.6	407
34	New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Review of Neurotherapeutics, 2007, 7, 1731-1750.	2.8	35
36	Non-motor Symptoms of Parkinson's Disease. International Journal of Gerontology, 2007, 1, 53-64.	0.6	44
37	Experimental Models and New, Emerging Therapies for Parkinson Disease. , 2007, , 205-231.		0
38	Current Concepts on the Etiology and Pathogenesis of Parkinson Disease. , 2007, , 105-127.		0
39	Parkinson's disease and sexuality. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 644-647.	0.5	11
40	Cardiac Autonomic Regulation During Sleep in Idiopathic REM Sleep Behavior Disorder. Sleep, 2007, 30, 1019-1025.	1.1	95

#	ARTICLE	IF	CITATIONS
41	Normal cardiovascular reflex testing in patients with <i>parkin</i> disease. Movement Disorders, 2007, 22, 528-532.	3.9	8
42	Prognostic factors for the progression of Parkinson's disease: A systematic review. Movement Disorders, 2007, 22, 1839-1851.	3.9	187
43	Bright light therapy in Parkinson's disease: A pilot study. Movement Disorders, 2007, 22, 1495-1498.	3.9	137
44	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 2007, 22, 1623-1629.	3.9	461
45	The metric properties of a novel nonâ€œmotor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
46	Future directions in the treatment of Parkinson's disease. Movement Disorders, 2007, 22, S385-S391.	3.9	28
47	A controlled trial of an educational programme for people with Parkinson's disease. Journal of Clinical Nursing, 2007, 16, 368-376.	3.0	25
48	Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochemical Pharmacology, 2007, 74, 177-190.	4.4	225
49	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	2.2	34
50	Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. , 2007, 114, 327-344.		58
51	Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease?. Lancet Neurology, The, 2007, 6, 848-849.	10.2	12
52	Rotigotine: first dopamine agonist transdermal patch. The Prescriber, 2007, 18, 19-30.	0.3	2
54	Cognitive-behavioral Strategies for Parkinsonâ€™s Disease: A Report of Three Cases. Journal of Clinical Psychology in Medical Settings, 2007, 14, 165-176.	1.4	11
55	Parkinsonâ€™s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathologica, 2007, 113, 421-429.	7.7	308
57	The PRIAMO study: background, methods and recruitment. Neurological Sciences, 2008, 29, 61-65.	1.9	28
58	Dopamine agonist-based strategies in the treatment of Parkinsonâ€™s disease. Neurological Sciences, 2008, 29, 371-374.	1.9	25
59	Bladder and bowel dysfunction in Parkinsonâ€™s disease. Journal of Neural Transmission, 2008, 115, 443-460.	2.8	134
60	Early Parkinsonâ€™s disease and non-motor issues. Journal of Neurology, 2008, 255, 33-38.	3.6	95

#	ARTICLE	IF	CITATIONS
61	Weight loss in neurodegenerative disorders. <i>Journal of Neurology</i> , 2008, 255, 1872-1880.	3.6	104
62	Nonmotor symptoms in Parkinson's disease: Investigating earlyâ€phase onset of behavioral dysfunction in the 6â€hydroxydopamineâ€lesioned rat model. <i>Journal of Neuroscience Research</i> , 2008, 86, 2050-2061.	2.9	110
63	Nighttime sleep problems and daytime sleepiness in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 35-41.	3.9	125
64	Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2008, 23, 101-106.	3.9	228
65	Validation of the â€QUICKâ€questionnaireâ€A tool for diagnosis of â€wearingâ€offâ€in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 830-836.	3.9	40
66	Levodopa might affect metaiodobenzylguanidine myocardial accumulation. <i>Movement Disorders</i> , 2008, 23, 2097-2098.	3.9	5
67	Neural control of the gastrointestinal tract: Implications for Parkinson disease. <i>Movement Disorders</i> , 2008, 23, 1065-1075.	3.9	174
68	Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. <i>Movement Disorders</i> , 2008, 23, 1665-1672.	3.9	159
69	Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1580-1587.	3.9	71
70	The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?. <i>Movement Disorders</i> , 2008, 23, 1799-1807.	3.9	115
71	Dopamine agonists in Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 671-677.	2.8	35
72	Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 379-386.	2.1	51
73	Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 441-444.	4.3	121
74	Is quality of life in nonâ€demented Parkinsonâ€™s disease patients related to cognitive performance? A clinicâ€based crossâ€sectional study. <i>European Journal of Neurology</i> , 2008, 15, 128-133.	3.3	120
75	Progress in neuroprotection in Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2008, 15, 5-13.	3.3	82
76	Quantitation of nonâ€motor symptoms in Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2008, 15, 2-8.	3.3	154
77	Neuroprotective effects of novel phosphatidylglycerolâ€based phospholipids in the 6â€hydroxydopamine model of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2008, 27, 294-300.	2.6	50
78	MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss. <i>Brain Research</i> , 2008, 1229, 218-223.	2.2	19

#	ARTICLE	IF	CITATIONS
79	Clinical applications of transcranial magnetic stimulation in patients with movement disorders. Lancet Neurology, The, 2008, 7, 827-840.	10.2	125
80	Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurology, The, 2008, 7, 927-938.	10.2	106
81	Specific patient-reported outcome measures for Parkinson's disease: analysis and applications. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 401-418.	1.4	14
82	Cross-diagnostic validity of the Nottingham health profile index of distress (NHPD). Health and Quality of Life Outcomes, 2008, 6, 47.	2.4	18
83	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. Advances in Anatomy, Embryology and Cell Biology, 2008, , .	1.6	85
84	Sleep and Quality of Life in Clinical Medicine. , 2008, , .		32
85	Clinical differential diagnosis of parkinsonism. Future Neurology, 2008, 3, 287-298.	0.5	1
86	Clinical Aspects of Parkinson Disease. , 2008, , 1-8.		11
87	Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2008, 9, 2881-2891.	1.8	4
88	Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 102-108.	2.2	96
89	Nonmotor symptoms of Parkinson's disease: Prevalence and awareness of patients and families. Parkinsonism and Related Disorders, 2008, 14, 286-290.	2.2	83
90	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). Parkinsonism and Related Disorders, 2008, 14, 641-645.	2.2	14
91	Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: A new genetic model for Parkinson's disease?. Parkinsonism and Related Disorders, 2008, 14, S107-S111.	2.2	18
92	Disease-modifying drugs and Parkinson's disease. Progress in Neurobiology, 2008, 84, 25-39.	5.7	43
93	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. Experimental Neurology, 2008, 214, 112-116.	4.1	101
94	Manage levodopa-induced motor complications in patients with Parkinson's disease with careful selection of other antiparkinsonian agents. Drugs and Therapy Perspectives, 2008, 24, 17-21.	0.6	0
95	Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology, 2008, 70, 1916-1925.	1.1	471
96	Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?. Neurology, 2008, 71, 1877-1882.	1.1	57

#	ARTICLE	IF	CITATIONS
97	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study). Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	0
98	Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1202-1207.	1.9	56
100	Neurobiology of Sleep Disturbances in Neurodegenerative Disorders. Current Pharmaceutical Design, 2008, 14, 3430-3445.	1.9	55
101	Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opinion on Pharmacotherapy, 2008, 9, 523-535.	1.8	18
102	Single photon-emission computed tomography imaging in early Parkinson's disease. Expert Review of Neurotherapeutics, 2008, 8, 1853-1864.	2.8	4
103	Therapeutic Strategies in Parkinsons Disease. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2008, 2, 135-147.	0.6	4
104	Course, Prognosis, and Management of Psychosis in Parkinson's Disease: Are Current Treatments Really Effective?. CNS Spectrums, 2008, 13, 26-33.	1.2	35
105	Antiparkinsonian Medication and Pathological Gambling. CNS Drugs, 2008, 22, 407-416.	5.9	40
106	Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 261-266.	0.7	70
107	Treatment Challenges in Parkinson's Disease. Nurse Practitioner, 2008, 33, 32.	0.3	6
108	Nondemented Parkinson Disease Patients. Cognitive and Behavioral Neurology, 2008, 21, 87-91.	0.9	14
109	Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study). , 0, , 73-84.		0
110	The Cambridge Behavioural Inventory revised. Dementia E Neuropsychologia, 2008, 2, 102-107.	0.8	181
111	Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 835.	2.2	19
112	Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatric Disease and Treatment, 2008, 4, 39.	2.2	93
113	Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. Arquivos De Neuro-Psiquiatria, 2008, 66, 26-29.	0.8	27
114	Parkinsonian Syndromes. , 2009, , 453-459.		0
115	Non-Motor Off Symptoms in Parkinson's Disease. Journal of Korean Medical Science, 2009, 24, 311.	2.5	26

#	ARTICLE	IF	CITATIONS
116	Neuropsychiatry of Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2009, 67, 930-939.	0.8	35
117	Functional magnetic stimulation in constipation associated with Parkinson's disease. Journal of Rehabilitation Medicine, 2009, 41, 1085-1089.	1.1	36
119	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evidence, 2009, , 1.	4.7	5
120	Review: Improving symptom control in early Parkinson's disease. Therapeutic Advances in Neurological Disorders, 2009, 2, 393-400.	3.5	9
121	Patterns of motor and non-motor features in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 846-850.	1.9	52
122	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology, 2009, 73, 1584-1591.	1.1	213
123	mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. Future Medicinal Chemistry, 2009, 1, 501-513.	2.3	59
124	Handbook of Movement Disorders. , 2009, , .		2
125	Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain, 2009, 132, 3298-3307.	7.6	238
126	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology, The, 2009, 8, 464-474.	10.2	1,367
127	Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology, 2008, 64, S47-S55.	5.3	29
128	Nonmotor manifestations of Parkinson's disease. Annals of Neurology, 2008, 64, S65-S80.	5.3	154
129	Functional models of Parkinson's disease: A valuable tool in the development of novel therapies. Annals of Neurology, 2009, 64, S16-S29.	5.3	66
130	Beneficial effect of transcranial magnetic stimulation on sleep in Parkinson's disease. Movement Disorders, 2009, 24, 878-884.	3.9	29
131	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement Disorders, 2009, 24, 1028-1033.	3.9	53
132	Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. Movement Disorders, 2009, 24, 1747-1751.	3.9	53
133	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders, 2009, 24, 1468-1474.	3.9	233
134	Physical assessment as a predictor of mortality in people with Parkinson's disease: A study over 7 years. Movement Disorders, 2009, 24, 1934-1940.	3.9	22

#	ARTICLE	IF	CITATIONS
135	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	3.9	1,171
136	When does Parkinson's disease begin?. <i>Movement Disorders</i> , 2009, 24, S656-64.	3.9	113
137	Validity of a self-rated method to identify a lifetime history of depression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2436-2438.	3.9	2
138	Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. <i>Movement Disorders</i> , 2009, 24, 2430-2431.	3.9	19
139	Do autonomic function tests in people with Parkinson's disease predict survival rates at 7 years follow-up?. <i>Movement Disorders</i> , 2009, 24, 2432-2434.	3.9	10
140	Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. <i>Movement Disorders</i> , 2009, 24, 2431-2432.	3.9	0
141	Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2434-2435.	3.9	8
142	Identification of a novel THAP1 mutation at R29 amino acid residue in sporadic patients with early-onset dystonia. <i>Movement Disorders</i> , 2009, 24, 2428-2429.	3.9	32
143	Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations. <i>Movement Disorders</i> , 2009, 24, 2442-2443.	3.9	10
144	HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly active antiretroviral therapy. <i>Movement Disorders</i> , 2009, 24, 2441-2442.	3.9	12
145	Subacute dopa-responsive parkinsonism after successful surgical treatment of aqueductal stenosis. <i>Movement Disorders</i> , 2009, 24, 2438-2440.	3.9	8
146	Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. <i>Journal of Neural Transmission</i> , 2009, 116, 1257-1266.	2.8	27
147	Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. <i>Acta Neuropathologica</i> , 2009, 118, 777-784.	7.7	67
148	Mood and energy determinants of quality of life in dystonia. <i>Journal of Neurology</i> , 2009, 256, 996-1001.	3.6	34
149	Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. <i>Neurogastroenterology and Motility</i> , 2009, 21, 215-222.	3.0	75
150	Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2009, 111, 1075-1093.	3.9	93
151	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 1090-1099.	3.3	64
152	Treatment options for the management of parkinsonism. <i>The Prescriber</i> , 2009, 20, 32-45.	0.3	0

#	ARTICLE	IF	CITATIONS
153	Parkinson's Disease: Barriers and Facilitators to Optimizing Function. <i>Rehabilitation Nursing</i> , 2009, 34, 54-60.	0.5	37
154	Multi-target strategy for Parkinsonian patients: The role of deep brain stimulation in the centromedianâ€“parafascicularis complex. <i>Brain Research Bulletin</i> , 2009, 78, 113-118.	3.0	89
155	The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: Evidence from functional imaging. <i>Experimental Neurology</i> , 2009, 216, 247-248.	4.1	15
156	The relation of testosterone levels with fatigue and apathy in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 412-414.	1.4	33
157	Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: Results from Chinese l-dopa exposed cohort. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 733-737.	1.4	15
158	Neurobiology and treatment of Parkinson's disease. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 41-47.	8.7	193
159	A Lethal Convergence of Dopamine and Calcium. <i>Neuron</i> , 2009, 62, 163-164.	8.1	8
160	Pain in Parkinsonâ€™s disease (PD). <i>Pain</i> , 2009, 141, 2-3.	4.2	4
161	Pain in Parkinsonâ€™s disease: Prevalence and characteristics. <i>Pain</i> , 2009, 141, 173-177.	4.2	381
162	A pathophysiological model of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 333-338.	2.2	280
163	Adenosine, adenosine A2A antagonists, and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 406-413.	2.2	183
164	Understanding the dopaminergic deficits in Parkinsonâ€™s disease: Insights into disease heterogeneity. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 620-625.	1.5	60
165	Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. <i>Journal of the Neurological Sciences</i> , 2009, 287, 200-204.	0.6	82
166	Novel investigational adenosine A _{2A} receptor antagonists for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1619-1631.	4.1	76
167	Recognition and management of Parkinsonâ€™s disease during the premotor (prodromal) phase. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 847-857.	2.8	13
168	Diagnosis and the premotor phase of Parkinson disease. <i>Neurology</i> , 2009, 72, S12-20.	1.1	210
169	Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. <i>European Journal of Neuroscience</i> , 2009, 30, 207-216.	2.6	45
170	Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S26-S30.	2.2	52

#	ARTICLE	IF	CITATIONS
171	Predicting Parkinson's disease – why, when, and how?. Parkinsonism and Related Disorders, 2009, 15, S105-S109.	2.2	52
172	Neuroprotection in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S41-S43.	2.2	23
173	Benign Prostatic Obstruction and Parkinson's Disease – Should Transurethral Resection of the Prostate be Avoided?. Journal of Urology, 2009, 181, 2209-2213.	0.4	65
174	Medical Treatment of Parkinson Disease. Neurologic Clinics, 2009, 27, 605-631.	1.8	36
175	Etiology and Pathogenesis of Parkinson Disease. Neurologic Clinics, 2009, 27, 583-603.	1.8	105
176	Pain and Its Relationship to Depression in Parkinson Disease. American Journal of Geriatric Psychiatry, 2009, 17, 269-275.	1.2	79
177	What is Parkinson's Disease? From Pathophysiology to Symptoms. , 0, , 1-39.		3
178	Assessment of Parkinson Disease Manifestations. Current Protocols in Neuroscience, 2009, 49, Unit10.1.	2.6	104
179	Treatment of Parkinson's Disease. , 0, , 40-62.		0
180	Current and Future Therapeutic Strategies for Parkinsons Disease. Current Pharmaceutical Design, 2009, 15, 3968-3976.	1.9	11
181	An Overview of Surgical Therapy for Movement Disorders. Proceedings of Singapore Healthcare, 2010, 19, 303-311.	0.6	0
182	Role of the glucose-dependent insulintropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behavioural Pharmacology, 2010, 21, 394-408.	1.7	51
183	Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 319-329.	1.4	17
185	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Journal of Neurology, 2010, 257, 5-14.	3.6	140
186	Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. Journal of Neurology, 2010, 257, 969-976.	3.6	49
187	Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, 2010, 257, 1004-1011.	3.6	36
188	Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. Journal of Neurology, 2010, 257, 1073-1082.	3.6	216
189	Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2010, 117, 69-76.	2.8	43

#	ARTICLE	IF	CITATIONS
190	The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 837-846.	2.8	53
191	Proanthocyanidin-rich fraction from <i>Croton celtidifolius</i> Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1337-1351.	2.8	53
192	The Epidemiology of Parkinson's Disease. <i>Tzu Chi Medical Journal</i> , 2010, 22, 73-81.	1.1	22
193	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010, 40, 216-221.	4.4	213
194	The lived experience of sleep disturbance in people with Parkinson's disease. <i>Journal of Nursing and Healthcare of Chronic Illness</i> , 2010, 2, 292-301.	0.5	3
195	A pilot randomized controlled trial of sleep therapy in Parkinson's disease: effect on patients and caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1073-1079.	2.7	22
196	Genitourinary dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2-12.	3.9	105
197	Examining Braak's hypothesis by imaging Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, S83-8.	3.9	25
198	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	3.9	130
199	Parkinson's disease: 10 years of progress, 1997–2007. <i>Movement Disorders</i> , 2010, 25, S2-14.	3.9	40
200	Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia. <i>Movement Disorders</i> , 2010, 25, 1269-1273.	3.9	25
201	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010, 25, 704-709.	3.9	342
202	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	3.9	25
203	Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. <i>Movement Disorders</i> , 2010, 25, 1284-1288.	3.9	44
204	Nonmotor symptoms in <i>Parkin</i> gene-related parkinsonism. <i>Movement Disorders</i> , 2010, 25, 1279-1284.	3.9	31
205	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> , 2010, 25, 560-569.	3.9	223
206	Sensory alien hand syndrome in corticobasal degeneration: A cerebral blood flow study. <i>Movement Disorders</i> , 2010, 25, 1288-1291.	3.9	10
207	The identification of Parkinson's disease subtypes using cluster analysis: A systematic review. <i>Movement Disorders</i> , 2010, 25, 969-978.	3.9	179

#	ARTICLE	IF	CITATIONS
208	Rationale for delayedâ€start study of pramipexole in Parkinson's disease: The PROUD study. Movement Disorders, 2010, 25, 1627-1632.	3.9	38
209	Restless legs syndrome and Parkinson's disease in men. Movement Disorders, 2010, 25, 2654-2657.	3.9	36
210	Restless legs syndrome in patients with amyotrophic lateral sclerosis. Movement Disorders, 2010, 25, 2658-2661.	3.9	42
211	Distinct basal ganglia hyperechogenicity in idiopathic basal ganglia calcification. Movement Disorders, 2010, 25, 2661-2664.	3.9	10
212	Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson's disease. Movement Disorders, 2010, 25, 2272-2273.	3.9	11
213	Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Movement Disorders, 2010, 25, 2665-2669.	3.9	53
214	Advanced magnetic resonance imaging in benign hereditary chorea: Study of two familial cases. Movement Disorders, 2010, 25, 2670-2674.	3.9	12
215	What is the functional significance of nondominant arm tremor in essential tremor?. Movement Disorders, 2010, 25, 2674-2678.	3.9	11
216	<i>POLG</i> , but not <i>PEO1</i> , is a frequent cause of cerebellar ataxia in Central Europe. Movement Disorders, 2010, 25, 2678-2682.	3.9	31
217	CSF A β ₄₂ and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 2010, 25, 2682-2685.	3.9	162
218	Nonmotor symptoms are independently associated with impaired healthâ€related quality of life in Chinese patients with Parkinson's disease. Movement Disorders, 2010, 25, 2740-2746.	3.9	101
219	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Movement Disorders, 2010, 25, 2493-2500.	3.9	405
220	Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders, 2010, 25, 2649-2653.	3.9	3,493
221	Neurotransmission in Parkinsonâ€™s disease: beyond dopamine. European Journal of Neurology, 2010, 17, 364-376.	3.3	152
222	Psychiatric aspects of Parkinson's disease. , 0, , 116-125.		1
223	Non-Motor Symptoms of Parkinson's Disease: Diagnosis and Management. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2010, 19, 126-31.	0.1	34
224	Current concepts in the management of Parkinson disease. Medical Journal of Australia, 2010, 192, 144-149.	1.7	37
225	Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease?. Frontiers in Psychiatry, 2010, 1, 128.	2.6	37

#	ARTICLE	IF	CITATIONS
226	Treatment of Advanced Parkinson's Disease. Parkinson's Disease, 2010, 2010, 1-9.	1.1	55
227	Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Frontiers in Neuroanatomy, 2010, 4, .	1.7	27
228	Occurrence Risk and Structure of Depression in Parkinson Disease With and Without Dementia: Results From the GEPAD Study. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 27-34.	2.3	69
229	Neuroprotection in Parkinson's Disease. Blue Books of Neurology, 2010, , 301-320.	0.1	9
230	Pathology of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 132-154.	0.1	6
231	Depression Impairs Learning Whereas Anticholinergics Impair Transfer Generalization in Parkinson Patients Tested on Dopaminergic Medications. Cognitive and Behavioral Neurology, 2010, 23, 98-105.	0.9	21
232	Frontal Assessment Battery in Patients With Parkinson Disease in a Turkish Population. Cognitive and Behavioral Neurology, 2010, 23, 26-28.	0.9	13
233	The challenge of non-motor symptoms in Parkinson's disease. Progress in Brain Research, 2010, 184, 325-341.	1.4	142
234	Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1008-1013.	1.9	92
235	Parkinson's Disease: Is It a Toxic Syndrome?. Neurology Research International, 2010, 2010, 1-10.	1.3	3
236	DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human α -syn toxicity. Human Molecular Genetics, 2010, 19, 1425-1437.	2.9	31
237	Sleep Patterns in Parkinson's Disease Patients with Visual Hallucinations. International Journal of Neuroscience, 2010, 120, 564-569.	1.6	27
238	Nonmotor Symptoms in Genetic Parkinson Disease. Archives of Neurology, 2010, 67, 670-6.	4.5	53
239	Cognitive Performance in Nondemented Nonpsychotic Parkinson Disease Patients With or Without a History of Depression Prior to the Onset of Motor Symptoms. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 15-26.	2.3	17
240	Narcolepsy in Parkinson's disease. Expert Review of Neurotherapeutics, 2010, 10, 879-884.	2.8	28
241	Pharmacotherapy in Parkinson's disease: case studies. Therapeutic Advances in Neurological Disorders, 2010, 3, 117-126.	3.5	5
242	Scales for Assessing Nonmotor Symptom Severity Changes in Parkinson's Disease Patients With Symptom Fluctuations. International Journal of Neuroscience, 2010, 120, 523-530.	1.6	11
243	Effects of Dopamine Agonists on Neuropsychiatric Symptoms of Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 206-209.	1.4	12

#	ARTICLE	IF	CITATIONS
244	Future Strategies for Neuroprotection in Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 210-212.	1.4	5
245	Importance of ¹²³ I-Metaiodobenzylguanidine Scintigraphy/Single Photon Emission Computed Tomography for Diagnosis and Differential Diagnostics of Parkinson Syndromes. Neurodegenerative Diseases, 2010, 7, 341-347.	1.4	27
246	Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia?. Current Medicinal Chemistry, 2010, 17, 3253-3261.	2.4	24
247	Safinamide in the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2010, 11, 2261-2268.	1.8	41
250	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.5	10
251	Epidemiology of psychosis in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 12-17.	0.6	280
252	The pathophysiological basis of sensory disturbances in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 60-65.	0.6	62
253	Brainstem pathology and non-motor symptoms in PD. Journal of the Neurological Sciences, 2010, 289, 81-88.	0.6	137
254	Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. NeuroImage, 2010, 51, 512-520.	4.2	143
255	Understanding clinical benefits of modeling clay exploration with patients diagnosed with Parkinson's disease. Arts and Health, 2010, 2, 140-148.	1.6	6
256	Functional Representation of Olfactory Impairment in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 581-591.	2.6	66
257	Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease. Behavioural Brain Research, 2010, 208, 137-143.	2.2	45
258	Behavioral phenotyping of mouse models of Parkinson's disease. Behavioural Brain Research, 2010, 211, 1-10.	2.2	147
259	Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behavioural Brain Research, 2010, 213, 253-262.	2.2	101
260	Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients. Parkinsonism and Related Disorders, 2010, 16, 21-27.	2.2	13
261	A timeline for Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 79-84.	2.2	470
262	Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiology of Aging, 2010, 31, 2103-2114.	3.1	51
263	Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease. Sleep Medicine, 2010, 11, 759-765.	1.6	26

#	ARTICLE	IF	CITATIONS
264	Parkinson's Disease: Definition, Diagnosis, and Management. , 2010, , 405-412.		4
265	Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nature Reviews Neurology, 2010, 6, 309-317.	10.1	166
266	Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Progress in Brain Research, 2010, 184, 35-51.	1.4	38
267	Ghrelin prevents 1-methyl-4-phenylpyridinium ion-induced cytotoxicity through antioxidation and NF- κ B modulation in MES23.5 cells. Experimental Neurology, 2010, 222, 25-29.	4.1	40
268	Understanding graft-induced dyskinesia. Regenerative Medicine, 2010, 5, 787-797.	1.7	9
270	Imaging non-motor aspects of Parkinson's disease. Progress in Brain Research, 2010, 184, 205-218.	1.4	25
271	Sleep Disturbances in Parkinson Disease and Their Potential Role in Heterogeneity. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 131-137.	2.3	46
272	The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson's disease. Aging and Mental Health, 2011, 15, 913-921.	2.8	25
273	Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Research and Therapy, 2011, 2, 37.	5.5	40
274	Nonmotor presentations of multiple system atrophy. Nature Reviews Neurology, 2011, 7, 295-298.	10.1	43
275	Can α -synuclein be targeted in novel therapies for Parkinson's disease?. Expert Review of Neurotherapeutics, 2011, 11, 917-919.	2.8	11
276	Perceptions of persons with Parkinson's disease, family and professionals on quality of life: an international focus group study. Disability and Rehabilitation, 2011, 33, 2490-2508.	1.8	34
277	Excessive Daytime Sleepiness in Patients with Parkinson's Disease. CNS Drugs, 2011, 25, 203-212.	5.9	101
278	The Use of Decision-Analytic Models in Parkinson's Disease. Applied Health Economics and Health Policy, 2011, 9, 243-258.	2.1	8
279	Pupil Light Reflex in Parkinson's Disease: Evaluation With Pupillometry. International Journal of Neuroscience, 2011, 121, 37-43.	1.6	63
280	Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Therapeutic Advances in Neurological Disorders, 2011, 4, 297-317.	3.5	79
281	The Influence of Repetitive Transcranial Magnetic Stimulation on Sleep in Parkinson's Disease. Biocybernetics and Biomedical Engineering, 2011, 31, 35-46.	5.9	4
282	Clinical evidence linking coffee and tea intake with Parkinson's disease. Basal Ganglia, 2011, 1, 127-130.	0.3	8

#	ARTICLE	IF	CITATIONS
283	Changes in the non-motor symptom scale in Parkinson's disease after deep brain stimulation. Basal Ganglia, 2011, 1, 131-133.	0.3	17
284	Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies. Handbook of Experimental Pharmacology, 2011, , 267-310.	1.8	71
285	The importance of non-motor disturbances to quality of life in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 12-16.	0.6	129
286	Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 21-24.	0.6	111
287	A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: Absence of co-morbid association. Journal of the Neurological Sciences, 2011, 310, 286-288.	0.6	61
288	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
289	Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opinion on Pharmacotherapy, 2011, 12, 1985-1998.	1.8	35
290	Methylxanthines. Handbook of Experimental Pharmacology, 2011, , .	1.8	22
292	Pain is common in Parkinson's disease. Clinical Neurology and Neurosurgery, 2011, 113, 11-13.	1.4	78
293	Pathological considerations in the treatment of Parkinson's disease: More than just a wiring diagram. Clinical Neurology and Neurosurgery, 2011, 113, 1-6.	1.4	3
294	Theory of Mind in Parkinson's disease. Behavioural Brain Research, 2011, 219, 342-350.	2.2	72
295	Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 2011, 42, 131-141.	2.1	65
296	Age- and duration-dependent effects of MPTP on cortical serotonin systems. Neuroscience Letters, 2011, 504, 160-164.	2.1	7
297	Sleep disorders and the natural history of Parkinson's disease: The contribution of epidemiological studies. Sleep Medicine Reviews, 2011, 15, 41-50.	8.5	86
298	Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism and Related Disorders, 2011, 17, 77-83.	2.2	93
299	Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 119-122.	2.2	36
300	Parkinson's disease: The non-motor issues. Parkinsonism and Related Disorders, 2011, 17, 717-723.	2.2	313
301	Imaging biomarkers in Parkinson's disease. Progress in Neurobiology, 2011, 95, 614-628.	5.7	151

#	ARTICLE	IF	CITATIONS
303	Sleep-Related Symptoms. , 2011, , 57-66.		0
308	Loss-of-Function Rodent Models for Parkin and PINK1. Journal of Parkinson's Disease, 2011, 1, 229-251.	2.8	30
309	Effects of a Multimodal Exercise Program on Clinical, Functional Mobility and Cognitive Parameters of Idiopathic Parkinson's Disease Patients. , 0, , .		3
310	27 Extrapiramidale Syndrome und Ataxien. , 2011, , .		0
311	Advances in Drug Therapy: Alternative Treatments for the Control of Motor Fluctuations and Dyskinesias. , 0, , .		0
312	Dementia in Parkinson's disease: a Brazilian sample. Arquivos De Neuro-Psiquiatria, 2011, 69, 733-738.	0.8	9
313	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. Parkinson's Disease, 2011, 2011, 1-7.	1.1	13
314	Side of Onset in Parkinson's Disease and Alterations in Religiosity: Novel Behavioral Phenotypes. Behavioural Neurology, 2011, 24, 133-141.	2.1	52
315	MAO-inhibitors in Parkinson's Disease. Experimental Neurobiology, 2011, 20, 1-17.	1.6	170
316	Gastrointestinal Disorders in Parkinson's Disease: Prevalence and Health Outcomes in a US Claims Database. Journal of Parkinson's Disease, 2011, 1, 65-74.	2.8	38
317	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. Parkinson's Disease, 2011, 2011, 1-13.	1.1	30
318	Neurobiology of Depression and Anxiety in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-5.	1.1	71
319	The differential diagnosis of parkinsonism: A clinical approach. , 2011, , 126-141.		0
320	Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-21.	1.1	79
321	Effects of Subthalamic Nucleus Stimulation on Emotional Prosody Comprehension in Parkinson's Disease. PLoS ONE, 2011, 6, e19140.	2.5	30
322	Case Control Polysomnographic Studies of Sleep Disorders in Parkinson's Disease. PLoS ONE, 2011, 6, e22511.	2.5	121
323	Parkinson's disease in sub-Saharan Africa: step-by-step into the challenge. Neurodegenerative Disease Management, 2011, 1, 193-202.	2.2	11
324	The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease. Current Pharmaceutical Design, 2011, 17, 489-507.	1.9	75

#	ARTICLE	IF	CITATIONS
325	Parkinson's disease: will therapy move beyond dopaminergic medication?. <i>Clinical Investigation</i> , 2011, 1, 381-398.	0.0	1
326	Anhedonia in Japanese patients with Parkinson's disease. <i>Geriatrics and Gerontology International</i> , 2011, 11, 275-281.	1.5	15
327	Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2011, 116, 426-437.	3.9	26
328	Differences in odor identification among clinical subtypes of Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 425-429.	3.3	36
329	Risk of incident depression in patients with Parkinson disease in the UK. <i>European Journal of Neurology</i> , 2011, 18, 448-453.	3.3	49
330	The management of Parkinson's disease – what is new?. <i>European Journal of Neurology</i> , 2011, 18, 1-2.	3.3	6
331	Activities of daily living and quality of life in persons with newly diagnosed Parkinson's disease according to subtype of disease, and in comparison to healthy controls. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 20-27.	2.1	138
332	Priorities in Parkinson's disease research. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 377-393.	46.4	364
333	MPTP-mediated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity. <i>Toxicology and Applied Pharmacology</i> , 2011, 254, 332-341.	2.8	31
334	Serotonergic mediated body mass index changes in Parkinson's disease. <i>Neurobiology of Disease</i> , 2011, 43, 609-615.	4.4	40
335	Preservation of function in Parkinson's disease: What's learning got to do with it?. <i>Brain Research</i> , 2011, 1423, 96-113.	2.2	27
336	Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 694-703.	2.8	29
337	Gene therapy: a viable therapeutic strategy for Parkinson's disease?. <i>Journal of Neurology</i> , 2011, 258, 179-188.	3.6	25
338	Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 627-633.	3.6	114
339	Eyelid retraction in dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1542-1544.	3.6	5
340	How well do we recognise non-motor symptoms in a British Parkinson's disease population?. <i>Journal of Neurology</i> , 2011, 258, 1513-1517.	3.6	44
341	Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study. <i>Journal of Neurology</i> , 2011, 258, 1835-1840.	3.6	61
342	Vagus nerve somatosensory evoked potentials in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 2276-2277.	3.6	16

#	ARTICLE	IF	CITATIONS
343	What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?. Journal of Neural Transmission, 2011, 118, 907-914.	2.8	21
344	Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease. Journal of Neural Transmission, 2011, 118, 1215-1225.	2.8	34
345	Parkinson's disease mouse models in translational research. Mammalian Genome, 2011, 22, 401-419.	2.2	65
347	Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology, 2011, 218, 621-634.	3.1	26
348	Comparison of parameters of 123I-metaiodobenzylguanidine scintigraphy for differential diagnosis in patients with parkinsonism: correlation with clinical features. Annals of Nuclear Medicine, 2011, 25, 478-485.	2.2	8
349	The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials, 2011, 12, 251.	1.6	8
350	Self estimated quality of life in monogenetic Parkinson's disease. Movement Disorders, 2011, 26, 187-188.	3.9	5
351	D216H polymorphism within <i>TOR1A</i> does not affect penetrance in DRD and is not a general modifier in primary dystonia. Movement Disorders, 2011, 26, 182-183.	3.9	2
352	Lacosamide, another therapeutic failure in essential tremor: An open-label trial. Movement Disorders, 2011, 26, 183-184.	3.9	5
353	Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Movement Disorders, 2011, 26, 188-190.	3.9	72
354	Clinical subtypes of Parkinson's disease. Movement Disorders, 2011, 26, 51-58.	3.9	186
355	Pallidal stimulation in siblings with pantothenate kinase-associated neurodegeneration: Four-year follow-up. Movement Disorders, 2011, 26, 184-187.	3.9	34
356	Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild. Movement Disorders, 2011, 26, 65-72.	3.9	86
357	The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders, 2011, 26, 399-406.	3.9	744
358	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Movement Disorders, 2011, 26, 1259-1265.	3.9	69
359	Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	3.9	4
360	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. Movement Disorders, 2011, 26, 1348-1352.	3.9	18
361	Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease. Movement Disorders, 2011, 26, 1341-1343.	3.9	6

#	ARTICLE	IF	CITATIONS
362	Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Movement Disorders, 2011, 26, 1344-1347.	3.9	17
363	Do nonmotor symptoms in Parkinson's disease differ from normal aging?. Movement Disorders, 2011, 26, 2110-2113.	3.9	75
364	Idiopathic Parkinson's disease patients at the urologic clinic. Neurourology and Urodynamics, 2011, 30, 1258-1261.	1.5	44
365	Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2953-2957.	2.2	25
366	Evaluation and management of the non-motor features of Parkinson's disease. Therapeutic Advances in Chronic Disease, 2011, 2, 69-85.	2.5	21
368	10 Commonly Asked Questions About Parkinson Disease. Neurologist, 2011, 17, 57-62.	0.7	0
369	Behavioural disorders, disability and quality of life in Parkinson's disease. Age and Ageing, 2011, 40, 614-621.	1.6	90
370	A Prospective Study of Bowel Movement Frequency and Risk of Parkinson's Disease. American Journal of Epidemiology, 2011, 174, 546-551.	3.4	95
371	Nonmotor Disorders and Their Correlation With Dopamine. Neurologist, 2011, 17, S9-S17.	0.7	6
372	Initial Motor Symptoms of Parkinson Disease. Neurologist, 2011, 17, S18-S20.	0.7	18
373	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0
375	Preclinical Biomarkers of Parkinson Disease. Archives of Neurology, 2011, 68, 22-30.	4.5	141
376	Nonmotor Disturbances in Parkinson's Disease. Neurodegenerative Diseases, 2011, 8, 95-108.	1.4	42
377	E46K Human α -Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment. Journal of Biological Chemistry, 2011, 286, 35104-35118.	3.4	115
378	Utility and Limitations of Addenbrooke's Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2011, 31, 349-357.	1.5	27
380	Management of sexual dysfunction in Parkinson's disease. Therapeutic Advances in Neurological Disorders, 2011, 4, 375-383.	3.5	91
381	Parkinson Hastalıklarının Klinik Subtipleri Arasındaki Kokuların Tanıma Yeteneği Farklılık Gösterir mi?. Türk Noroloji Dergisi = Turkish Journal of Neurology, 2012, 18, 151-154.	0.3	0
382	Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	1.2	107

#	ARTICLE	IF	CITATIONS
383	Pupillometry and 123I-DaTSCAN imaging in Parkinson's Disease: A Comparison Study. International Journal of Neuroscience, 2012, 122, 26-34.	1.6	15
384	Classic and New Animal Models of Parkinson's Disease. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	360
385	Parkinson's disease is a risk factor for late onset hypogonadism: a cross-sectional, controlled study. Turk Uroloji Dergisi, 2012, 38, 205-210.	0.4	0
386	Sleep Disturbances in Parkinson's Disease With Emphasis on Rapid Eye Movement Sleep Behavior Disorder. International Journal of Neuroscience, 2012, 122, 407-412.	1.6	23
387	Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery. Annals of Neurosciences, 2012, 19, 133-46.	1.7	9
388	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	12.4	107
389	Parkinson's disease: treatment and non-motor features. Reviews in Clinical Gerontology, 2012, 22, 243-260.	0.5	4
390	Clinical Characteristics of Exacerbations in Parkinson Disease. Neurologist, 2012, 18, 120-124.	0.7	43
391	Associations Between Bilateral Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) and Anxiety in Parkinson's Disease Patients: A Controlled Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 316-325.	1.8	16
392	Inpatient Management of Parkinson Disease. Neurohospitalist, The, 2012, 2, 28-35.	0.8	48
393	The relationship of depression and disease stage to patient perceptions of Parkinson's disease. Journal of Health Psychology, 2012, 17, 1076-1088.	2.3	22
394	EEG dynamics in neurological disorders: Parkinson's disease and stroke. , 2012, , .		8
395	A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 167-177.	2.5	91
396	Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?. Stem Cells International, 2012, 2012, 1-10.	2.5	4
397	Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 100-106.	2.3	45
398	Future treatments for Parkinson's disease. Clinical Medicine, 2012, 12, s86-s90.	1.9	0
399	Factors Affecting Pain in Parkinson's Disease. Journal of Parkinson's Disease, 2012, 2, 273-279.	2.8	0
400	Depression in Parkinson's disease: diagnosis and treatment. Arquivos De Neuro-Psiquiatria, 2012, 70, 617-620.	0.8	41

#	ARTICLE	IF	CITATIONS
401	Cognitive Behavioral Therapy for Depression and Anxiety in Parkinson's Disease: A Clinical Review. <i>Journal of Parkinson's Disease</i> , 2012, 2, 135-151.	2.8	45
402	Supplement 4: Canadian Guidelines on Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, S1-S30.	0.5	103
403	Cognition, coping, and outcome in Parkinson's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1656-1663.	1.0	41
404	Effect of Selective Serotonin Reuptake Inhibitors via 5-HT _{1A} Receptors on L-DOPA-Induced Rotational Behavior in a Hemiparkinsonian Rat Model. <i>Journal of Pharmacological Sciences</i> , 2012, 119, 10-19.	2.5	20
405	Parkinson disease and driving. <i>Neurology</i> , 2012, 79, 2067-2074.	1.1	94
406	Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 939-958.	1.8	14
407	Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <i>Behavioural Brain Research</i> , 2012, 235, 263-272.	2.2	39
408	Color discrimination deficits in Parkinson's disease are related to cognitive impairment and white-matter alterations. <i>Movement Disorders</i> , 2012, 27, 1781-1788.	3.9	66
409	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2012, 27, 1679-1682.	3.9	48
411	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	3.6	211
412	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	3.6	28
413	Suppression of Bladder Overactivity by Adenosine A2A Receptor Antagonist in a Rat Model of Parkinson Disease. <i>Journal of Urology</i> , 2012, 187, 1890-1897.	0.4	41
414	Different Approaches, One Target: Understanding Cellular Mechanisms of Parkinson's and Alzheimer's Diseases. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, 194-218.	1.7	9
415	Pharmacological and Biochemical Interventions of Cigarette Smoke, Alcohol, and Sexual Mating Frequency on Idiopathic Rat Model of Parkinson's Disease. <i>Journal of Young Pharmacists</i> , 2012, 4, 177-183.	0.2	11
416	Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration. <i>Pharmacological Reports</i> , 2012, 64, 1081-1090.	3.3	42
417	Neurophysiological assessment of painful neuropathies. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1297-1310.	2.8	9
418	Metabotropic glutamate receptor 4 (mGlu ₄)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 461-481.	5.0	35
419	Olfactory dysfunction and parasympathetic dysautonomia in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2012, 22, 161-166.	2.5	25

#	ARTICLE	IF	CITATIONS
420	Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. <i>Neuropsychopharmacology</i> , 2012, 37, 213-246.	5.4	185
421	Anxiety in Parkinson's disease: A critical review of experimental and clinical studies. <i>Neuropharmacology</i> , 2012, 62, 115-124.	4.1	167
422	Neurotoxin-based models of Parkinson's disease. <i>Neuroscience</i> , 2012, 211, 51-76.	2.3	425
423	Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 35-39.	2.2	38
424	Validation of the non-motor symptoms questionnaire (NMS-Quest). <i>Parkinsonism and Related Disorders</i> , 2012, 18, 54-58.	2.2	101
425	Body mass index in Parkinson's disease: A meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 263-267.	2.2	129
426	The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 382-385.	2.2	29
427	Non-motor symptoms of Parkinson's disease in China: A review of the literature. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 446-452.	2.2	39
428	Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. <i>Progress in Neurobiology</i> , 2012, 98, 222-238.	5.7	84
429	Late-stage Parkinson disease. <i>Nature Reviews Neurology</i> , 2012, 8, 435-442.	10.1	183
430	Fibroblast growth factor 2 regulates dopaminergic neuron development <i>in vivo</i> . <i>Journal of Neurochemistry</i> , 2012, 122, 94-105.	3.9	37
431	Studies of protein aggregation in A53T α -synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. <i>Neuroscience Letters</i> , 2012, 507, 137-142.	2.1	7
432	Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. <i>Behavioural Brain Research</i> , 2012, 229, 208-215.	2.2	67
433	Anhedonia in Japanese patients with Parkinson's disease: Analysis using the Snaith's Hamilton Pleasure Scale. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 352-355.	1.4	19
434	Sleep problems in Parkinson's disease: a community-based study in Norway. <i>BMC Neurology</i> , 2012, 12, 71.	1.8	29
435	Optimizing treatment for Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 1483-1486.	3.3	2
436	Effect of cognitive behavior therapy on sleep disorder in Parkinson's disease in China: A pilot study. <i>Australian Journal of Cancer Nursing</i> , 2012, 14, 458-463.	1.6	19
438	Sleep disturbance in Parkinson disease. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2012, 3, 53-61.	0.7	9

#	ARTICLE	IF	CITATIONS
439	Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1041-1051.	5.0	479
442	Healthcare utilization in patients with Parkinson's disease: A population-based analysis. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 930-935.	2.2	26
443	Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 994-997.	2.2	63
444	Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1089-1093.	2.2	54
445	Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkers. <i>Journal of the Neurological Sciences</i> , 2012, 313, 57-63.	0.6	106
446	Clinical correlates of periodic limb movements in sleep in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 316, 131-136.	0.6	50
447	Affective symptoms and cognitive functions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 317, 97-102.	0.6	52
448	Management of Pain in Parkinson's Disease. <i>CNS Drugs</i> , 2012, 26, 937-948.	5.9	47
449	Parkinson's Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 389-455.	2.4	283
450	Separate, Causal Roles of the Caudate in Saccadic Choice and Execution in a Perceptual Decision Task. <i>Neuron</i> , 2012, 75, 865-874.	8.1	106
451	When does Parkinson's disease begin? From prodromal disease to motor signs. <i>Revue Neurologique</i> , 2012, 168, 809-814.	1.5	37
453	Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?. <i>Progress in Brain Research</i> , 2012, 200, 113-142.	1.4	9
454	Current status of clinical trials of neural transplantation in Parkinson's disease. <i>Progress in Brain Research</i> , 2012, 200, 169-198.	1.4	27
455	The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia. <i>PLoS ONE</i> , 2012, 7, e45451.	2.5	107
456	Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects. <i>Parkinson's Disease</i> , 2012, 2012, 1-15.	1.1	79
457	Bright Light Therapy in Parkinson's Disease: An Overview of the Background and Evidence. <i>Parkinson's Disease</i> , 2012, 2012, 1-9.	1.1	38
458	Gene Therapy for Parkinson's Disease. <i>Parkinson's Disease</i> , 2012, 2012, 1-13.	1.1	21
459	Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. <i>Patient Preference and Adherence</i> , 2012, 6, 49.	1.8	7

#	ARTICLE	IF	CITATIONS
460	Static posturography in aging and Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 2012, 4, 20.	3.4	43
462	Transcranial sonography in Parkinson's disease. <i>Einstein (Sao Paulo, Brazil)</i> , 2012, 10, 242-246.	0.7	5
463	A clinical and family history study of Parkinson's disease in heterozygous <i>glucocerebrosidase</i> mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 853-854.	1.9	99
464	Prospects for Cell Replacement Therapies for Neurodegenerative Diseases. <i>SpringerBriefs in Neuroscience</i> , 2012, , 43-54.	0.1	0
465	Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. <i>Journal of Neuroscience Research</i> , 2012, 90, 2306-2316.	2.9	37
466	Lewy pathology and neurodegeneration in premotor Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 597-607.	3.9	141
467	Attenuated heart rate response in REM sleep behavior disorder and Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 888-894.	3.9	42
468	Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 996-1003.	3.9	164
469	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1262-1267.	3.9	45
470	Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 221-230.	1.4	112
471	SVM Feature Selection Based Rotation Forest Ensemble Classifiers to Improve Computer-Aided Diagnosis of Parkinson Disease. <i>Journal of Medical Systems</i> , 2012, 36, 2141-2147.	3.6	104
472	Progression of motor symptoms in Parkinson's disease. <i>Neuroscience Bulletin</i> , 2012, 28, 39-48.	2.9	125
473	Adherence to antiparkinsonian medication: An in-depth qualitative study. <i>International Journal of Nursing Studies</i> , 2012, 49, 863-871.	5.6	21
474	Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3223-3228.	2.2	20
475	Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 46, 559-564.	4.4	220
476	Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. <i>Neurobiology of Disease</i> , 2012, 47, 258-267.	4.4	93
477	Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. <i>Pain</i> , 2012, 153, 744-754.	4.2	130
478	Move for Change Part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 402-410.	3.3	56

#	ARTICLE	IF	CITATIONS
479	Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy. <i>European Journal of Neurology</i> , 2012, 19, 510-516.	3.3	28
480	Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?. <i>European Journal of Neuroscience</i> , 2012, 35, 1894-1907.	2.6	46
481	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , 2012, 27, 312-315.	3.9	56
482	Parkinson's disease motor subtypes and mood. <i>Movement Disorders</i> , 2012, 27, 379-386.	3.9	114
483	Prevalence of pain in Parkinson's disease: A systematic review using the modified QUADAS tool. <i>Movement Disorders</i> , 2012, 27, 480-484.	3.9	166
484	Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 42-59.	4.1	284
485	Synaptic Protein Alterations in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2012, 45, 126-143.	4.0	27
486	Intranasal Administration of Neurotoxins in Animals: Support for the Olfactory Vector Hypothesis of Parkinson's Disease. <i>Neurotoxicity Research</i> , 2012, 21, 90-116.	2.7	76
487	Measuring outcomes in Parkinson's disease: a multi-perspective concept mapping study. <i>Quality of Life Research</i> , 2012, 21, 453-463.	3.1	36
488	Behavioral characterization of the 6-hydroxydopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. <i>Molecular Neurodegeneration</i> , 2013, 8, 14.	10.8	142
489	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 811-821.	10.2	165
490	Data Collection (Integration) from Distributed Sources. , 2013, , 519-519.		1
491	Mesocortical dopamine system modulates mechanical nociceptive responses recorded in the rat prefrontal cortex. <i>BMC Neuroscience</i> , 2013, 14, 65.	1.9	30
492	Diphenyl Diselenide Reduces Mechanical and Thermal Nociceptive Behavioral Responses After Unilateral Intrastriatal Administration of 6-Hydroxydopamine in Rats. <i>Biological Trace Element Research</i> , 2013, 154, 372-378.	3.5	17
493	Pramipexole Reduces Phosphorylation of α -Synuclein at Serine-129. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 573-580.	2.3	14
494	Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). <i>Archives of Gerontology and Geriatrics</i> , 2013, 57, 288-291.	3.0	28
495	Disease System, Parkinson's Disease. , 2013, , 589-592.		0
496	Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. <i>Trends in Neurosciences</i> , 2013, 36, 543-554.	8.6	180

#	ARTICLE	IF	CITATIONS
497	Costs of Parkinson's Disease in a Privately Insured Population. Pharmacoeconomics, 2013, 31, 799-806.	3.3	27
498	Stem Cells and Cancer Stem Cells, Volume 10. , 2013, , .		0
499	Parkinson's Disease: Diagnosis, Motor Symptoms and Non-motor Features. , 2013, , .		2
500	Fatigue assessment of Parkinson's disease patient in clinic: specific versus holistic. Journal of Neural Transmission, 2013, 120, 577-581.	2.8	19
501	Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI. Clinical Neurology and Neurosurgery, 2013, 115, 2419-2425.	1.4	147
502	Negative influence of L-dopa on subjectively assessed sleep but not on nocturnal polysomnography in Parkinson's disease. Pharmacological Reports, 2013, 65, 614-623.	3.3	16
503	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Movement Disorders, 2013, 28, 1980-1986.	3.9	39
505	Calcium dysregulation in Parkinson's disease. Brain, 2013, 136, 2015-2016.	7.6	50
506	Advanced Parkinson's disease: Clinical characteristics and treatment (part 1). Neurología (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	80.4	26
507	Depression and Parkinson's Disease: Current Knowledge. Current Neurology and Neuroscience Reports, 2013, 13, 409.	4.2	251
508	Physical exercise and Parkinson's disease: influence on symptoms, disease course and prevention. Reviews in the Neurosciences, 2013, 24, 139-52.	2.9	46
509	Clinical outcome of deep brain stimulation for Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 107-128.	1.8	93
510	Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Expert Review of Neurotherapeutics, 2013, 13, 1329-1342.	2.8	5
511	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Therapeutic Advances in Psychopharmacology, 2013, 3, 101-113.	2.7	79
512	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. Journal of Neurology, 2013, 260, 2849-2855.	3.6	83
513	Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. Neurología (English) Tj ETQq1 1 0.784314 rgBT /Overlock 3	80.4	3
514	Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	2.8	79
516	Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiology of Aging, 2013, 34, 408-418.	3.1	130

#	ARTICLE	IF	CITATIONS
517	Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. Journal of Neurology, 2013, 260, 131-137.	3.6	72
518	Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?. Journal of Neural Transmission, 2013, 120, 197-210.	2.8	17
519	Expanded and independent validation of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Journal of Neurology, 2013, 260, 228-236.	3.6	169
520	Selective expression of α -synuclein immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon. Journal of Comparative Neurology, 2013, 521, 657-676.	1.6	23
521	Nonmotor Symptoms in Parkinson's Disease. Neurologic Clinics, 2013, 31, S1-S16.	1.8	60
522	Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II. Neurología, 2013, 28, 558-583.	0.7	37
523	Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. Artificial Intelligence in Medicine, 2013, 58, 195-202.	6.5	50
524	Fatigue in Parkinson's disease: Motor or non-motor symptom?. Parkinsonism and Related Disorders, 2013, 19, 148-152.	2.2	37
525	Impact of the Parkinson's disease medication protocol program on nurses' knowledge and management of Parkinson's disease medicines in acute and aged care settings. Nurse Education Today, 2013, 33, 458-464.	3.3	16
526	Prevalence of non motor features in a cohort of Parkinson's disease patients. Clinical Neurology and Neurosurgery, 2013, 115, 673-677.	1.4	65
528	Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease. Neuroscience Letters, 2013, 550, 64-68.	2.1	87
529	Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology, 2013, 66, 53-64.	4.1	66
530	Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. NeuroImage, 2013, 81, 484-495.	4.2	135
531	Dysphagia in Parkinson's disease is responsive to levodopa. Parkinsonism and Related Disorders, 2013, 19, 282-284.	2.2	47
532	Decreased and increased cerebral regional homogeneity in early Parkinson's disease. Brain Research, 2013, 1527, 230-237.	2.2	55
533	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. Annals of Neurology, 2013, 73, 565-575.	5.3	67
534	Spinal Cord Stimulation for the Treatment of Sensory Symptoms in Advanced Parkinson's Disease. Neuromodulation, 2013, 16, 276-279.	0.8	40
535	Nonmotor fluctuations in Parkinson disease. Neurology, 2013, 80, 800-809.	1.1	284

#	ARTICLE	IF	CITATIONS
536	Developing dopaminergic cell therapy for Parkinson's diseaseâ€”give up or move forward?. Movement Disorders, 2013, 28, 268-273.	3.9	63
537	Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. Parkinsonism and Related Disorders, 2013, 19, 660-665.	2.2	112
538	Handbook of Parkinsonâ€™s Disease. , 2013, , .		14
539	Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. Journal of Neuropsychology, 2013, 7, 225-240.	1.4	28
540	Pharmacology of Metabotropic Glutamate Receptor Allosteric Modulators. Progress in Molecular Biology and Translational Science, 2013, 115, 61-121.	1.7	44
541	The Serendipity Case of the Pedunculopontine Nucleus Low-Frequency Brain Stimulation: Chasing a Gait Response, Finding Sleep, and Cognition Improvement. Frontiers in Neurology, 2013, 4, 68.	2.4	40
542	Pain perception in patients with Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2013, 20, 663-666.	1.5	13
543	Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinsonâ€™s disease. Annals of Nuclear Medicine, 2013, 27, 444-451.	2.2	27
544	Effectiveness of multidisciplinary care for Parkinson's disease: A randomized, controlled trial. Movement Disorders, 2013, 28, 605-611.	3.9	111
545	Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of parkinsonâ€™s disease. Chronobiology International, 2013, 30, 741-755.	2.0	27
546	Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 751-754.	2.2	25
547	Gene therapy for Parkinsonâ€™s disease: state-of-the-art treatments for neurodegenerative disease. Expert Review of Neurotherapeutics, 2013, 13, 695-705.	2.8	11
548	Schizophrenia and Parkinsonâ€™s disease: Selected therapeutic advances beyond the dopaminergic etiologies. Alexandria Journal of Medicine, 2013, 49, 287-291.	0.6	26
549	Critical Analysis of Parkinsonâ€™s Disease Models and Cell-Based Therapy. , 2013, , 199-210.		0
550	Independent validation of the Non motor Symptoms Scale for Parkinson's disease in Brazilian patients. Parkinsonism and Related Disorders, 2013, 19, 115-119.	2.2	12
551	Understanding cognitive deficits in Parkinsonâ€™s disease: lessons from preclinical animal models. Learning and Memory, 2013, 20, 592-600.	1.3	54
552	Validation of the Bulgarian version of scales for outcomes in Parkinsonâ€™s disease â€” autonomic (SCOPA-AUT-BG). Folia Medica, 2013, 55, 56-62.	0.5	6
553	Implicit olfactory processing attenuates motor disturbances in idiopathic Parkinson's disease. Cortex, 2013, 49, 1241-1251.	2.4	7

#	ARTICLE	IF	CITATIONS
554	Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1073-1078.	2.2	43
555	An economic model of <scp>P</scp>arkinson's disease: Implications for slowing progression in the United States. <i>Movement Disorders</i> , 2013, 28, 319-326.	3.9	48
556	What is measured with verbal fluency tests in Parkinsonâ€™s disease patients at different stages of the disease?. <i>Journal of Neural Transmission</i> , 2013, 120, 403-411.	2.8	28
557	Rotigotine transdermal patch for the treatment of Parkinsonâ€™s Disease. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 81-95.	1.9	20
558	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. <i>Neurology</i> , 2013, 81, 1226-1234.	1.1	153
560	Thalamic Projection Fiber Integrity in de novo Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2013, 34, 74-79.	2.4	48
561	Use of Indian smell identification test for evaluating olfaction in idiopathic Parkinsonâ€™s disease patients in India. <i>Neurology India</i> , 2013, 61, 365.	0.4	18
562	Mild Cognitive Impairment in Parkinsonâ€™s Disease: A Review of Current Concepts. <i>Neurology Research International</i> , 2013, 2013, 1-8.	1.3	29
563	Twenty-Four Hour Non-Invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinsonâ€™s Disease. <i>Frontiers in Neurology</i> , 2013, 4, 49.	2.4	57
564	Recent developments in biomarkers in Parkinson disease. <i>Current Opinion in Neurology</i> , 2013, 26, 395-400.	3.6	88
565	Non-Motor Symptoms and Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 1-2.	0.5	23
566	Erken Evre Parkinson HastalÄ±Ä±nda Motor Olmayan SemptomlarÄ±n DeÄ±erlendirilmesi. <i>Turk Noroloji Dergisi</i> = <i>Turkish Journal of Neurology</i> , 2013, 19, 97-103.	0.3	4
567	Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1714-1721.	2.6	62
568	Keep moving to retain the healthy self: the meaning of physical exercise in individuals with Parkinsonâ€™s disease. <i>Disability and Rehabilitation</i> , 2013, 35, 2237-2244.	1.8	25
569	Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. <i>RSC Drug Discovery Series</i> , 2013, , 392-413.	0.3	1
570	Molecular biomarkers of neurodegeneration. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 845-861.	3.1	26
573	Sleep disturbances. , 0, , 192-210.		0
574	The Effects of Parkinson's Disease on Caregivers and People with Parkinson's Disease: A Literature Review. <i>Proceedings of Singapore Healthcare</i> , 2013, 22, 191-197.	0.6	0

#	ARTICLE	IF	CITATIONS
575	Nonmotor Symptoms in Drug-Induced Parkinsonism and Drug-Naïve Parkinson Disease. Canadian Journal of Neurological Sciences, 2013, 40, 36-41.	0.5	35
578	Predictors of Cognitive Decline in the Early Stages of Parkinson's Disease: A Brief Cognitive Assessment Longitudinal Study. Parkinson's Disease, 2013, 2013, 1-8.	1.1	8
579	Frequency of non-motor symptoms in Peruvian patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 216-219.	0.8	20
580	Differentiating Non-Motor Symptoms in Parkinson's Disease from Controls and Hemifacial Spasm. PLoS ONE, 2013, 8, e49596.	2.5	9
581	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
582	Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors. PLoS ONE, 2013, 8, e64844.	2.5	21
583	Subthalamic Nucleus Deep Brain Stimulation Does Not Improve Visuo-Motor Impairment in Parkinson's Disease. PLoS ONE, 2013, 8, e65270.	2.5	6
584	Chrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease. Current Pharmaceutical Design, 2013, 19, 6773-6790.	1.9	47
585	Functional Neuroanatomy and Behavioural Correlates of the Basal Ganglia: Evidence from Lesion Studies. Behavioural Neurology, 2013, 26, 219-223.	2.1	29
586	High Prevalence of Gastroesophageal Reflux Disease in Parkinson's Disease: A Questionnaire-Based Study. Parkinson's Disease, 2013, 2013, 1-6.	1.1	14
587	The Pathophysiology of Impulse control Disorders in Parkinson Disease. Behavioural Neurology, 2013, 26, 237-244.	2.1	16
588	Visual Hallucinations in PD and Lewy Body Dementias: Old and New Hypotheses. Behavioural Neurology, 2013, 27, 479-493.	2.1	68
589	Relação entre qualidade do sono e funções cognitivas em pacientes com doença de Parkinson. Universitas Scientiarum, 2013, 18, .	0.4	2
590	Effects of Sleep Disorders on the Non-Motor Symptoms of Parkinson Disease. Journal of Clinical Sleep Medicine, 2013, 09, 1119-1129.	2.6	97
592	Alteration of Daily and Circadian Rhythms following Dopamine Depletion in MPTP Treated Non-Human Primates. PLoS ONE, 2014, 9, e86240.	2.5	61
593	Serum Leptin Concentrations in Turkish Parkinson's Disease Population. Parkinson's Disease, 2014, 2014, 1-5.	1.1	5
594	Quantitative Electromyographic Analysis of Reaction Time to External Auditory Stimuli in Drug-Naïve Parkinson's Disease. Parkinson's Disease, 2014, 2014, 1-8.	1.1	4
595	Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism. Parkinson's Disease, 2014, 2014, 1-10.	1.1	25

#	ARTICLE	IF	CITATIONS
596	Delayed latencies of auditory evoked potential P300 are associated with the severity of Parkinson's disease in older patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 296-300.	0.8	24
597	Metamemory and Parkinson's Disease. , 0, , 144-174.		0
598	Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 33-37.	0.8	12
599	ATP13A2/PARK9 Deficiency Neither Cause Lysosomal Impairment Nor Alter α -Synuclein Metabolism in SH-SY5Y Cells. <i>Experimental Neurobiology</i> , 2014, 23, 365-371.	1.6	8
600	Sleep Disturbances in Patients with Parkinson's Disease. , 0, , .		3
601	Exercise and cognitive functions in Parkinson's disease: Gender differences and disease severity. <i>Motriz Revista De Educacao Fisica</i> , 2014, 20, 461-469.	0.2	7
603	Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease. <i>Neurological Sciences</i> , 2014, 35, 1991-1996.	1.9	41
604	Palliative care and neurology. <i>Neurology</i> , 2014, 83, 561-567.	1.1	185
605	Smoking and Parkinson disease. <i>Neurology</i> , 2014, 83, 1392-1393.	1.1	10
606	Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson's Disease. <i>Drugs</i> , 2014, 74, 2175-2190.	10.9	20
607	Targeting α -Synuclein as a Parkinson's Disease Therapeutic. <i>Topics in Medicinal Chemistry</i> , 2014, , 43-109.	0.8	0
608	Smartphone- and internet-assisted self-management and adherence tools to manage Parkinson's disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014). <i>Trials</i> , 2014, 15, 374.	1.6	29
609	What light have resting state fMRI studies shed on cognition and mood in Parkinson's disease?. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 4.	2.2	3
610	Advances in Drug Development for Parkinson's Disease: Present Status. <i>Pharmacology</i> , 2014, 93, 260-271.	2.2	17
611	Anxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 133.	2.0	78
612	Pedunculopontine Nucleus Stimulation: Where are We Now and What Needs to be Done to Move the Field Forward?. <i>Frontiers in Neurology</i> , 2014, 5, 243.	2.4	53
613	Adult Hippocampal Neurogenesis in Parkinson's Disease: Impact on Neuronal Survival and Plasticity. <i>Neural Plasticity</i> , 2014, 2014, 1-12.	2.2	62
614	Role of Trichloroethylene in Parkinson's Disease. <i>Molecular and Integrative Toxicology</i> , 2014, , 91-129.	0.5	0

#	ARTICLE	IF	CITATIONS
615	The Central Clock in Patients With Parkinson Disease—Reply. JAMA Neurology, 2014, 71, 1456.	9.0	4
616	Dementia and Cognitive Impairment in Patients With Parkinson's Disease From India. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 630-636.	1.9	18
617	Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology, 2014, 83, 1096-1103.	1.1	116
618	The Central Clock in Patients With Parkinson Disease. JAMA Neurology, 2014, 71, 1455.	9.0	9
619	An Efficient Diagnosis System for Parkinson's Disease Using Kernel-Based Extreme Learning Machine with Subtractive Clustering Features Weighting Approach. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-14.	1.3	50
620	Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson's Disease. Frontiers in Neurology, 2014, 5, 188.	2.4	6
621	Mechanisms of Body Weight Fluctuations in Parkinson's Disease. Frontiers in Neurology, 2014, 5, 84.	2.4	85
622	Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiology of Disease, 2014, 61, 55-71.	4.4	193
623	Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. Journal of the Neurological Sciences, 2014, 337, 47-54.	0.6	54
624	Cardiovascular autonomic nervous system evaluation in Parkinson disease and multiple system atrophy. Journal of the Neurological Sciences, 2014, 336, 197-202.	0.6	30
625	Serotonin transporter polymorphic region 5-HTTLPR modulates risk for Parkinson's disease. Neurobiology of Aging, 2014, 35, 1957.e9-1957.e14.	3.1	10
626	Innovations in e-health. Quality of Life Research, 2014, 23, 195-203.	3.1	105
628	Irritable bowel syndrome correlates with increased risk of Parkinson's disease in Taiwan. European Journal of Epidemiology, 2014, 29, 57-62.	5.7	72
629	An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. Journal of Neural Transmission, 2014, 121, 275-281.	2.8	29
630	Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?. Journal of Comparative Neurology, 2014, 522, 2802-2816.	1.6	49
631	Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Expert Opinion on Pharmacotherapy, 2014, 15, 1097-1107.	1.8	21
632	Nigral 6-hydroxydopamine lesion impairs performance in a lateralised choice reaction time task—Impact of training and task parameters. Behavioural Brain Research, 2014, 266, 207-215.	2.2	5
633	Associations between Severity of Motor Function and Nonmotor Symptoms in Parkinson's Disease: A Post Hoc Analysis of the RECOVER Study. European Neurology, 2014, 71, 140-147.	1.4	16

#	ARTICLE	IF	CITATIONS
634	How to organize multispecialty care for patients with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S167-S173.	2.2	45
635	Selective Attention and Facial Expression Recognition in Patients with Parkinson's Disease. Archives of Clinical Neuropsychology, 2014, 29, 374-384.	0.5	12
636	Role of cardiorespiratory synchronization and sleep physiology: effects on membrane potential in the restorative functions of sleep. Sleep Medicine, 2014, 15, 279-288.	1.6	32
637	The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis. Journal of Neural Transmission, 2014, 121, 123-134.	2.8	81
638	Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients. Journal of Neurology, 2014, 261, 382-391.	3.6	29
639	Non-motor symptoms of Parkinson's disease A review from the past. Journal of the Neurological Sciences, 2014, 338, 30-33.	0.6	93
640	Neurobiology of Interval Timing. Advances in Experimental Medicine and Biology, 2014, , .	1.6	26
641	Fatigue in neurological disorders: a review of self-regulation and mindfulness-based interventions. Fatigue: Biomedicine, Health and Behavior, 2014, 2, 202-218.	1.9	3
642	Neuroimaging in Parkinson disease: from research setting to clinical practice. Nature Reviews Neurology, 2014, 10, 708-722.	10.1	195
643	Importance of nondopaminergic features in evaluating disease severity of Parkinson disease. Neurology, 2014, 82, 412-418.	1.1	36
644	Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: A national register-based study. Parkinsonism and Related Disorders, 2014, 20, 1124-1128.	2.2	26
645	Disrupted white matter integrity in depressed versus non-depressed Parkinson's disease patients: A tract-based spatial statistics study. Journal of the Neurological Sciences, 2014, 346, 145-148.	0.6	51
646	ParkDetect: Early diagnosing Parkinson's Disease. , 2014, , .		8
647	Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Behavioural Brain Research, 2014, 274, 390-399.	2.2	75
648	Clinical features associated with sleep disturbances in Parkinson's disease. Clinical Neurology and Neurosurgery, 2014, 124, 37-43.	1.4	32
649	Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. Neurobiology of Disease, 2014, 71, 359-369.	4.4	58
650	Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Research, 2014, 1593, 95-105.	2.2	62
651	6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses. Journal of Neural Transmission, 2014, 121, 1245-1257.	2.8	30

#	ARTICLE	IF	CITATIONS
652	The effects of exercise on cognition in Parkinson's disease: a systematic review. <i>Translational Neurodegeneration</i> , 2014, 3, 5.	8.0	139
653	Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2014, 29, 562-566.	3.9	17
654	The effect of additional noradrenergic and serotonergic depletion on a lateralised choice reaction time task in rats with nigral 6-OHDA lesions. <i>Experimental Neurology</i> , 2014, 253, 52-62.	4.1	9
655	The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 149-152.	2.2	60
656	The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 99-105.	2.2	223
657	Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , 2014, 10, 432-433.	10.1	10
658	Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued. <i>CNS Drugs</i> , 2014, 28, 455-474.	5.9	164
659	Early Versus Delayed Initiation of Pharmacotherapy in Parkinson's Disease. <i>Drugs</i> , 2014, 74, 645-657.	10.9	13
660	Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson's Disease. <i>Drugs and Aging</i> , 2014, 31, 239-261.	2.7	25
661	The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed. <i>Journal of Biomedical Science</i> , 2014, 21, 27.	7.0	47
662	Preventing α -synuclein aggregation: The role of the small heat-shock molecular chaperone proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1830-1843.	3.8	70
663	Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade. <i>Behavioural Brain Research</i> , 2014, 275, 136-145.	2.2	22
664	Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. <i>Brain</i> , 2014, 137, 197-207.	7.6	224
665	Long-Term Exposure to Paraquat Alters Behavioral Parameters and Dopamine Levels in Adult Zebrafish (<i>Danio Rerio</i>). <i>Zebrafish</i> , 2014, 11, 142-153.	1.1	72
666	Parkinson's disease and mitochondrial gene variations: A review. <i>Journal of the Neurological Sciences</i> , 2014, 346, 11-19.	0.6	26
667	Dynamic of neurochemical alterations in striatum, hippocampus and cortex after the 6-OHDA mesostriatal lesion. <i>International Journal of Developmental Neuroscience</i> , 2014, 36, 32-37.	1.6	12
668	Parkinson Disease in Long Term Care Facilities: A Review of the Literature. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 90-94.	2.5	31
669	Treatment effects for dysphagia in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 800-807.	2.2	77

#	ARTICLE	IF	CITATIONS
670	Parkinson's disease and REM sleep behavior disorder result in increased non-motor symptoms. <i>Sleep Medicine</i> , 2014, 15, 959-966.	1.6	50
671	Emerging therapies for Parkinson's disease: From bench to bedside. , 2014, 144, 123-133.		84
672	Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model. <i>International Journal of Molecular Medicine</i> , 2014, 34, 440-450.	4.0	16
673	Screening for Impaired Cognitive Domains in a Large Parkinson's Disease Population and Its Application to the Diagnostic Procedure for Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 147-159.	1.3	13
674	Contributions of the Basal Ganglia to Temporal Processing: Evidence from Parkinson's Disease. <i>Timing and Time Perception</i> , 2014, 2, 87-127.	0.6	51
675	Continuous Positive Airway Pressure Improves Sleep and Daytime Sleepiness in Patients with Parkinson Disease and Sleep Apnea. <i>Sleep</i> , 2014, 37, 177-185.	1.1	115
676	Non-motor symptoms: the core of multi-morbid Parkinson's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 18-24.	0.5	38
677	The Impact of DaTscan in the Diagnosis of Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2015, 40, 390-393.	1.3	26
678	New clinical trials for nonmotor manifestations of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1490-1504.	3.9	81
679	The range and nature of non-motor symptoms in drug-naïve Parkinson's disease patients: a state-of-the-art systematic review. <i>Npj Parkinson's Disease</i> , 2015, 1, 15013.	5.3	67
680	Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors. <i>Journal of Parkinson's Disease</i> , 2015, 5, 625-636.	2.8	67
681	Knowledge of Parkinson's Disease in a Multiethnic Urban Asian Setting. <i>Journal of Parkinson's Disease</i> , 2015, 5, 865-879.	2.8	16
682	Pain Perception in Acute Model Mice of Parkinson's Disease Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP). <i>Molecular Pain</i> , 2015, 11, s12990-015-0026.	2.1	51
683	Diminished event-related cortical arousals and altered heart rate response in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 866-870.	3.9	15
684	Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1825-1830.	3.9	34
685	Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and heidelberg retina tomography. <i>Acta Ophthalmologica</i> , 2015, 93, e578-84.	1.1	31
686	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.	3.9	189
687	The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies. <i>Brain Pathology</i> , 2015, 25, 121-135.	4.1	214

#	ARTICLE	IF	CITATIONS
688	Risk of Parkinson's disease following anxiety disorders: a nationwide population-based cohort study. <i>European Journal of Neurology</i> , 2015, 22, 1280-1287.	3.3	43
689	The impact of non-motor manifestations of Parkinson's disease on partners: understanding and application of chronic sorrow theory. <i>Journal of Primary Health Care</i> , 2015, 7, 221.	0.6	7
690	Non-Motor Symptoms in Parkinson's Disease and Efficacy of Treatment in a Complex Therapy Using Fetal Stem Cells. <i>Journal of Stem Cell Research & Therapy</i> , 2015, 05, .	0.3	0
691	Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2015, 8, 92-97.	1.3	109
692	The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2865.	2.2	31
693	Wearing-off in Parkinson's disease: neuropsychological differences between on and off periods. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1175.	2.2	15
694	Nitric Oxide a new player in L-DOPA-induced dyskinesia. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 193-221.	1.8	13
695	Nonmotor symptoms in Parkinson's disease: classification and management. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2015, , 1.	0.8	5
696	The behavior of migraine in patients with Parkinson's disease. <i>Neurology International</i> , 2015, 7, 6133.	2.8	4
697	Sleep Disturbances in Patients with Parkinson's Disease according to Disease Severity. <i>Korean Journal of Clinical Neurophysiology</i> , 2015, 17, 17.	0.1	1
698	Differentiated Cells Derived from Fetal Neural Stem Cells Improve Motor Deficits in a Rat Model of Parkinson's Disease. <i>Translational Neuroscience and Clinics</i> , 2015, 1, 75-85.	0.1	5
699	L-Dopa and Brain Serotonin System Dysfunction. <i>Toxics</i> , 2015, 3, 75-88.	3.7	42
700	Lower Limb Progressive Resistance Training Improves Leg Strength but Not Gait Speed or Balance in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 40.	3.4	20
701	Sleep spindle alterations in patients with Parkinson's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 233.	2.0	42
702	Partnered Dancing to Improve Mobility for People With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 444.	2.8	15
703	Prevalence and correlates of sleep disorders in Parkinson's disease: a polysomnographic study. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 241-245.	0.8	42
704	Altered Resting-State Brain Activity and Connectivity in Depressed Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0131133.	2.5	53
705	Emotion Processing in Parkinson's Disease: A Three-Level Study on Recognition, Representation, and Regulation. <i>PLoS ONE</i> , 2015, 10, e0131470.	2.5	67

#	ARTICLE	IF	CITATIONS
706	Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1. <i>Frontiers in Pharmacology</i> , 2015, 6, 275.	3.5	40
707	Non-motor signs in Parkinsonâ€™s disease: a review. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 454-462.	0.8	57
708	Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinsonâ€™s Disease. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	1.5	46
709	Foetal Cell Transplantation for Parkinsonâ€™s Disease: Focus on Graft-Induced Dyskinesia. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	1.1	11
710	Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinsonâ€™s Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties. <i>Journal of Neurodegenerative Diseases</i> , 2015, 2015, 1-14.	1.1	29
711	Effect of Exercise on Motor and Nonmotor Symptoms of Parkinsonâ€™s Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-5.	1.1	39
712	Nitric Oxide a new player in L-DOPA-induced dyskinesia. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 193-221.	1.8	0
713	Amplitude of Low-frequency Oscillations in Parkinson's Disease. <i>Chinese Medical Journal</i> , 2015, 128, 593-601.	2.3	30
714	Development of Tablet Device App for Parkinsonâ€™s Disease Patientsâ€™ Continuous Self-Monitoring and Management. <i>Neuroscience and Biomedical Engineering</i> , 2015, 3, 40-48.	0.4	2
715	A longitudinal study of non-motor symptom burden in Parkinson's disease after a transition to expert care. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 843-847.	2.2	11
716	Thinking about motor fluctuations: An examination of metacognitions in Parkinson's disease. <i>Journal of Psychosomatic Research</i> , 2015, 79, 669-673.	2.6	19
717	Measuring illness beliefs in neurodegenerative disease: Why we need to be specific. <i>Journal of Health Psychology</i> , 2015, 20, 69-79.	2.3	4
718	Potential sex differences in nonmotor symptoms in early drug-naïve Parkinson disease. <i>Neurology</i> , 2015, 84, 2107-2115.	1.1	90
719	How to make a midbrain dopaminergic neuron. <i>Development (Cambridge)</i> , 2015, 142, 1918-1936.	2.5	286
720	Fiber grating compression of giant-chirped nanosecond pulses from an ultra-long nanotube mode-locked fiber laser. <i>Optics Letters</i> , 2015, 40, 387.	3.3	28
721	Abnormal amygdala function in Parkinson's disease patients and its relationship to depression. <i>Journal of Affective Disorders</i> , 2015, 183, 263-268.	4.1	66
722	Telemedicine multimedia system to support neurodegenerative diseases participatory management. , 2015, 2015, 4982-5.		2
724	Anxiety and depression in Parkinson's disease patients in Saudi Arabia Global neurology. <i>Journal of the Neurological Sciences</i> , 2015, 358, 457-458.	0.6	3

#	ARTICLE	IF	CITATIONS
725	Prostate volume and prostate-specific antigen in men with Parkinson's disease are not different compared to age-matched control group: A prospective, case-controlled multicenter study. Prostate International, 2015, 3, 62-64.	2.3	1
726	A characterization of Parkinson's disease by describing the visual field motion during gait. Proceedings of SPIE, 2015, , .	0.8	1
727	Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism. Neuroepidemiology, 2015, 45, 59-69.	2.3	11
728	Euro<sc>I</sc>nf: <sc>A</sc> <sc>M</sc>ulticenter <sc>C</sc>omparative <sc>O</sc>bservational <sc>S</sc>tudy of <sc>A</sc>pomorphine and <sc>L</sc>evodopa <sc>I</sc>nfusion in <sc>P</sc>arkinson's <sc>D</sc>isease. Movement Disorders, 2015, 30, 510-516.	3.9	203
729	Cutaneous autonomic denervation in Parkinson's disease. Journal of Neural Transmission, 2015, 122, 1149-1155.	2.8	29
730	Interaction of Noradrenergic Pharmacological Manipulation and Subthalamic Stimulation on Movement Initiation Control in Parkinson's Disease. Brain Stimulation, 2015, 8, 27-35.	1.6	22
731	A comparison between rate of nonmotor symptom development in essential tremor and Parkinson's disease. Acta Neurologica Belgica, 2015, 115, 289-294.	1.1	13
732	Validation of the nonmotor symptoms questionnaire for Parkinson's disease: results from a Chinese pilot study. International Journal of Neuroscience, 2015, 125, 929-935.	1.6	12
733	Homocysteine and Cognitive Decline in Parkinson's Disease. , 2015, , 511-519.		0
734	Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. Journal of Neurochemistry, 2015, 133, 750-765.	3.9	54
735	NREM sleep alpha and sigma activity in Parkinson's disease: Evidence for conflicting electrophysiological activity?. Clinical Neurophysiology, 2015, 126, 951-958.	1.5	17
736	Assessing the non-motor symptoms of Parkinson's disease: <sc>MDS</sc> <sc>UPDRS</sc> and <sc>NMS</sc> Scale. European Journal of Neurology, 2015, 22, 37-43.	3.3	82
737	The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology, 2015, 96, 55-69.	4.1	174
738	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 2015, 36, 1160-1173.	3.1	29
739	Compensatory fronto-parietal hyperactivation during set-shifting in unmedicated patients with Parkinson's disease. Neuropsychologia, 2015, 68, 107-116.	1.6	42
740	Management of Parkinson's disease: Current and future pharmacotherapy. European Journal of Pharmacology, 2015, 750, 74-81.	3.5	68
741	Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?. Rejuvenation Research, 2015, 18, 257-269.	1.8	48
742	Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease. Brain, Behavior, and Immunity, 2015, 46, 154-167.	4.1	42

#	ARTICLE	IF	CITATIONS
743	Human adipose-Derived Mesenchymal Stem Cells Improve Motor Functions and are Neuroprotective in the 6-Hydroxydopamine-Rat Model for Parkinson's Disease when Cultured in Monolayer Cultures but Suppress Hippocampal Neurogenesis and Hippocampal Memory Function when Cultured in Spheroids. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 133-149.	5.6	50
744	Dysautonomias in Parkinson's disease: cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H250-H257.	3.2	28
745	The measurement and importance of non-motor symptoms in Parkinson disease. <i>European Journal of Neurology</i> , 2015, 22, 2-3.	3.3	17
746	Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 238-244.	3.9	112
747	Evolution of Prodromal Clinical Markers of Parkinson Disease in a <i>GBA</i> Mutation-Positive Cohort. <i>JAMA Neurology</i> , 2015, 72, 201.	9.0	180
748	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. <i>Trends in Genetics</i> , 2015, 31, 140-149.	6.7	193
749	Are Sleep Disturbances Preclinical Markers of Parkinson's Disease?. <i>Neurochemical Research</i> , 2015, 40, 421-427.	3.3	26
750	Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants. <i>Journal of Neural Transmission</i> , 2015, 122, 661-667.	2.8	18
751	Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α -Synuclein for Assessing Antiparkinson Agents. <i>Molecular Neurobiology</i> , 2015, 52, 226-235.	4.0	6
752	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	3.9	41
753	Self-regulatory fatigue after neurological and musculoskeletal injury: implications for physiotherapy management. <i>Physical Therapy Reviews</i> , 2015, 20, 42-58.	0.8	1
754	Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning. <i>Life Sciences</i> , 2015, 137, 28-36.	4.3	30
755	Environment-contact administration of rotenone: A new rodent model of Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 294, 149-161.	2.2	49
756	Efficient Expression of Igf-1 from Lentiviral Vectors Protects In Vitro but Does Not Mediate Behavioral Recovery of a Parkinsonian Lesion in Rats. <i>Human Gene Therapy</i> , 2015, 26, 719-733.	2.7	6
757	Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 483-488.	2.2	23
758	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
759	Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 10058-10077.	3.6	136
760	Apomorphine hydrochloride for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 723-732.	2.8	21

#	ARTICLE	IF	CITATIONS
761	Clinical phenotype of drug-naïve Parkinson's disease based on nonmotor symptoms. Archives of Gerontology and Geriatrics, 2015, 61, 517-522.	3.0	4
762	Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. Parkinsonism and Related Disorders, 2015, 21, 1056-1060.	2.2	37
763	Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats. Translational Research, 2015, 166, 152-162.	5.0	43
764	Validity of Montreal Cognitive Assessment in Non-English speaking patients with Parkinson's disease. Neurology India, 2015, 63, 63.	0.4	23
765	Associations between Vitamin D Status, Supplementation, Outdoor Work and Risk of Parkinson's Disease: A Meta-Analysis Assessment. Nutrients, 2015, 7, 4817-4827.	4.1	32
766	Implementation of an Integrative Holistic Healthcare Model for People Living with Parkinson's Disease. Gerontologist, The, 2015, 55, S146-S153.	3.9	24
767	Alpha-synuclein as a Pathological Link Between Chronic Traumatic Brain Injury and Parkinson's Disease. Journal of Cellular Physiology, 2015, 230, 1024-1032.	4.1	127
768	Non-motor symptoms in an Indian cohort of Parkinson's disease patients and correlation of progression of non-motor symptoms with motor worsening. Neurology India, 2015, 63, 166.	0.4	18
769	Genetic Models of Parkinson's Disease. , 2015, , 289-314.		0
770	Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders. Movement Disorders, 2015, 30, 1155-1170.	3.9	168
771	Support supplied by Parkinson's disease specialist nurses to Parkinson's disease patients and their spouses. Applied Nursing Research, 2015, 28, 86-91.	2.2	39
772	Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease. European Journal of Neuroscience, 2015, 42, 2028-2035.	2.6	29
773	Nonmotor symptoms in sporadic versus familial forms of Parkinson's disease. Neurodegenerative Disease Management, 2015, 5, 147-153.	2.2	4
774	Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease. Journal of Neurology, 2015, 262, 881-889.	3.6	5
775	The heterogeneity of non-motor symptoms of Parkinson's disease. Neurological Sciences, 2015, 36, 577-584.	1.9	11
776	Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Medicine, 2015, 13, 28.	5.5	121
777	Association of TLR4 gene polymorphisms with sporadic Parkinson's disease in a Han Chinese population. Neurological Sciences, 2015, 36, 1659-1665.	1.9	28
778	Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. Journal of Neurology, 2015, 262, 1568-1578.	3.6	59

#	ARTICLE	IF	CITATIONS
779	Parkinson's disease: a review of non-motor symptoms. Expert Review of Neurotherapeutics, 2015, 15, 549-562.	2.8	79
780	Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. Clinical Autonomic Research, 2015, 25, 109-116.	2.5	13
781	Trastornos del movimiento (I): Conceptos generales, clasificación de los síndromes parkinsonianos y enfermedad de Parkinson. Medicine, 2015, 11, 4415-4426.	0.0	1
782	Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 431-443.	2.2	71
783	Dopamine signals and physiological origin of cognitive dysfunction in Parkinson's disease. Movement Disorders, 2015, 30, 472-483.	3.9	24
784	Automatic identification of dysprosody in idiopathic Parkinson's disease. Biomedical Signal Processing and Control, 2015, 17, 47-54.	5.7	26
785	Heart rate variability shows different cardiovascular modulation in Parkinson's disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype. Journal of Neural Transmission, 2015, 122, 1441-1446.	2.8	17
786	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 751-767.	3.3	98
787	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Movement Disorders, 2015, 30, 589-592.	3.9	22
789	The relevance of pre-motor symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1205-1217.	2.8	29
790	Classification of Parkinson's Disease Gait Using Spatial-Temporal Gait Features. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1794-1802.	6.3	163
791	Initial drug treatment in Parkinson's disease. BMJ, The, 2015, 351, h4669.	6.0	12
792	What Engineering Technology Could Do for Quality of Life in Parkinson's Disease: A Review of Current Needs and Opportunities. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1862-1872.	6.3	66
793	Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nature Reviews Neurology, 2015, 11, 625-636.	10.1	465
794	Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's disease. Behavioral and Brain Functions, 2015, 11, 26.	3.3	29
795	Prolonged-release oxycodone–naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 1161-1170.	10.2	102
796	Optical coherence tomography as a tool to evaluate retinal changes in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1164-1169.	2.2	62
797	Adenosine A2A Receptor Antagonists as Drugs for Symptomatic Control of Parkinson's Disease in Preclinical Studies. Current Topics in Neurotoxicity, 2015, , 127-148.	0.4	0

#	ARTICLE	IF	CITATIONS
798	Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Review of Neurotherapeutics, 2015, 15, 1231-1240.	2.8	22
799	Development of stem cell-based therapy for Parkinson's disease. Translational Neurodegeneration, 2015, 4, 16.	8.0	52
800	Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits. Neurochemistry International, 2015, 89, 181-190.	3.8	32
801	Depressive-like phenotype induced by AAV-mediated overexpression of human α -synuclein in midbrain dopaminergic neurons. Experimental Neurology, 2015, 273, 243-252.	4.1	50
804	Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2015, 49, 157-170.	6.1	31
805	Potential Neuroprotective Activity of Ginseng in Parkinson's Disease: A Review. Journal of NeuroImmune Pharmacology, 2015, 10, 14-29.	4.1	78
806	Patterns and Predictors of Mental Health Service Utilization in People With Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 12-18.	2.3	14
807	Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cerebral Cortex, 2015, 25, 2783-2792.	2.9	42
808	The major impact of freezing of gait on quality of life in Parkinson's disease. Journal of Neurology, 2015, 262, 108-115.	3.6	105
809	Serotonin in Parkinson's disease. Behavioural Brain Research, 2015, 277, 136-145.	2.2	224
810	Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 767-773.	1.9	93
811	Sleep spindles in Parkinson's disease may predict the development of dementia. Neurobiology of Aging, 2015, 36, 1083-1090.	3.1	130
812	Clinical and Experimental Cell Therapy in Parkinson's Disease. , 2016, , .		0
813	LINEAR ASSESSMENT OF CEREBRAL AUTOREGULATION IN IDIOPATHIC PARKINSON'S DISEASE. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 14.	0.3	0
814	Neurotoxin-Induced Catecholaminergic Loss in the Colonic Myenteric Plexus of Rhesus Monkeys. , 2016, 06, .		11
815	Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson's Disease. , 2016, 6, .		0
816	Morning akinesia in Parkinson's disease: challenges and solutions. Journal of Parkinsonism and Restless Legs Syndrome, 2016, , 57.	0.8	1
817	Presence or absence of cognitive complaints in Parkinson's disease: mood disorder or anosognosia?. Arquivos De Neuro-Psiquiatria, 2016, 74, 439-444.	0.8	16

#	ARTICLE	IF	CITATIONS
818	The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group. Journal of Clinical		

#	ARTICLE	IF	CITATIONS
837	Striatal Dopamine Depletion Patterns and Early Non-Motor Burden in Parkinsons Disease. PLoS ONE, 2016, 11, e0161316.	2.5	11
838	Association between Parkinson's Disease and <i>Helicobacter Pylori</i> . Journal of Clinical Neurology		

838 Association between Parkinson's Disease and *Helicobacter Pylori*. Journal of Clinical Neurology

#	ARTICLE	IF	CITATIONS
856	A clinical survey of pain in Parkinson's disease in Eastern China. International Psychogeriatrics, 2016, 28, 283-289.	1.0	18
857	Parkinson disease patients' perspectives on palliative care needs. Neurology: Clinical Practice, 2016, 6, 209-219.	1.6	75
858	Implicit and explicit processing of emotional facial expressions in Parkinson's disease. Behavioural Brain Research, 2016, 303, 182-190.	2.2	34
859	Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study. Journal of Neurology, 2016, 263, 1111-1119.	3.6	57
860	Cognitive rehabilitation for Parkinson's disease dementia: a study protocol for a pilot randomised controlled trial. Trials, 2016, 17, 152.	1.6	21
861	Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. Parkinsonism and Related Disorders, 2016, 27, 54-60.	2.2	23
862	Progression and biomarkers for Parkinson disease. Neurology, 2016, 87, 128-129.	1.1	5
863	How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. BMC Neurology, 2016, 16, 63.	1.8	41
864	Cognitive predictors of balance in Parkinson's disease. Somatosensory & Motor Research, 2016, 33, 67-71.	0.9	12
865	Neural mechanisms underlying cognitive inflexibility in Parkinson's disease. Neuropsychologia, 2016, 93, 142-150.	1.6	37
866	Diffusion alterations associated with Parkinson's disease symptomatology: A review of the literature. Parkinsonism and Related Disorders, 2016, 33, 12-26.	2.2	70
867	Treatment Options for Urogenital Dysfunction in Parkinson's Disease. Current Treatment Options in Neurology, 2016, 18, 45.	1.8	26
868	Interventions for age-related diseases: Shifting the paradigm. Mechanisms of Ageing and Development, 2016, 160, 69-92.	4.6	57
869	Characterisation of foot clearance during gait in people with early Parkinson's disease: Deficits associated with a dual task. Journal of Biomechanics, 2016, 49, 2763-2769.	2.1	29
870	The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson's disease. Neuroscience Letters, 2016, 633, 279-289.	2.1	17
871	Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease. Journal of the Neurological Sciences, 2016, 370, 167-172.	0.6	17
872	Exergames for Parkinson's Disease patients: The balloon goon game. , 2016, , .		6
873	Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. Psychology and Health, 2016, 31, 1391-1414.	2.2	10

#	ARTICLE	IF	CITATIONS
874	Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's disease. <i>Brain</i> , 2016, 139, 2706-2721.	7.6	96
875	Mild Cognitive Impairment in Patients with Early-Onset Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 17-30.	1.5	9
876	Molecular changes in the postmortem parkinsonian brain. <i>Journal of Neurochemistry</i> , 2016, 139, 27-58.	3.9	74
877	Sexual dysfunction in women with Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1685-1693.	3.9	30
879	The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 23-38.	3.9	104
880	Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. <i>Journal of Neurochemistry</i> , 2016, 139, 240-255.	3.9	163
881	The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 137, 331-359.	3.9	186
882	SUMO-regulated mitochondrial function in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 137, 673-686.	3.9	53
884	Review: Sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 33-50.	3.2	309
885	Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. <i>Human Brain Mapping</i> , 2016, 37, 4500-4510.	3.6	75
886	Subcortical contributions to large-scale network communication. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 313-322.	6.1	129
887	Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease. <i>Stem Cell Research</i> , 2016, 17, 352-366.	0.7	61
888	An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. <i>Neuropharmacology</i> , 2016, 110, 48-58.	4.1	47
889	Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , 2016, 37, 1785-1792.	1.9	23
890	The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. <i>Movement Disorders</i> , 2016, 31, 1080-1094.	3.9	112
892	Generating Late-Onset Human iPSC-Based Disease Models by Inducing Neuronal Age-Related Phenotypes through Telomerase Manipulation. <i>Cell Reports</i> , 2016, 17, 1184-1192.	6.4	126
894	The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. <i>Translational Neurodegeneration</i> , 2016, 5, 12.	8.0	47
895	Patient's Loss of Empathy Is Associated With Caregiver Burden. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 717-722.	1.0	19

#	ARTICLE	IF	CITATIONS
896	Can <scp>COMT</scp>â€inhibitor delay the clinical progression of <scp>P</scp>arkinson's disease? 2 years follow up pilot study. International Journal of Imaging Systems and Technology, 2016, 26, 38-42.	4.1	1
897	<scp>G</scp>lycation in <scp>P</scp>arkinson's disease and Alzheimer's disease. Movement Disorders, 2016, 31, 782-790.	3.9	104
898	Effect of Acupuncture on the Motor and Nonmotor Symptoms in Parkinson's Diseaseâ€”A Review of Clinical Studies. CNS Neuroscience and Therapeutics, 2016, 22, 333-341.	3.9	42
899	Transcranial direct current stimulation lessens dual task cost in people with Parkinsonâ€™s disease. Neuroscience Letters, 2016, 626, 1-5.	2.1	36
900	An image registration pipeline for analysis of transsynaptic tracing in mice. , 2016, , .		0
902	Evaluating and managing sleep disorders in the parkinsonâ€™s disease clinic. Basal Ganglia, 2016, 6, 165-172.	0.3	5
903	Caregiversâ€™ Impressions Predicting Fitness to Drive in Persons With Parkinsonâ€™s. OTJR Occupation, Participation and Health, 2016, 36, 5-13.	0.8	4
904	Joint feature-sample selection and robust diagnosis of Parkinson's disease from MRI data. NeuroImage, 2016, 141, 206-219.	4.2	87
905	Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment. Journal of Neuroscience Research, 2016, 94, 685-692.	2.9	21
906	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. Movement Disorders, 2016, 31, 270-279.	3.9	55
907	Modeling sleep alterations in Parkinson's disease: How close are we toâ€valid translational animal models?. Sleep Medicine Reviews, 2016, 25, 95-111.	8.5	27
908	The prediagnostic phase of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 871-878.	1.9	122
909	Dysphagia in Parkinsonâ€™s Disease. Dysphagia, 2016, 31, 24-32.	1.8	313
910	Progression of non-motor symptoms in Parkinson's disease among different age populations: A two-year follow-up study. Journal of the Neurological Sciences, 2016, 360, 72-77.	0.6	28
911	Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease. Journal of Voice, 2016, 30, 766.e1-766.e11.	1.5	31
912	Obstructive Sleep Apnea and Cognition in Parkinson's disease. Sleep Medicine, 2016, 21, 28-34.	1.6	62
913	Parkinson Disease Risk in Patients With Rosacea. JAMA Neurology, 2016, 73, 501.	9.0	2
914	Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism and Related Disorders, 2016, 27, 25-34.	2.2	74

#	ARTICLE	IF	CITATIONS
915	Metacognitive knowledge of olfactory dysfunction in Parkinson's disease. <i>Brain and Cognition</i> , 2016, 104, 1-6.	1.8	36
916	Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 39-44.	2.2	16
917	PET Imaging of Mitochondrial Complex I with ¹⁸ F-BCPP-EF in the Brains of MPTP-Treated Monkeys. <i>Journal of Nuclear Medicine</i> , 2016, 57, 950-953.	5.0	30
918	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2016, 21, 140-144.	1.6	55
919	Genetic substrates of psychosis in patients with Parkinson's disease: A critical review. <i>Journal of the Neurological Sciences</i> , 2016, 364, 33-41.	0.6	33
920	Low Serum Vitamin D Levels May Contribute to Gastric Dysmotility in de novo Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 199-205.	1.4	20
921	Evaluation of an Arabic version of the non-motor symptoms scale in Parkinson's disease. <i>Neurological Sciences</i> , 2016, 37, 963-968.	1.9	9
922	Non-motor signs in patients with Parkinson's disease at the University Hospital of Point à l'Étoile, Mali. <i>ENeurologicalSci</i> , 2016, 3, 35-36.	1.3	6
923	What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?. <i>Translational Psychiatry</i> , 2016, 6, e753-e753.	4.8	60
924	Association between antidepressants and falls in Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 76-82.	3.6	12
925	Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats. <i>Behavioural Brain Research</i> , 2016, 301, 43-54.	2.2	27
926	Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies. <i>Neurochemistry International</i> , 2016, 93, 6-25.	3.8	46
927	Unravelling the nonmotor mysteries of Parkinson disease. <i>Nature Reviews Neurology</i> , 2016, 12, 10-11.	10.1	28
928	Role of the Anterior Cingulate Cortex in the Control of Micturition Reflex in a Rat Model of Parkinson's Disease. <i>Journal of Urology</i> , 2016, 195, 1613-1620.	0.4	24
929	Proton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease. <i>Radiology</i> , 2016, 278, 505-513.	7.3	35
930	Multiple factors, including non-motor impairments, influence decision making with regard to exercise participation in Parkinson's disease: a qualitative enquiry. <i>Disability and Rehabilitation</i> , 2016, 38, 472-481.	1.8	38
931	Non motor subtypes and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S41-S46.	2.2	268
932	Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats. <i>Molecular Neurobiology</i> , 2016, 53, 3891-3899.	4.0	29

#	ARTICLE	IF	CITATIONS
933	MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease. International Journal of Neuroscience, 2016, 126, 25-29.	1.6	12
934	Factors contributing to malnutrition in patients with Parkinson's disease. International Journal of Nursing Practice, 2016, 22, 129-137.	1.7	14
935	A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourology and Urodynamics, 2016, 35, 551-563.	1.5	114
936	Effects of singing on voice, respiratory control and quality of life in persons with Parkinson's disease. Disability and Rehabilitation, 2017, 39, 594-600.	1.8	63
937	Impaired topological architecture of brain structural networks in idiopathic Parkinson's disease: a DTI study. Brain Imaging and Behavior, 2017, 11, 113-128.	2.1	54
938	Differentiating Patients with Parkinson's Disease from Normal Controls Using Gray Matter in the Cerebellum. Cerebellum, 2017, 16, 151-157.	2.5	29
940	Chronic Treatment with Paraquat Induces Brain Injury, Changes in Antioxidant Defenses System, and Modulates Behavioral Functions in Zebrafish. Molecular Neurobiology, 2017, 54, 3925-3934.	4.0	70
941	Drugs Against Neurodegenerative Diseases: Design and Synthesis of 6-Amino-substituted Imidazo[1,2-a]pyridazines as Acetylcholinesterase Inhibitors. ChemistrySelect, 2017, 2, 842-847.	1.5	21
942	Reprint of "Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease". Journal of the Neurological Sciences, 2017, 374, 3-8.	0.6	26
943	Comorbid conditions associated with Parkinson's disease: A longitudinal and comparative study with Alzheimer disease and control subjects. Journal of the Neurological Sciences, 2017, 373, 210-215.	0.6	29
944	Esophageal dysfunction in different stages of Parkinson's disease. Neurogastroenterology and Motility, 2017, 29, e12915.	3.0	63
945	The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence. Npj Parkinson's Disease, 2017, 3, 16024.	5.3	99
946	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	1.9	70
947	Silymarin promotes longevity and alleviates Parkinson's associated pathologies in Caenorhabditis elegans. Journal of Functional Foods, 2017, 31, 32-43.	3.4	27
948	Treatment of Older Parkinson's Disease. International Review of Neurobiology, 2017, 132, 381-405.	2.0	15
949	Mapping visual dominance in human sleep. NeuroImage, 2017, 150, 250-261.	4.2	9
950	LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochemical Society Transactions, 2017, 45, 113-122.	3.4	53
951	Nonmotor symptoms in de novo Parkinson disease comparing to normal aging. Clinical Neurology and Neurosurgery, 2017, 155, 7-11.	1.4	4

#	ARTICLE	IF	CITATIONS
952	Behavioral Phenotyping Assays for Genetic Mouse Models of Neurodevelopmental, Neurodegenerative, and Psychiatric Disorders. Annual Review of Animal Biosciences, 2017, 5, 371-389.	7.4	46
953	Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets () Tj ETQq1 1 0.784314 rgBT /Overlook	2.2	19
954	Cognition in non-demented Parkinson's disease vs essential tremor: A population-based study. Acta Neurologica Scandinavica, 2017, 136, 393-400.	2.1	18
955	Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. Parkinsonism and Related Disorders, 2017, 38, 54-60.	2.2	45
956	Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys. Journal of Nuclear Medicine, 2017, 58, 1111-1116.	5.0	18
957	Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. Journal of Neurology, 2017, 264, 758-769.	3.6	74
958	Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 38, 41-47.	2.2	66
959	Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease. Physiology and Behavior, 2017, 173, 132-143.	2.1	28
961	Walking in fully immersive virtual environments: an evaluation of potential adverse effects in older adults and individuals with Parkinson's disease. Journal of NeuroEngineering and Rehabilitation, 2017, 14, 16.	4.6	128
962	Selective A2A receptors blockade reduces degeneration of substantia nigra dopamine neurons in a rotenone-induced rat model of Parkinson's disease: A histological study. Neuroscience Letters, 2017, 643, 89-96.	2.1	14
963	The role of the retina in visual hallucinations: A review of the literature and implications for psychosis. Neuropsychologia, 2017, 99, 128-138.	1.6	29
965	Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis. Cortex, 2017, 92, 119-138.	2.4	101
966	Donepezil for Constipation in Lewy Body Diseases: Four Case Studies. Activitas Nervosa Superior, 2017, 59, 19-27.	0.4	6
967	Changes in resting-state directed connectivity in cortico-subcortical networks correlate with cognitive function in Parkinson's disease. Clinical Neurophysiology, 2017, 128, 1319-1326.	1.5	34
969	The role of Ca2+ signaling in Parkinson's disease. DMM Disease Models and Mechanisms, 2017, 10, 519-535.	2.4	132
970	Treatment of Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 361-379.	2.0	15
972	Bee venom for the treatment of Parkinson's disease: How far is it possible?. Biomedicine and Pharmacotherapy, 2017, 91, 295-302.	5.6	23
973	Drosophila PINK1 and parkin loss-of-function mutants display a range of non-motor Parkinson's disease phenotypes. Neurobiology of Disease, 2017, 104, 15-23.	4.4	65

#	ARTICLE	IF	CITATIONS
974	Cognitive Training in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2017, 31, 207-216.	2.9	38
975	Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse. <i>Molecular Neurobiology</i> , 2018, 55, 4240-4252.	4.0	24
976	The implication of neuron-immunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3741-3768.	5.4	9
977	Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 989-1018.	2.0	16
978	Olfaction in <i>Parkin</i> carriers in Chinese patients with Parkinson disease. <i>Brain and Behavior</i> , 2017, 7, e00680.	2.2	11
979	Association of Restless Legs Syndrome With Incident Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	1.1	33
980	Screening of neuropsychiatric symptoms in patients with Parkinson's disease in a UK general practice. <i>European Geriatric Medicine</i> , 2017, 8, 284.	2.8	0
981	Non-motor features of Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 435-450.	10.2	1,182
982	Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features. <i>Science China Life Sciences</i> , 2017, 60, 1223-1233.	4.9	316
983	Neurotransmitter receptor availability in the rat brain is constant in a 24 hour-period. <i>Chronobiology International</i> , 2017, 34, 866-875.	2.0	1
984	Psychosis in Parkinson's disease: From the soft signs to the hard science. <i>Journal of the Neurological Sciences</i> , 2017, 379, 169-176.	0.6	20
985	Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. <i>Human Molecular Genetics</i> , 2017, 26, 2231-2246.	2.9	121
986	The factor structure of the Brief Symptom Inventory-18 (BSI-18) in Parkinson disease patients. <i>Journal of Psychosomatic Research</i> , 2017, 96, 21-26.	2.6	13
987	Neurotransmission systems in Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2017, 28, 509-536.	2.9	54
988	Association among type D personality, non-motor symptoms, and quality of life in Parkinson's disease: A cross-sectional study. <i>Geriatric Nursing</i> , 2017, 38, 431-436.	1.9	12
989	Early start of progressive motor deficits in Line 61 Δ -synuclein transgenic mice. <i>BMC Neuroscience</i> , 2017, 18, 22.	1.9	32
990	Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial. <i>Pilot and Feasibility Studies</i> , 2017, 3, 4.	1.2	8
991	The Nonmotor Features of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 33-54.	2.0	56

#	ARTICLE	IF	CITATIONS
992	Effect and Mechanism of Chinese Herbal Medicine on Parkinson's Disease. International Review of Neurobiology, 2017, 135, 57-76.	2.0	25
994	Therapeutic singing as an early intervention for swallowing in persons with Parkinson's disease. Complementary Therapies in Medicine, 2017, 31, 127-133.	2.7	34
996	Non-pharmacological Approaches Based on Mind-Body Medicine to Enhancement of Cognitive and Brain Reserve in Humans. , 2017, , 129-151.		0
997	Enhanced neuroprotection with decellularized brain extracellular matrix containing bFGF after intracerebral transplantation in Parkinson's disease rat model. International Journal of Pharmaceutics, 2017, 517, 383-394.	5.2	25
998	Physical therapy and occupational therapy in Parkinson's disease. International Journal of Neuroscience, 2017, 127, 930-943.	1.6	109
999	The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor- κ B/Nuclear Transcription Factor Related to NF-E2. Antioxidants and Redox Signaling, 2017, 27, 453-471.	5.4	107
1000	Impact of autonomic dysfunctions on the quality of life in Parkinson's disease patients. Acta Neurologica Belgica, 2017, 117, 207-211.	1.1	34
1001	Parkinson's: a syndrome rather than a disease?. Journal of Neural Transmission, 2017, 124, 907-914.	2.8	168
1002	Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations. Journal of the Neurological Sciences, 2017, 372, 279-287.	0.6	25
1003	Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease. Journal of the Neurological Sciences, 2017, 373, 173-178.	0.6	93
1004	Pattern of cognitive impairment in patients with Parkinson's disease and psychosis: A critical review. Parkinsonism and Related Disorders, 2017, 37, 11-18.	2.2	28
1005	Emotional prosody of Parkinsonians following subthalamic nucleus deep brain stimulation. Journal of Neurolinguistics, 2017, 42, 23-30.	1.1	3
1006	Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal Control of Action in Dopamine-Depleted Mice. Current Biology, 2017, 27, 39-47.	3.9	81
1007	A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson's disease. International Journal of Pharmaceutics, 2017, 533, 298-314.	5.2	17
1008	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. Parkinsonism and Related Disorders, 2017, 45, 7-12.	2.2	9
1009	Palliative Care and Nonmotor Symptoms in Parkinson's Disease and Parkinsonism. International Review of Neurobiology, 2017, 134, 1239-1255.	2.0	7
1011	Understanding and Treating Pain Syndromes in Parkinson's Disease. International Review of Neurobiology, 2017, 134, 827-858.	2.0	26
1012	The Gut and Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 134, 787-809.	2.0	47

#	ARTICLE	IF	CITATIONS
1013	Impact of pain and pain subtypes on the quality of life of patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 105-109.	1.5	24
1014	Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 276-280.	1.4	25
1015	Nonmotor Symptoms in Experimental Models of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 63-89.	2.0	24
1016	The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease. <i>Journal of Medical Economics</i> , 2017, 20, 1207-1215.	2.1	22
1017	The Status of "Nonmotor" Features of the Malady in an Essay on the Shaking Palsy (1817). <i>International Review of Neurobiology</i> , 2017, 133, 3-12.	2.0	4
1018	Predictors of onset of psychosis in patients with Parkinson's disease: Who gets it early?. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 91-94.	2.2	17
1019	Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?. <i>Npj Parkinson's Disease</i> , 2017, 3, 28.	5.3	14
1020	Comparative Patient Satisfaction and Feasibility of a Pilot Parkinson's Disease Enrichment Program. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 253-260.	2.3	3
1021	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. <i>Progress in Medicinal Chemistry</i> , 2017, 56, 37-80.	10.4	17
1022	Síndromes parkinsonianos. <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-6.	0.0	0
1023	Gender differences in Parkinson's disease: A clinical perspective. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 570-584.	2.1	132
1024	Nonmotor Subtyping in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 447-478.	2.0	18
1025	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017, 8, 44-53.	1.3	10
1026	Neurobiological correlates of emotional processing in Parkinson's disease: A systematic review of experimental studies. <i>Journal of Psychosomatic Research</i> , 2017, 100, 65-76.	2.6	12
1027	Occurrence of spleen qi deficiency as defined by Chinese medicine in Parkinson disease. <i>Journal of Traditional Chinese Medical Sciences</i> , 2017, 4, 24-30.	0.2	3
1028	Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 543-551.	2.9	29
1029	Multidisciplinary Care in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 511-523.	2.0	24
1030	Sexual Dysfunctions in Parkinson's Disease: An Underrated Problem in a Much Discussed Disorder. <i>International Review of Neurobiology</i> , 2017, 134, 859-876.	2.0	35

#	ARTICLE	IF	CITATIONS
1031	Paraquat-Induced Movement Disorder in Relation to Oxidative Stress-Mediated Neurodegeneration in the Brain of <i>Drosophila melanogaster</i> . <i>Neurochemical Research</i> , 2017, 42, 3310-3320.	3.3	20
1032	Two hundred years since James Parkinson's essay on the shaking palsyâ€”Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017. <i>Movement Disorders</i> , 2017, 32, 1311-1315.	3.9	7
1033	Latent Cognitive Phenotypes in <i>De Novo</i> Parkinsonâ€™s Disease: A Person-Centered Approach. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 551-563.	1.8	8
1035	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. <i>Movement Disorders</i> , 2017, 32, 1738-1747.	3.9	43
1036	Swallowing Dysfunctions in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 1207-1238.	2.0	54
1037	Open Label Trial of the Efficacy and Safety Profile of Rikkunshito used for the Treatment of Gastrointestinal Symptoms in Patients with Parkinsonâ€™s Disease: A Pilot Study. <i>Current Therapeutic Research</i> , 2017, 87, 1-8.	1.2	4
1038	Altered neurofilament protein expression in the lateral vestibular nucleus in Parkinsonâ€™s disease. <i>Experimental Brain Research</i> , 2017, 235, 3695-3708.	1.5	22
1039	Depression and associated factors in nondemented Chinese patients with Parkinsonâ€™s disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 163, 142-148.	1.4	12
1040	Using non-invasive transcranial stimulation to improve motor and cognitive function in Parkinsonâ€™s disease: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 14840.	3.3	56
1041	Hypothesis of Ascension in Idiopathic Parkinsonâ€™s Disease. <i>Neurology International Open</i> , 2017, 01, E28-E35.	0.4	0
1042	Associations between cognitive impairment and motor dysfunction in Parkinson's disease. <i>Brain and Behavior</i> , 2017, 7, e00719.	2.2	35
1043	Colonic diverticular disease: A new risk factor for Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 61-65.	2.2	4
1044	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinsonâ€™s disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	5.3	29
1045	Nonmotor Fluctuations in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 947-971.	2.0	22
1046	Deep Brain Stimulation and Nonmotor Symptoms. <i>International Review of Neurobiology</i> , 2017, 134, 1045-1089.	2.0	20
1047	Parkinsonâ€™s Disease: Basic Pathomechanisms and a Clinical Overview. <i>Advances in Neurobiology</i> , 2017, 15, 55-92.	1.8	2
1048	The Epidemiology of Nonmotor Symptoms in Parkinson's Disease (Cohort and Other Studies). <i>International Review of Neurobiology</i> , 2017, 133, 91-110.	2.0	24
1049	Synaptic proteins in CSF relate to Parkinsonâ€™s disease stage markers. <i>Npj Parkinson's Disease</i> , 2017, 3, 7.	5.3	49

#	ARTICLE	IF	CITATIONS
1050	Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. <i>Acta Neuropathologica Communications</i> , 2017, 5, 51.	5.2	24
1051	Post translational changes to α -synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 45.	10.8	61
1052	Brain infusion of α -synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. <i>Behavioural Brain Research</i> , 2017, 333, 150-160.	2.2	27
1053	Factors associated with life satisfaction in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 64-71.	2.1	38
1054	Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis. <i>Bioorganic Chemistry</i> , 2017, 70, 17-26.	4.1	17
1055	Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 38-42.	2.2	32
1056	Alterations of the circadian system in Parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 682-692.	3.9	46
1057	Auditing the Physical Activity and Parkinson Disease Literature Using the Behavioral Epidemiologic Framework. <i>PM and R</i> , 2017, 9, 612-621.	1.6	2
1058	Selected C8 two-chain linkers enhance the adenosine A1/A2A receptor affinity and selectivity of caffeine. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 652-656.	5.5	14
1059	Perioperative management of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 301-308.	2.8	7
1060	Discussing sexuality with patients with Parkinson's disease: a survey among Dutch neurologists. <i>Journal of Neural Transmission</i> , 2017, 124, 361-368.	2.8	15
1061	The Perceive, Recall, Plan and Perform (PRPP) system for persons with Parkinson's disease: a psychometric study. <i>Scandinavian Journal of Occupational Therapy</i> , 2017, 24, 65-73.	1.7	7
1062	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017, 3, 35.	5.3	29
1063	Nonmotor Signs in Genetic Forms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 129-178.	2.0	31
1064	Glucocerebrosidase Mutations in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 411-422.	2.8	108
1065	Efficacy and safety of SQJZ herbal mixtures on nonmotor symptoms in Parkinson disease patients. <i>Medicine (United States)</i> , 2017, 96, e8824.	1.0	11
1066	Experiences of Persons With Parkinson's Disease Engaged in Group Therapeutic Singing. <i>Journal of Music Therapy</i> , 2017, 54, 405-431.	0.9	17
1067	Gait Disturbance Associated with Cholinergic Dysfunction in Early Parkinson's Disease. , 2017, 07, .		0

#	ARTICLE	IF	CITATIONS
1069	Relationship between Apolipoprotein Superfamily and Parkinson's Disease. Chinese Medical Journal, 2017, 130, 2616-2623.	2.3	13
1070	Cognitive Behavioral Group Therapy Reduces Stress and Improves the Quality of Life in Patients with Parkinson's Disease. Frontiers in Psychology, 2016, 7, 1975.	2.1	10
1071	Depression in Parkinson's Disease: The Contribution from Animal Studies. Parkinson's Disease, 2017, 2017, 1-8.	1.1	13
1072	Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 629-634.	2.8	50
1073	Hyposmia Is Associated with RBD for PD Patients with Variants of SNCA. Frontiers in Aging Neuroscience, 2017, 9, 303.	3.4	20
1074	Biological and Clinical Implications of Comorbidities in Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 394.	3.4	67
1075	Roles of Multiple Globus Pallidus Territories of Monkeys and Humans in Motivation, Cognition and Action: An Anatomical, Physiological and Pathophysiological Review. Frontiers in Neuroanatomy, 2017, 11, 30.	1.7	53
1076	Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease. Frontiers in Behavioral Neuroscience, 2017, 11, 75.	2.0	44
1077	Circadian Clock Protein Content and Daily Rhythm of Locomotor Activity Are Altered after Chronic Exposure to Lead in Rat. Frontiers in Behavioral Neuroscience, 2017, 11, 178.	2.0	7
1078	The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity. Frontiers in Cellular Neuroscience, 2017, 11, 102.	3.7	9
1079	Correlation between Dopamine Transporter Degradation and Striatocortical Network Alteration in Parkinson's Disease. Frontiers in Neurology, 2017, 8, 323.	2.4	12
1080	Increase of Reproductive Life Span Delays Age of Onset of Parkinson's Disease. Frontiers in Neurology, 2017, 8, 397.	2.4	17
1081	Localized vs. Systematic Neurodegeneration: A Paradigm Shift in Understanding Neurodegenerative Diseases. Frontiers in Systems Neuroscience, 2017, 11, 62.	2.5	9
1082	Roles of Microglia in Inflammation-Mediated Neurodegeneration: Models, Mechanisms, and Therapeutic Interventions for Parkinson's Disease. Advances in Neurotoxicology, 2017, 1, 185-209.	1.9	6
1083	Quantitative Evaluation of Chinese Herb Medicine in the Treatment of Sialorrhea and Frequent Nighttime Urination in Patients with Parkinson's Disease. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-6.	1.2	3
1084	Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-2.	1.1	12
1085	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	2.5	32
1087	Skin disorders in Parkinson's disease: potential biomarkers and risk factors. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 87-92.	1.8	45

#	ARTICLE	IF	CITATIONS
1088	Basal Ganglia Disorders. , 2017, , 137-148.		0
1089	Progressive Changes in the Retinal Structure of Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 85-92.	2.8	29
1090	Caregiver burden and its related factors in advanced Parkinsonâ€™s disease: data from the PREDICT study. Journal of Neurology, 2018, 265, 1124-1137.	3.6	52
1091	Abnormal restingâ€state functional connectivity in posterior cingulate cortex of Parkinson's disease with mild cognitive impairment and dementia. CNS Neuroscience and Therapeutics, 2018, 24, 897-905.	3.9	46
1092	Delivery systems for theranostics in neurodegenerative diseases. Nano Research, 2018, 11, 5535-5555.	10.4	29
1093	Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. NeuroImage: Clinical, 2018, 18, 456-466.	2.7	47
1094	Revealing brain mechanisms of mTOR-mediated translational regulation: Implications for chronic pain. Neurobiology of Pain (Cambridge, Mass), 2018, 4, 27-34.	2.5	14
1095	Obstructive Sleep Apnea in Parkinsonâ€™s Diseaseâ€™a Mini-Review. Current Sleep Medicine Reports, 2018, 4, 118-124.	1.4	0
1096	Detecting neurodegenerative disorders from web search signals. Npj Digital Medicine, 2018, 1, 8.	10.9	36
1097	Early fine motor impairment and behavioral dysfunction in (Thyâ€1)â€h[A30P] alphaâ€synuclein mice. Brain and Behavior, 2018, 8, e00915.	2.2	34
1098	Decreased sleep quality in Parkinsonâ€™s patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality. Neurological Research, 2018, 40, 1-6.	1.3	22
1099	Re-examining the Parkinsonian Personality hypothesis: A systematic review. Personality and Individual Differences, 2018, 130, 41-50.	2.9	9
1100	Current development of nanocarrier delivery systems for Parkinson's disease pharmacotherapy. Journal of the Taiwan Institute of Chemical Engineers, 2018, 87, 15-25.	5.3	17
1101	Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 110-116.	2.8	15
1102	Multimodal neuroimaging and behavioral assessment of Î±-synuclein polymorphism rs356219 in older adults. Neurobiology of Aging, 2018, 66, 32-39.	3.1	8
1103	Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality. American Journal of Geriatric Psychiatry, 2018, 26, 700-710.	1.2	5
1104	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist, 2018, 24, 540-559.	3.5	81
1105	Poor sleep is responsible for the impaired nocturnal blood pressure dipping in elderly hypertensive: A cross-sectional study of elderly. Clinical and Experimental Hypertension, 2018, 40, 582-588.	1.3	7

#	ARTICLE	IF	CITATIONS
1106	Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 360.	9.0	79
1107	Functional Anatomy of Basal Ganglia Circuits with the Cerebral Cortex and the Cerebellum. <i>Progress in Neurological Surgery</i> , 2018, 33, 50-61.	1.3	61
1108	Feature-based information filtering in visual working memory is impaired in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 111, 317-323.	1.6	9
1109	Variability of presynaptic nigrostriatal dopaminergic function and clinical heterogeneity in a dopa-responsive dystonia family with GCH-1 gene mutation. <i>Journal of Neurology</i> , 2018, 265, 478-485.	3.6	6
1110	The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study. <i>International Journal of Neuroscience</i> , 2018, 128, 369-375.	1.6	13
1111	Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 828-835.	1.9	81
1112	Depression and posture in patients with Parkinson's disease. <i>Gait and Posture</i> , 2018, 61, 81-85.	1.4	22
1113	LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT _{1A} Receptor Upregulation in Mice. <i>Journal of Neuroscience</i> , 2018, 38, 1611-1621.	3.6	41
1114	Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease. <i>Brain</i> , 2018, 141, 1455-1469.	7.6	106
1115	Early Life Stress, Depression And Parkinson's Disease: A New Approach. <i>Molecular Brain</i> , 2018, 11, 18.	2.6	69
1116	Interoceptive processing deficit: A behavioral marker for subtyping Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 64-69.	2.2	24
1117	Egogram characteristics in Japanese patients with Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2018, 6, 71-76.	0.4	3
1118	Increased serum levels of TNF- α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. <i>Clinical Neurology and Neurosurgery</i> , 2018, 166, 76-79.	1.4	53
1119	The Molecular, Cellular, and Systems-Level Structure of the Basal Ganglia. <i>Cognitive Science and Technology</i> , 2018, , 5-19.	0.4	1
1120	Extraction of large-scale structural covariance networks from grey matter volume for Parkinson's disease classification. <i>European Radiology</i> , 2018, 28, 3296-3305.	4.5	17
1121	Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e131-e139.	2.7	9
1122	Facial emotion recognition in Parkinson's disease: Association with age and olfaction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 274-284.	1.3	11
1123	The developing utility of zebrafish models of neurological and neuropsychiatric disorders: A critical review. <i>Experimental Neurology</i> , 2018, 299, 157-171.	4.1	188

#	ARTICLE	IF	CITATIONS
1124	Autonomic symptoms in patients with moderate and severe chronic obstructive pulmonary disease. <i>Acta Clinica Belgica</i> , 2018, 73, 182-190.	1.2	9
1125	The pathophysiological mechanisms of motivational deficits in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 138-152.	4.8	10
1126	Serotonergic neurons mediate the anxiolytic effect of L-DOPA: Neuronal correlates in the amygdala. <i>Neurobiology of Disease</i> , 2018, 110, 20-28.	4.4	11
1127	Effects of chronic aspartame consumption on MPTP-induced Parkinsonism in male and female mice. <i>Archives of Physiology and Biochemistry</i> , 2018, 124, 292-299.	2.1	8
1128	7-Fluoro-1,3-diphenylisoquinoline reverses motor and non-motor symptoms induced by MPTP in mice: Role of striatal neuroinflammation. <i>European Journal of Pharmacology</i> , 2018, 819, 129-135.	3.5	14
1129	Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. <i>International Journal of Biological Macromolecules</i> , 2018, 109, 27-35.	7.5	123
1130	Complex Dynamics in the Basal Ganglia: Health and Disease Beyond the Motor System. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 101-114.	1.8	17
1131	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018, 25, 503-511.	3.3	18
1132	Nonmotor Symptoms of Parkinson's Disease as Predictors of Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 97-99.	0.5	10
1133	Impaired long contact white matter fibers integrity is related to depression in Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 108-114.	3.9	38
1134	Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 297-308.	1.3	30
1135	Facial emotion decoding in patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2018, 128, 71-78.	1.6	12
1136	Ausência de Prejuízo no Reconhecimento de Expressões Faciais entre Indivíduos com Parkinson. <i>Psicologia: Teoria E Pesquisa</i> , 2018, 34, .	0.1	0
1137	Research on Wind & Thermal Power Joint Bidding Strategy Considering Penalties for Wind Power's Bidding Deviation. , 2018, , .		0
1138	Kinect-Based Exergames Tailored to Parkinson Patients. <i>International Journal of Computer Games Technology</i> , 2018, 2018, 1-14.	2.5	12
1139	Potential Application of Yokukansan as a Remedy for Parkinson's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-19.	1.2	9
1141	Gender and onset age related-differences of non-motor symptoms and quality of life in drug-naïve Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 124-129.	1.4	22
1142	Motor Impairment Estimates via Touchscreen Typing Dynamics Toward Parkinson's Disease Detection From Data Harvested In-the-Wild. <i>Frontiers in ICT</i> , 2018, 5, .	3.6	25

#	ARTICLE	IF	CITATIONS
1143	Assessment of Health-Related Quality of Life between People with Parkinson's Disease and Non-Parkinson's: Using Data Drawn from the ~100 for Parkinson's Smartphone-Based Prospective Study. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2538.	2.6	13
1144	Psychiatric Manifestation in Patients with Parkinson's Disease. <i>Journal of Korean Medical Science</i> , 2018, 33, e300.	2.5	58
1145	The imbalance of serotonergic circuitry impairing the crop supercontractile muscle activity and the mitochondrial morphology of PD PINK1B9 <i>Drosophila melanogaster</i> are rescued by <i>Mucuna pruriens</i> . <i>Journal of Insect Physiology</i> , 2018, 111, 32-40.	2.0	7
1146	Cognitive Impairment in Parkinson's Disease. <i>International Journal of School and Cognitive Psychology</i> , 2018, 05, .	0.2	0
1147	Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2018, 50, 79-92.	0.2	7
1148	Advances in Parkinson's Disease: 200 Years Later. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 113.	1.7	102
1149	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1081.	2.4	91
1150	Analysis of Parkinson's Disease SPECT Images Using Geometric Measures and Orthogonal Moments. , 2018, , .		0
1151	Clinical correlates of quantitative EEG in Parkinson disease. <i>Neurology</i> , 2018, 91, 871-883.	1.1	112
1152	Prevalent cerebrovascular and cardiovascular disease in people with Parkinson's disease: a meta-analysis. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1147-1154.	3.0	29
1153	Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 959-971.	2.7	22
1154	Performance of Patients with Early Parkinson Disease on an Executive and Social Cognition Battery. <i>Cognitive and Behavioral Neurology</i> , 2018, 31, 142-150.	0.9	8
1155	Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 91.	4.2	6
1156	Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. <i>Scientific Reports</i> , 2018, 8, 15715.	3.3	12
1157	Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial. <i>Trials</i> , 2018, 19, 492.	1.6	23
1158	Striatal cholinergic interneurons regulate cognitive and affective dysfunction in partially dopamine-depleted mice. <i>European Journal of Neuroscience</i> , 2018, 48, 2988-3004.	2.6	25
1159	Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders. <i>Journal of Palliative Medicine</i> , 2018, 21, 1507-1517.	1.1	18
1160	Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2018, 51, 190-206.	2.3	29

#	ARTICLE	IF	CITATIONS
1161	Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. <i>Journal of Parkinson's Disease</i> , 2018, 8, 479-493.	2.8	34
1162	The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 477-482.	1.2	5
1163	Loudness Perception of Pure Tones in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 1487-1496.	1.6	12
1164	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. <i>Biomedical Journal</i> , 2018, 41, 63-87.	3.1	122
1165	Melanopsin-mediated pupil function is impaired in Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7796.	3.3	58
1166	Frequency of non-motor symptoms in Parkinson's disease presenting to tertiary care centre in Pakistan: an observational, cross-sectional study. <i>BMJ Open</i> , 2018, 8, e019172.	1.9	18
1167	Complex networks reveal early MRI markers of Parkinson's disease. <i>Medical Image Analysis</i> , 2018, 48, 12-24.	11.6	112
1168	Touchscreen typing-pattern analysis for detecting fine motor skills decline in early-stage Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7663.	3.3	59
1169	Serum Homocysteine Level in Parkinson's Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	1.1	14
1170	Oral Health of Parkinson's Disease Patients: A Case-Control Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-8.	1.1	33
1171	Parkinson's disease-related non-motor features as risk factors for post-operative delirium in spinal surgery. <i>PLoS ONE</i> , 2018, 13, e0195749.	2.5	19
1172	Absent Audiovisual Integration Elicited by Peripheral Stimuli in Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-10.	1.1	8
1173	Clustering Parkinson's and Age-Related Voice Impairment Signal Features for Unsupervised Learning. <i>Advances in Data Science and Adaptive Analysis</i> , 2018, 10, 1840007.	0.4	10
1174	LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. <i>Journal of Biomedical Science</i> , 2018, 25, 52.	7.0	29
1175	Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 409-420.	2.8	18
1176	mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2226.	4.1	84
1177	Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials. <i>Journal of the Neurological Sciences</i> , 2018, 393, 31-38.	0.6	25
1179	Disruption of Inferior Longitudinal Fasciculus Microstructure in Parkinson's Disease: A Systematic Review of Diffusion Tensor Imaging Studies. <i>Frontiers in Neurology</i> , 2018, 9, 598.	2.4	23

#	ARTICLE	IF	CITATIONS
1180	Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 1.	3.4	259
1181	Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 112.	3.7	30
1182	A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders. <i>Frontiers in Neurology</i> , 2018, 9, 369.	2.4	48
1183	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. <i>Frontiers in Neurology</i> , 2018, 9, 500.	2.4	45
1184	Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 381.	2.8	51
1185	Noninvasive options for "wearing-off" in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. <i>Neurodegenerative Disease Management</i> , 2018, 8, 349-360.	2.2	22
1186	Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity. <i>Non-coding RNA</i> , 2018, 4, 13.	2.6	55
1187	Sensor Array for Detection of Early Stage Parkinson's Disease before Medication. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2548-2553.	3.5	25
1188	Analysis of the clinical features of early Parkinson's disease with comparatively integrated intestinal function. <i>Neurological Sciences</i> , 2018, 39, 1847-1856.	1.9	7
1189	Inhibition of microRNA-505 suppressed MPPA-induced cytotoxicity of SHSY5Y cells in an in vitro Parkinson's disease model. <i>European Journal of Pharmacology</i> , 2018, 835, 11-18.	3.5	22
1190	Constraints, Facilitators, and Stages of Behavioral Change in Physical Activity for Individuals with Parkinson's Disease. <i>American Journal of Health Education</i> , 2018, 49, 179-189.	0.6	2
1191	A new framework for conceptualizing symptoms in frontotemporal dementia: from animal models to the clinic. <i>Brain</i> , 2018, 141, 2245-2254.	7.6	19
1192	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. <i>Molecular Neurodegeneration</i> , 2018, 13, 1.	10.8	143
1193	What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis. <i>Journal of Parkinson's Disease</i> , 2018, 8, 247-258.	2.8	47
1194	Degenerative or Debilitative Neurologic Syndromes. <i>Nursing Clinics of North America</i> , 2018, 53, 447-457.	1.5	2
1195	Clinical pain and functional network topology in Parkinson's disease: a resting-state fMRI study. <i>Journal of Neural Transmission</i> , 2018, 125, 1449-1459.	2.8	10
1196	Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0202770.	2.5	35
1197	Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 855-870.	1.7	38

#	ARTICLE	IF	CITATIONS
1198	Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function. <i>Neurobiology of Disease</i> , 2018, 119, 121-135.	4.4	44
1199	Importance of Balance-Gait Disorder as a Risk Factor for Cognitive Impairment, Dementia and Related Non-Motor Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 539-552.	2.8	17
1200	Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?. <i>Cell and Tissue Research</i> , 2018, 373, 267-286.	2.9	32
1201	Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 127-132.	1.4	14
1202	Cross-cultural adaptation and psychometric evaluations of the Turkish version of Parkinson Fatigue Scale. <i>Quality of Life Research</i> , 2018, 27, 2719-2730.	3.1	5
1203	Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease. <i>Journal of Experimental Neuroscience</i> , 2018, 12, 117906951877982.	2.3	164
1204	Parkinson's Disease in Humans and in Nonhuman Primate Aging and Neurotoxin Models. , 2018, , 617-639.		1
1205	Cell Therapy for Parkinson's Disease. , 2018, , 659-672.		1
1206	NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. <i>Translational Psychiatry</i> , 2018, 8, 117.	4.8	49
1207	Non-motor Parkinson disease: new concepts and personalised management. <i>Medical Journal of Australia</i> , 2018, 208, 404-409.	1.7	77
1208	Analysis of nocturnal hypokinesia and sleep quality in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 54, 96-101.	1.5	17
1209	Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder. <i>International Journal of Neuroscience</i> , 2019, 129, 55-93.	1.6	57
1210	Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 1082-1095.	4.0	21
1211	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. <i>European Journal of Neuroscience</i> , 2019, 49, 328-338.	2.6	137
1212	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. <i>Chemical Reviews</i> , 2019, 119, 1221-1322.	47.7	360
1213	Frailty in Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2019, 9, 517-524.	2.8	21
1214	Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α -Synuclein Over-Expressing Mouse Model. <i>Frontiers in Neuroscience</i> , 2019, 13, 839.	2.8	122
1215	Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. <i>Journal of Neural Transmission</i> , 2019, 126, 1273-1280.	2.8	11

#	ARTICLE	IF	CITATIONS
1216	High-throughput 16S rRNA gene sequencing reveals that 6-hydroxydopamine affects gut microbial environment. PLoS ONE, 2019, 14, e0217194.	2.5	16
1217	Motor speech and non-motor language endophenotypes of Parkinson's disease. Expert Review of Neurotherapeutics, 2019, 19, 1191-1200.	2.8	28
1218	Orexins alleviate motor deficits via increasing firing activity of pallidal neurons in a mouse model of Parkinson's disease. American Journal of Physiology - Cell Physiology, 2019, 317, C800-C812.	4.6	16
1219	CogBeacon: A Multi-Modal Dataset and Data-Collection Platform for Modeling Cognitive Fatigue. Technologies, 2019, 7, 46.	5.1	17
1220	REM sleep without atonia and the relation with Lewy body disease. Parkinsonism and Related Disorders, 2019, 67, 90-98.	2.2	21
1221	Altered Global Synchronizations in Patients With Parkinson's Disease: A Resting-State fMRI Study. Frontiers in Aging Neuroscience, 2019, 11, 139.	3.4	21
1222	Olfactory Identification among Various Subtypes of Parkinson Disease. European Neurology, 2019, 81, 167-173.	1.4	10
1223	Altered Prefrontal Theta and Gamma Activity during an Emotional Face Processing Task in Parkinson Disease. Journal of Cognitive Neuroscience, 2019, 31, 1768-1776.	2.3	7
1224	Parkinson's progression prediction using machine learning and serum cytokines. Npj Parkinson's Disease, 2019, 5, 14.	5.3	63
1225	Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread. Brain, 2019, 142, 3072-3085.	7.6	32
1226	Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs, 2019, 33, 707-718.	5.9	36
1227	Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease. Pharmacotherapy, 2019, 39, 798-808.	2.6	27
1228	Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat. Journal of Molecular Neuroscience, 2019, 69, 298-311.	2.3	15
1229	Cellular models of alpha-synuclein toxicity and aggregation. Journal of Neurochemistry, 2019, 150, 566-576.	3.9	75
1230	The Central Autonomic Network and Regulation of Bladder Function. Frontiers in Neuroscience, 2019, 13, 535.	2.8	40
1231	The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review. Frontiers in Aging Neuroscience, 2019, 11, 130.	3.4	76
1232	Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor. Brain Research, 2019, 1725, 146460.	2.2	13
1233	Editorial: Movement Disorders and Sleep – Underlying Mechanisms, Clinical Aspects and Treatment. Frontiers in Neurology, 2019, 10, 1034.	2.4	2

#	ARTICLE	IF	CITATIONS
1234	Non-motor correlates of wrist-worn wearable sensor use in Parkinson's disease: an exploratory analysis. <i>Npj Parkinson's Disease</i> , 2019, 5, 22.	5.3	21
1235	Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson's Disease-Associated Pathology. <i>Cells</i> , 2019, 8, 1359.	4.1	5
1236	Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1114.	2.4	39
1237	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. <i>BMC Neuroscience</i> , 2019, 20, 55.	1.9	9
1238	Serotonin 5-HT ₄ Receptor Agonists Improve Facilitation of Contextual Fear Extinction in An MPTP-Induced Mouse Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5340.	4.1	17
1239	Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders. <i>Advances in Pharmacology</i> , 2019, 86, 273-305.	2.0	30
1240	Why would Parkinson's disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 100, 129-165.	6.1	17
1241	Quantitative Susceptibility Mapping and Resting State Network Analyses in Parkinsonian Phenotypes—A Systematic Review of the Literature. <i>Frontiers in Neural Circuits</i> , 2019, 13, 50.	2.8	5
1242	Probiotics for Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4121.	4.1	97
1243	Genetic risk of Parkinson disease and progression. <i>Neurology: Genetics</i> , 2019, 5, e348.	1.9	109
1244	Parkinson's disease and changes in the appreciation of art: A comparison of aesthetic and formal evaluations of paintings between PD patients and healthy controls. <i>Brain and Cognition</i> , 2019, 136, 103597.	1.8	12
1245	Visual Temporal Perception in Parkinson's Disease Analyzed Using a Computer-Generated Graphical Tool. , 2019, , .		1
1246	Voltage-Gated Sodium Channels Are Involved in Cognitive Impairments in Parkinson's Disease- like Rats. <i>Neuroscience</i> , 2019, 418, 231-243.	2.3	13
1247	Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions. <i>Parkinson's Disease</i> , 2019, 2019, 1-12.	1.1	13
1248	The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	1.1	5
1249	PDVocal. , 2019, , .		33
1250	Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2019, 119, 607-613.	1.1	20
1251	Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 45, 273-283.	1.3	54

#	ARTICLE	IF	CITATIONS
1252	Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations. <i>Molecular Brain</i> , 2019, 12, 5.	2.6	19
1253	Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 13.	1.4	7
1254	Chronotherapies for Parkinson's disease. <i>Progress in Neurobiology</i> , 2019, 174, 16-27.	5.7	37
1255	Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 901-915.	3.3	29
1256	Preserved caudate function in young-onset patients with Parkinson's disease: a dual-tracer PET imaging study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641985140.	3.5	7
1257	Asymptomatic Hearing Impairment Frequently Occurs in Early-Onset Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2019, 12, 84-90.	1.3	15
1258	Differential impairment of short working and spatial memories in a rat model of progressive Parkinson's disease onset: A focus on the prodromal stage. <i>Brain Research Bulletin</i> , 2019, 150, 307-316.	3.0	14
1259	Disease stage dependency of motor and non-motor fluctuations in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 841-851.	2.8	9
1260	Î±-Synuclein pathology in Parkinson's disease and related Î±-synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	2.1	177
1261	Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype. <i>Journal of Neuroinflammation</i> , 2019, 16, 120.	7.2	20
1262	Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. <i>Drugs</i> , 2019, 79, 1037-1051.	10.9	48
1263	The burden of care and the understanding of disease in Parkinson's disease. <i>PLoS ONE</i> , 2019, 14, e0217581.	2.5	26
1264	The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners. <i>Quality of Life Research</i> , 2019, 28, 2705-2716.	3.1	11
1265	The role of Optical Coherence Tomography in Parkinsonism: A critical review. <i>Journal of the Neurological Sciences</i> , 2019, 403, 67-74.	0.6	22
1266	Effects of inspiratory muscle training on respiratory muscle strength, lung function, functional capacity and cardiac autonomic function in Parkinson's disease: Randomized controlled clinical trial protocol. <i>Physiotherapy Research International</i> , 2019, 24, e1777.	1.5	7
1267	White Matter Tract Alterations in Drug-Naïve Parkinson's Disease Patients With Excessive Daytime Sleepiness. <i>Frontiers in Neurology</i> , 2019, 10, 378.	2.4	9
1268	Monoaminergic regulation of nociceptive circuitry in a Parkinson's disease rat model. <i>Experimental Neurology</i> , 2019, 318, 12-21.	4.1	17
1269	Dopamine Released from TiO ₂ Semicrystalline Lattice Implants Attenuates Motor Symptoms in Rats Treated with 6-Hydroxydopamine. <i>ACS Omega</i> , 2019, 4, 7953-7962.	3.5	4

#	ARTICLE	IF	CITATIONS
1270	Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience and Biobehavioral Reviews, 2019, 102, 56-84.	6.1	159
1271	Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson's disease with cognitive decline. Acta Neuropathologica Communications, 2019, 7, 61.	5.2	47
1272	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. American Journal of Geriatric Psychiatry, 2019, 27, 998-1018.	1.2	82
1273	The clinical correlates of suicidal ideation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 54-59.	2.2	18
1274	ALDH1A1 regulates postsynaptic $\frac{1}{4}$ opioid receptor expression in dorsal striatal projection neurons and mitigates dyskinesia through transsynaptic retinoic acid signaling. Scientific Reports, 2019, 9, 3602.	3.3	20
1275	Symptom dimensions in people affected by long-term neurological conditions: a factor analysis of a patient-centred palliative care outcome symptom scale. Scientific Reports, 2019, 9, 4972.	3.3	8
1276	Transient Daily Episodes of Vision Loss Due to Parkinson's Disease. Neuro-Ophthalmology, 2019, 43, 260-264.	1.0	0
1277	Emerging therapies in Parkinson disease " repurposed drugs and new approaches. Nature Reviews Neurology, 2019, 15, 204-223.	10.1	189
1278	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. American Journal of Geriatric Psychiatry, 2019, 27, 712-719.	1.2	13
1279	Multi-year whole-blood transcriptome data for the study of onset and progression of Parkinson's Disease. Scientific Data, 2019, 6, 20.	5.3	8
1280	Catastrophizing mediates the relationship between non-motor symptoms and quality of life in Parkinson's disease. Disability and Health Journal, 2019, 12, 673-678.	2.8	11
1281	Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders. Neuroscience and Biobehavioral Reviews, 2019, 102, 95-105.	6.1	64
1282	Systematic Review of Behavioral Therapy to Improve Swallowing Functions of Patients With Parkinson's Disease. Gastroenterology Nursing, 2019, 42, 65-78.	0.4	12
1283	Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia. BMC Neuroscience, 2019, 20, 5.	1.9	27
1284	Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety. Journal of Neuroscience, 2019, 39, 2735-2744.	3.6	36
1285	Physical activity mediates the association between striatal dopamine transporter availability and cognition in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 62, 68-72.	2.2	23
1286	Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease. Neurochemistry International, 2019, 126, 1-10.	3.8	62
1287	Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1288	Long-Term Partnerships in Lewy Body Dementias. , 2019, , .		1
1289	Identification of Early-stage Parkinson's Disease Utilizing Graph Theory and Machine Learning. , 2019, , .		1
1290	Role of Autophagy in Parkinson's Disease. Current Medicinal Chemistry, 2019, 26, 3702-3718.	2.4	91
1291	Implementation of an integrated multidisciplinary Movement Disorders Clinic: applying a knowledge translation framework to improve multidisciplinary care. Disability and Rehabilitation, 2019, 43, 1-13.	1.8	6
1292	Enfermedad de Parkinson y parkinsonismos. Medicine, 2019, 12, 4273-4284.	0.0	1
1293	Differential Temporal Perception Abilities in Parkinson's Disease Patients Based on Timing Magnitude. Scientific Reports, 2019, 9, 19638.	3.3	13
1294	Multilingual Validation of the First French Version of Munich Dysphagia Test in Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. Frontiers in Neurology, 2019, 10, 1180.	2.4	3
1295	A Luminescent Lanthanide-Functionalized Metal-Organic Framework as a Highly Selective and Sensitive Chemical Sensor for Dopamine. ChemistrySelect, 2019, 4, 12573-12579.	1.5	7
1296	Early Parkinson's Disease Detection via Touchscreen Typing Analysis using Convolutional Neural Networks. , 2019, 2019, 3535-3538.		14
1297	The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife. Frontiers in Neurology, 2019, 10, 1328.	2.4	16
1298	Functional outcomes after total joint arthroplasty are related to the severity of Parkinson's disease: a mid-term follow-up. Journal of Orthopaedic Surgery and Research, 2019, 14, 396.	2.3	11
1299	Pain in Parkinson's disease: new concepts in pathogenesis and treatment. Current Opinion in Neurology, 2019, 32, 579-588.	3.6	61
1300	Î±-Synuclein oligomers mediate the aberrant form of spike-induced calcium release from IP3 receptor. Scientific Reports, 2019, 9, 15977.	3.3	8
1301	Use of radiomic features and support vector machine to distinguish Parkinson's disease cases from normal controls. Annals of Translational Medicine, 2019, 7, 773-773.	1.7	49
1302	Non-motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life. European Journal of Neurology, 2019, 26, 400-406.	3.3	60
1303	The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol. Contemporary Clinical Trials Communications, 2019, 13, 100308.	1.1	6
1304	Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson's Disease. ACS Chemical Neuroscience, 2019, 10, 973-990.	3.5	39
1305	TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model. Brain, Behavior, and Immunity, 2019, 76, 236-247.	4.1	96

#	ARTICLE	IF	CITATIONS
1306	Genetically engineered animal models of Parkinson's disease: From worm to rodent. <i>European Journal of Neuroscience</i> , 2019, 49, 533-560.	2.6	27
1307	The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States. <i>Movement Disorders</i> , 2019, 34, 236-245.	3.9	56
1308	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	3.6	28
1309	Multidisciplinary care for people with Parkinson's disease: the new kids on the block!. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 145-157.	2.8	45
1310	Home monitoring of sleep with a temporary-tattoo EEG, EOG and EMG electrode array: a feasibility study. <i>Journal of Neural Engineering</i> , 2019, 16, 026024.	3.5	71
1311	Mental health in Parkinson's disease after receiving aquatic therapy: a clinical trial. <i>Acta Neurologica Belgica</i> , 2019, 119, 193-200.	1.1	22
1312	Neurocognitive Assessment in Virtual Reality Through Behavioral Response Analysis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 1899-1910.	6.3	6
1313	Inferring sleep stage from local field potentials recorded in the subthalamic nucleus of Parkinson's patients. <i>Journal of Sleep Research</i> , 2019, 28, e12806.	3.2	20
1314	<i>Tribolium castaneum</i> as a whole-animal screening system for the detection and characterization of neuroprotective substances. <i>Archives of Insect Biochemistry and Physiology</i> , 2019, 100, e21532.	1.5	6
1315	Sardinian Folk Dance for Individuals with Parkinson's Disease: A Randomized Controlled Pilot Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2019, 25, 305-316.	2.1	58
1316	Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery. <i>Cell Transplantation</i> , 2019, 28, 269-285.	2.5	30
1317	Lateral parietal cortex in the generation of behavior: Implications for apathy. <i>Progress in Neurobiology</i> , 2019, 175, 20-34.	5.7	33
1318	Parkinson's pain is more aching and interfering with social life in Caucasians compared to Indians. <i>International Journal of Neuroscience</i> , 2019, 129, 746-753.	1.6	1
1319	Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism. <i>Brain Research Bulletin</i> , 2019, 146, 213-223.	3.0	10
1320	The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 335-352.	6.1	42
1321	Marmosets in Neurologic Disease Research. , 2019, , 415-435.		1
1322	Dopamine D1 receptor activation improves adult hippocampal neurogenesis and exerts anxiolytic and antidepressant-like effect via activation of Wnt/ β -catenin pathways in rat model of Parkinson's disease. <i>Neurochemistry International</i> , 2019, 122, 170-186.	3.8	44
1323	Phosphorylated α -synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 57-63.	2.2	18

#	ARTICLE	IF	CITATIONS
1324	Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and Nrf2 regulation. <i>Neurobiology of Disease</i> , 2019, 121, 252-262.	4.4	67
1326	Pathology and Cell-Based Therapy of Parkinson's Disease. , 2019, , 31-38.		0
1327	The Diagnosis of Parkinson's Disease: Current Clinical Practice and Future Trends. , 2019, , 103-116.		1
1328	Comparison of structural connectivity in Parkinson's disease with depressive symptoms versus non-depressed: a diffusion MRI connectometry study. <i>International Psychogeriatrics</i> , 2019, 31, 5-12.	1.0	19
1329	Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 241-254.	2.1	8
1330	A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging. <i>NeuroImage</i> , 2019, 190, 69-78.	4.2	66
1331	The Effects of Respiratory Muscle Training on Phonatory Measures in Individuals with Parkinson's Disease. <i>Journal of Voice</i> , 2020, 34, 894-902.	1.5	23
1332	Care Burden and Mental Ill Health in Spouses of People With Parkinson Disease Dementia and Lewy Body Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 3-14.	2.3	26
1333	Management of Dysphagia in Patients with Parkinson's Disease and Related Disorders. <i>Internal Medicine</i> , 2020, 59, 7-14.	0.7	67
1334	Association Between Subglottic Pressure and Pulmonary Function in Individuals With Parkinson's Disease. <i>Journal of Voice</i> , 2020, 34, 732-737.	1.5	5
1335	Nocturnal blood pressure changes in Parkinson's disease: correlation with autonomic dysfunction and vitamin D levels. <i>Acta Neurologica Belgica</i> , 2020, 120, 915-920.	1.1	11
1336	Deep learning based diagnosis of Parkinson's disease using convolutional neural network. <i>Multimedia Tools and Applications</i> , 2020, 79, 15467-15479.	3.9	137
1337	Patient perceptions of visual, vestibular, and oculomotor deficits in people with Parkinson's disease. <i>Physiotherapy Theory and Practice</i> , 2020, 36, 701-708.	1.3	11
1338	Early-onset Parkinsonian behaviors in female Pink1 ^{-/-} rats. <i>Behavioural Brain Research</i> , 2020, 377, 112175.	2.2	24
1339	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 483-498.	6.1	30
1340	Direct cost of Parkinson's disease in a health system with high judicialization: evidence from Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 587-593.	1.4	4
1341	The Interaction Between Neuroinflammation and β^2 -Amyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	4.0	23
1342	Open questions on the nature of Parkinson's disease: from triggers to spreading pathology. <i>Journal of Medical Genetics</i> , 2020, 57, 73-81.	3.2	17

#	ARTICLE	IF	CITATIONS
1343	What Predicts Hospital Admissions in Community-Dwelling People With Parkinsonism?. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 103-108.	2.3	0
1344	Inflammasome and α -synuclein in Parkinson's disease: A cross-sectional study. Journal of Neuroimmunology, 2020, 338, 577089.	2.3	76
1345	Natural sources, dopaminergic and non-dopaminergic agents for therapeutic assessment of Parkinsonism in rats model. PharmaNutrition, 2020, 11, 100171.	1.7	6
1346	Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia. Neurobiology of Disease, 2020, 134, 104646.	4.4	20
1347	Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson's disease. Drug Discovery Today, 2020, 25, 392-405.	6.4	7
1348	Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study. Journal of the Neurological Sciences, 2020, 412, 116641.	0.6	4
1349	Madopar combined with acupuncture improves motor and non-motor symptoms in Parkinson's disease patients: A multicenter randomized controlled trial. European Journal of Integrative Medicine, 2020, 34, 101049.	1.7	15
1350	Dance and Parkinson's: A review and exploration of the role of cognitive representations of action. Neuroscience and Biobehavioral Reviews, 2020, 109, 16-28.	6.1	30
1351	Therapeutic implications of circadian clocks in neurodegenerative diseases. Journal of Neuroscience Research, 2020, 98, 1095-1113.	2.9	10
1352	CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE. Retina, 2020, 40, 1483-1491.	1.7	42
1353	The role of virtual reality on outcomes in rehabilitation of Parkinson's disease: meta-analysis and systematic review in 1031 participants. Neurological Sciences, 2020, 41, 529-536.	1.9	53
1354	Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A1 and/or A2A receptor antagonists. Bioorganic Chemistry, 2020, 94, 103459.	4.1	6
1355	Symptom burden among individuals with Parkinson disease. Neurology: Clinical Practice, 2020, 10, 65-72.	1.6	29
1356	Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 403-412.	6.4	49
1357	The Impact of Mind-Body Exercises on Motor Function, Depressive Symptoms, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 31.	2.6	55
1358	Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia. Frontiers in Aging Neuroscience, 2020, 12, 580199.	3.4	17
1359	A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease. Frontiers in Neuroinformatics, 2020, 14, 34.	2.5	7
1360	The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. Cells, 2020, 9, 2277.	4.1	98

#	ARTICLE	IF	CITATIONS
1361	Predictive Intelligence in Medicine. Lecture Notes in Computer Science, 2020, , .	1.3	2
1362	Subthalamic deep brain stimulation improves sleep and excessive sweating in Parkinson's disease. Npj Parkinson's Disease, 2020, 6, 29.	5.3	8
1363	Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson's disease. Journal of the Neurological Sciences, 2020, 418, 117157.	0.6	10
1364	Visual self-motion cues are impaired yet overweighted during visual-vestibular integration in Parkinson's disease. Brain Communications, 2020, 2, fcaa035.	3.3	31
1365	A comprehensive review of the diagnosis and treatment of Parkinson's disease dysphagia and aspiration. Expert Review of Gastroenterology and Hepatology, 2020, 14, 411-424.	3.0	21
1366	An Overview of Acoustic-Based Interventions to Improve Motor Symptoms in Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 243.	3.4	9
1367	Prioritising target non-pharmacological interventions for research in Parkinson's disease: achieving consensus from key stakeholders. Research Involvement and Engagement, 2020, 6, 35.	2.9	5
1368	Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease. Frontiers in Neurology, 2020, 11, 689.	2.4	4
1369	Ferroptosis Mechanisms Involved in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 8765.	4.1	204
1370	When Friendship Turns Sour: Effective Communication Between Mitochondria and Intracellular Organelles in Parkinson's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 607392.	3.7	12
1371	Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms. Frontiers in Neuroscience, 2020, 14, 602697.	2.8	77
1372	Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery, 2020, 8, 100070.	4.5	8
1373	Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches. Expert Review of Neurotherapeutics, 2020, 20, 1047-1064.	2.8	11
1374	Price and income elasticities of electricity in China: Estimation and policy implications. Regional Science Policy and Practice, 2020, , .	1.6	3
1375	The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. International Review of Neurobiology, 2020, 154, 345-391.	2.0	20
1376	Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain, 2020, 143, 2502-2518.	7.6	46
1377	Subcortical atrophy correlates with the perturbational complexity index in patients with disorders of consciousness. Brain Stimulation, 2020, 13, 1426-1435.	1.6	20
1378	Effects of Balance Training on Nonmotor Symptoms in Individuals With Parkinson Disease. Topics in Geriatric Rehabilitation, 2020, 36, 187-193.	0.4	1

#	ARTICLE	IF	CITATIONS
1379	Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson's disease. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 196, 111302.	5.0	18
1380	The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study. <i>Future Microbiology</i> , 2020, 15, 1393-1404.	2.0	4
1381	The Role of Electrochemical Skin Conductance as a Screening Test of Cardiovascular Autonomic Neuropathy in Patients with Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7751.	2.6	9
1382	Functional Recovery in Parkinson's Disease: Current State and Future Perspective. <i>Journal of Clinical Medicine</i> , 2020, 9, 3413.	2.4	3
1383	Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?. <i>Neuropsychologia</i> , 2020, 147, 107593.	1.6	17
1384	Analysis of Auditory Function of Patients With Parkinson Disease Based on Mandarin. <i>Topics in Geriatric Rehabilitation</i> , 2020, 36, 194-201.	0.4	1
1385	Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson's Disease Diagnostics. <i>Analytical Chemistry</i> , 2020, 92, 13647-13651.	6.5	47
1386	Mining genetic and transcriptomic data using machine learning approaches in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 24.	5.3	25
1387	Management of a Parkinson's disease patient with severe COVID-19 pneumonia. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232094942.	2.5	7
1388	Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6520.	4.1	8
1389	Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. <i>MSystems</i> , 2020, 5, .	3.8	161
1390	Smartwatch-based Activity Analysis During Sleep for Early Parkinson's Disease Detection. , 2020, 2020, 4326-4329.		7
1391	The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1301-1314.	2.8	5
1392	PET Imaging of Mitochondrial Function in the Living Brain. , 0, , .		1
1393	Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2265-2278.	1.8	6
1394	The potential role of 2D-speckle tracking echocardiography for detecting left ventricular systolic dysfunction in patients with Parkinson's disease: a case control study. <i>Acta Cardiologica</i> , 2021, 76, 979-986.	0.9	2
1395	Screening Patients with Early Stage Parkinson's Disease Using a Machine Learning Technique: Measuring the Amount of Iron in the Basal Ganglia. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 8732.	2.5	0
1396	AAV-Mediated GALC Gene Therapy Rescues Alpha-Synucleinopathy in the Spinal Cord of a Leukodystrophic Lysosomal Storage Disease Mouse Model. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 619712.	3.7	5

#	ARTICLE	IF	CITATIONS
1397	Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: The Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117172.	0.6	17
1398	Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder. <i>MSystems</i> , 2020, 5, .	3.8	63
1399	Hypomania, Depression, Euthymia: New Evidence in Parkinson's Disease. <i>Behavioural Neurology</i> , 2020, 2020, 1-8.	2.1	5
1400	Has resveratrol a potential for mucopolysaccharidosis treatment?. <i>European Journal of Pharmacology</i> , 2020, 888, 173534.	3.5	14
1401	Management and Treatment of Patients With Major Depressive Disorder and Chronic Diseases: A Multidisciplinary Approach. <i>Frontiers in Psychology</i> , 2020, 11, 542444.	2.1	19
1402	Energy Metabolism Decline in the Aging Brain—Pathogenesis of Neurodegenerative Disorders. <i>Metabolites</i> , 2020, 10, 450.	2.9	55
1403	Probiotics Treatment Improves Hippocampal Dependent Cognition in a Rodent Model of Parkinson's Disease. <i>Microorganisms</i> , 2020, 8, 1661.	3.6	30
1404	The correlation of helios and neuropilin-1 frequencies with parkinson disease severity. <i>Clinical Neurology and Neurosurgery</i> , 2020, 192, 105833.	1.4	4
1405	Î±-Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode. <i>Nanomaterials</i> , 2020, 10, 832.	4.1	31
1406	The Associations Between Physical Activity, Sleep, and Mood with Pain in People with Parkinson's Disease: An Observational Cross-Sectional Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1161-1170.	2.8	11
1407	Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint. <i>Frontiers in Neurology</i> , 2020, 11, 556.	2.4	28
1408	REM Sleep Behavior Disorder in Parkinson's Disease: Effects on Cognitive, Psychiatric, and Functional outcomes. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 894-905.	1.8	13
1409	Nonmotor Symptoms Affect Sleep Quality in Early-Stage Parkinson's Disease Patients With or Without Cognitive Dysfunction. <i>Frontiers in Neurology</i> , 2020, 11, 292.	2.4	9
1410	Alterations of the Motor and Olfactory Functions Related to Parkinson's Disease in Transgenic Mice With a VMAT2-Deficiency in Dopaminergic Neurons. <i>Frontiers in Neuroscience</i> , 2020, 14, 356.	2.8	8
1411	The effect of chronic neuropeptide-S treatment on non-motor parameters in experimental model of Parkinson's disease. <i>International Journal of Neuroscience</i> , 2021, 131, 765-774.	1.6	12
1412	Crocins Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway. <i>Molecular Neurobiology</i> , 2020, 57, 3158-3170.	4.0	32
1413	Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. <i>Advanced Functional Materials</i> , 2020, 30, 2003054.	14.9	83
1414	Management of psychiatric disorders in Parkinson's disease. <i>Neurotherapeutics</i> , 2020, 17, 1511-1524.	4.4	19

#	ARTICLE	IF	CITATIONS
1415	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020, 139, 1001-1024.	7.7	46
1416	Association Between Stroke and Parkinson's Disease: a Meta-analysis. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1169-1176.	2.3	22
1417	Potential Roles of Exosomes in Parkinson's Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 86.	3.7	84
1418	Impairments in face discrimination and emotion recognition are related to aging and cognitive dysfunctions in Parkinson's disease with dementia. <i>Scientific Reports</i> , 2020, 10, 4367.	3.3	16
1419	Palliative care and Parkinson's disease: outpatient needs and models of care over the disease trajectory. <i>Annals of Palliative Medicine</i> , 2020, 9, S44-S51.	1.2	24
1420	Orexin in Respiratory and Autonomic Regulation, Health and Diseases. , 2020, 10, 345-363.		13
1421	What are the considerations for anti-hypertensive treatment in patients with Parkinson's disease?. Expert Opinion on Pharmacotherapy, 2020, 21, 1127-1130.	1.8	7
1422	Autonomic failure in Parkinson's disease is associated with striatal dopamine deficiencies. <i>Journal of Neurology</i> , 2020, 267, 1922-1930.	3.6	28
1423	MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax. <i>Metabolic Brain Disease</i> , 2020, 35, 627-635.	2.9	32
1424	The relationship between cognitive decline and motor dysfunction in Parkinson's disease: A focused mini-review on cognitive-locomotor dual-task interference. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 372-377.	0.4	3
1425	Reduction of Peripheral Blood iNKT and $\gamma\delta$ T Cells in Patients With Parkinson's Disease: An Observational Study. <i>Frontiers in Immunology</i> , 2020, 11, 1329.	4.8	14
1426	Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph®. <i>Journal of Clinical Movement Disorders</i> , 2020, 7, 5.	2.2	17
1427	Focal alteration of the intraretinal layers in neurodegenerative disorders. <i>Annals of Eye Science</i> , 2020, 5, 8-8.	2.1	3
1428	The neuropathological basis of anxiety in Parkinson's disease. <i>Medical Hypotheses</i> , 2020, 144, 110048.	1.5	10
1429	Neurocognitive and psychiatric disorders-related axonal degeneration in Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2020, 98, 936-949.	2.9	15
1430	Association of orthostatic hypotension with Parkinson's disease: a meta-analysis. <i>Neurological Sciences</i> , 2020, 41, 1419-1426.	1.9	11
1431	Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice. <i>Behavioural Brain Research</i> , 2020, 383, 112539.	2.2	14
1432	Dopaminergic afferents from midbrain to dorsolateral bed nucleus of stria terminalis inhibit release and expression of corticotropin-releasing hormone in paraventricular nucleus. <i>Journal of Neurochemistry</i> , 2020, 154, 218-234.	3.9	6

#	ARTICLE	IF	CITATIONS
1433	Sicca Symptoms in Parkinson's Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life. <i>Parkinson's Disease</i> , 2020, 2020, 1-7.	1.1	7
1434	Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. <i>Sleep Medicine Reviews</i> , 2020, 51, 101281.	8.5	76
1435	Does REM sleep behavior disorder change in the progression of Parkinson's disease?. <i>Sleep Medicine</i> , 2020, 68, 190-198.	1.6	29
1436	Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?. <i>Frontiers in Neuroscience</i> , 2020, 14, 25.	2.8	30
1437	Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. <i>European Journal of Neurology</i> , 2020, 27, 779-786.	3.3	20
1438	Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104818.	4.4	15
1439	Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 959-968.	3.9	34
1440	Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 471-482.	6.1	45
1441	A Method for the Prediction of Clinical Outcome Using Diffusion Magnetic Resonance Imaging: Application on Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 647.	2.4	7
1442	Relationship of Movement Disorders Society's Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 279-283.	1.5	4
1443	The Rehabiano™ Detecting, Measuring, and Analyzing Action Tremor Using Strain Gauges. <i>Sensors</i> , 2020, 20, 663.	3.8	7
1444	RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease. <i>Molecular Pharmacology</i> , 2020, 98, 730-738.	2.3	10
1445	Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 307-317.	3.7	22
1446	Contrast sensitivity impairment in drug-naïve Parkinson's disease patients associates with early cognitive decline. <i>Neurological Sciences</i> , 2020, 41, 1837-1842.	1.9	3
1447	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	5.3	32
1448	Small fiber neuropathy in unexpected clinical settings: a review. <i>Muscle and Nerve</i> , 2020, 62, 167-175.	2.2	14
1449	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020, 10, 677-691.	2.8	15
1450	Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease. <i>Environmental Sciences: Processes and Impacts</i> , 2020, 22, 543-554.	3.5	29

#	ARTICLE	IF	CITATIONS
1451	The mutual interplay of gut microbiota, diet and human disease. <i>FEBS Journal</i> , 2020, 287, 833-855.	4.7	176
1452	Parkinson's disease: From bench to bedside. <i>Revue Neurologique</i> , 2020, 176, 543-559.	1.5	46
1453	The function of lysosomes and their role in Parkinson's disease. <i>Neuroforum</i> , 2020, 26, 43-51.	0.3	2
1454	Cerebellar Contribution to Motor and Non-motor Functions in Parkinson's Disease: A Meta-Analysis of fMRI Findings. <i>Frontiers in Neurology</i> , 2020, 11, 127.	2.4	30
1455	Simultaneously Improved Pulmonary and Cardiovascular Autonomic Function and Short-Term Functional Outcomes in Patients with Parkinson's Disease after Respiratory Muscle Training. <i>Journal of Clinical Medicine</i> , 2020, 9, 316.	2.4	8
1456	Effect of Olfactory and Gustatory Dysfunction and Motor Symptoms on Body Weight in Patients with Parkinson's Disease. <i>Brain Sciences</i> , 2020, 10, 218.	2.3	13
1457	Saliva in Health and Disease. , 2020, , .		15
1458	The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. <i>Purinergic Signalling</i> , 2020, 16, 167-174.	2.2	139
1459	Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study. <i>Neurological Sciences</i> , 2020, 41, 2867-2873.	1.9	6
1460	Illness Representations and Coping Strategies in Patients Treated with Deep Brain Stimulation for Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1186.	2.4	5
1461	Safety Study of Combination Treatment: Deep Brain Stimulation and Transcranial Magnetic Stimulation. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 123.	2.0	11
1462	A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116833.	0.6	9
1463	Update on the Management of Parkinson's Disease for General Neurologists. <i>Parkinson's Disease</i> , 2020, 1-13.	1.1	33
1464	Deconstructing Neurogenesis, Transplantation and Genome-Editing as Neural Repair Strategies in Brain Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 116.	3.7	5
1465	High-Resolution Motor State Detection in Parkinson's Disease Using Convolutional Neural Networks. <i>Scientific Reports</i> , 2020, 10, 5860.	3.3	39
1466	Prevalence and predictors of mood disturbances in idiopathic REM sleep behaviour disorder. <i>Journal of Sleep Research</i> , 2021, 30, e13040.	3.2	10
1467	Self-emotion perception in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 2376-2387.	2.6	23
1468	Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?. <i>Neurotoxicity Research</i> , 2021, 39, 504-532.	2.7	1

#	ARTICLE	IF	CITATIONS
1469	Brain Network Analysis by Stable and Unstable EEG Components. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 1080-1092.	6.3	5
1470	Translation, Adaptation and Validation of the European Portuguese Version of the NMS-Quest for Parkinson's Disease. Acta Medica Portuguesa, 2021, 34, 6.	0.4	2
1471	Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease. Medicinal Research Reviews, 2021, 41, 785-802.	10.5	42
1472	Increased rapid eye movement density in Chinese patients with Parkinson's disease and RBD. Neurological Sciences, 2021, 42, 961-968.	1.9	4
1473	Current and emerging therapeutic targets for Parkinson's disease. Metabolic Brain Disease, 2021, 36, 13-27.	2.9	10
1474	Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinson's Disease. Cell Biochemistry and Biophysics, 2021, 79, 25-36.	1.8	3
1475	Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis. Annals of Clinical and Translational Neurology, 2021, 8, 126-137.	3.7	8
1476	Leptin levels in patients with Parkinson's disease: A systematic review and meta-analysis. Clinical Nutrition ESPEN, 2021, 41, 104-109.	1.2	8
1477	Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 82, 16-23.	2.2	32
1478	Antinociceptive effects of rotigotine-loaded microspheres and its synergistic interactions with analgesics in inflammatory pain in rats. European Journal of Pharmacology, 2021, 891, 173693.	3.5	12
1479	Molecular landscape of long noncoding RNAs in brain disorders. Molecular Psychiatry, 2021, 26, 1060-1074.	7.9	33
1480	Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand?. Psychology and Psychotherapy: Theory, Research and Practice, 2021, 94, 760-797.	2.5	23
1481	Investigation of non-motor symptoms, balance, muscle strength, and functional mobility in patients with parkinson's disease. Somatosensory & Motor Research, 2021, 38, 20-26.	0.9	4
1482	Rho-kinase inhibition by fasudil modulates pre-synaptic vesicle dynamics. Journal of Neurochemistry, 2021, 157, 1052-1068.	3.9	1
1483	Associations Between Fluctuations in Daytime Sleepiness and Motor and Non-Motor Symptoms in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 44-50.	1.5	7
1484	Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease. Movement Disorders, 2021, 36, 570-580.	3.9	32
1485	Changes of olfactory tract in Parkinson's disease: a DTI tractography study. Neuroradiology, 2021, 63, 235-242.	2.2	13
1486	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. Acta Neurologica Scandinavica, 2021, 143, 3-12.	2.1	49

#	ARTICLE	IF	CITATIONS
1487	Suicidal ideation in early-onset Parkinson's disease. Journal of Neurology, 2021, 268, 1876-1884.	3.6	8
1488	A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	7
1489	Prevention of Parkinson's disease-related sudden death. Clinics, 2021, 76, e3266.	1.5	2
1490	Exosomes in Parkinson disease. Journal of Neurochemistry, 2021, 157, 413-428.	3.9	62
1491	Neurogenic Erectile Dysfunction. Where Do We Stand?. Medicines (Basel, Switzerland), 2021, 8, 3.	1.4	7
1492	Depression in Parkinson's disease. , 2021, , 83-97.		0
1493	An Innovative Personalised Management Program for Older Adults with Parkinson's Disease: New Concepts and Future Directions. Journal of Personalized Medicine, 2021, 11, 43.	2.5	3
1494	Neurophysiological investigation of auditory intensity dependence in patients with Parkinson's disease. Journal of Neural Transmission, 2021, 128, 345-356.	2.8	4
1495	Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 183, 175-196.	1.8	4
1497	The correlation of non-motor symptoms and sleep on balance in Parkinson's disease patients with normal cognition and mild cognitive impairment. Irish Journal of Medical Science, 2021, 190, 1577-1584.	1.5	4
1500	Hypothalamic α -synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.8	2
1501	Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson's Disease. Touch Reviews in Neurology, 2021, 17, 36.	0.2	1
1502	The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532098599.	2.7	7
1503	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 211-222.	1.8	3
1504	Why use pre-differentiated cells to address complex multi-factorial neurodegenerative diseases?. Neural Regeneration Research, 2021, 16, 1413.	3.0	1
1505	Drooling and dysphagia in Parkinson's disease. International Review of Movement Disorders, 2021, , 147-178.	0.1	0
1508	Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson's Disease. Biomedicines, 2021, 9, 167.	3.2	21
1509	Visual evoked potential abnormalities in dementia with Lewy bodies. Neurophysiologie Clinique, 2021, 51, 425-431.	2.2	6

#	ARTICLE	IF	CITATIONS
1510	Gastrointestinal dysfunction in movement disorders. <i>Neurological Sciences</i> , 2021, 42, 1355-1365.	1.9	11
1511	Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. <i>JAMA Ophthalmology</i> , 2021, 139, 182.	2.5	84
1512	Blood Pressure Patterns in Patients with Parkinson's Disease: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 129.	2.5	10
1514	Art therapy for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 148-154.	2.2	22
1515	The Feasibility and Positive Effects of Wuqinxi Exercise on the Cognitive and Motor Functions of Patients with Parkinson's Disease: A Pilot Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-7.	1.2	7
1516	Identifying Peripapillary Radial Capillary Plexus Alterations in Parkinson's Disease Using OCT Angiography. <i>Ophthalmology Retina</i> , 2022, 6, 29-36.	2.4	14
1517	Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. <i>Brain Research Bulletin</i> , 2021, 168, 63-73.	3.0	18
1518	VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease. <i>Aging Cell</i> , 2021, 20, e13347.	6.7	21
1519	Setting up a clozapine service for Parkinson's psychosis. <i>BJ Psych Advances</i> , 2022, 28, 90-98.	0.7	4
1520	Sociability-based fitness approach in Parkinson's disease: Comparison with conventional rehabilitation. <i>European Journal of Neurology</i> , 2021, 28, 1893-1900.	3.3	3
1521	Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing. <i>Npj Parkinson's Disease</i> , 2021, 7, 28.	5.3	11
1522	Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside. <i>Frontiers in Neuroscience</i> , 2021, 15, 654238.	2.8	10
1523	Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson's Disease. <i>Brain Sciences</i> , 2021, 11, 361.	2.3	9
1524	The Importance of <i>Drosophila melanogaster</i> Research to Uncover Cellular Pathways Underlying Parkinson's Disease. <i>Cells</i> , 2021, 10, 579.	4.1	17
1525	Association of Gyrification Pattern, White Matter Changes, and Phenotypic Profile in Patients With Parkinson Disease. <i>Neurology</i> , 2021, 96, e2387-e2394.	1.1	11
1526	Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment. <i>Frontiers in Neurology</i> , 2021, 12, 640137.	2.4	8
1527	Divergent pallidal pathways underlying distinct Parkinsonian behavioral deficits. <i>Nature Neuroscience</i> , 2021, 24, 504-515.	14.8	44
1528	How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review. <i>Npj Parkinson's Disease</i> , 2021, 7, 25.	5.3	56

#	ARTICLE	IF	CITATIONS
1529	Morphological analysis of subcortical structures for assessment of cognitive dysfunction in Parkinson's disease using multi-atlas based segmentation. <i>Cognitive Neurodynamics</i> , 2021, 15, 835-845.	4.0	4
1530	Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. <i>Biomolecules</i> , 2021, 11, 612.	4.0	80
1531	Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and IGF-1 in rat model of the Parkinson's disease. <i>Journal of Chemical Neuroanatomy</i> , 2021, 113, 101921.	2.1	4
1532	Association of Stress-Health Factors among Parkinson's Disease Patient/Caregiving-Partner Dyads. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 12-18.	0.5	2
1533	People with Parkinson's Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 715-724.	2.8	33
1534	A Qualitative Exploration of Factors Influencing Physical Activity Behaviour for Individuals with Parkinson's Disease Using the Social Ecological Model. <i>European Journal of Adapted Physical Activity</i> , 2021, 14, 4-4.	0.5	1
1535	Mitochondrial CHCHD2: Disease-Associated Mutations, Physiological Functions, and Current Animal Models. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 660843.	3.4	28
1536	Low Sustainment of High-Dose Oral Medication Regimens for Advanced Parkinson's Disease in Medicare Beneficiaries. <i>Journal of Parkinson's Disease</i> , 2021, 11, 675-684.	2.8	4
1537	Laterality in Parkinson's disease: A neuropsychological review. <i>Applied Neuropsychology Adult</i> , 2023, 30, 126-140.	1.2	6
1538	Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes in <i>Drosophila</i> . <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	9
1539	REM Sleep Behavior Disorder in Parkinson's Disease: Change in Cognitive, Psychiatric, and Functional Outcomes from Baseline to 16-47-Month Follow-Up. <i>Archives of Clinical Neuropsychology</i> , 2021, .	0.5	2
1540	Odor Recognition Memory in Parkinson's Disease: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 625171.	3.4	5
1541	Motor Cortex Stimulation Reversed Hypernociception, Increased Serotonin in Raphe Neurons, and Caused Inhibition of Spinal Astrocytes in a Parkinson's Disease Rat Model. <i>Cells</i> , 2021, 10, 1158.	4.1	5
1542	Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 24.	1.4	5
1543	Golf as a Physical Activity to Potentially Reduce the Risk of Falls in Older Adults with Parkinson's Disease. <i>Sports</i> , 2021, 9, 72.	1.7	8
1544	Subthalamic nucleus deep brain stimulation and impulsivity in Parkinson's disease: a descriptive review. <i>Acta Neurologica Belgica</i> , 2021, 121, 837-847.	1.1	4
1545	Apathy and Anhedonia: Clinical and Neurophysiological Assessment of a Romanian Cohort. <i>Brain Sciences</i> , 2021, 11, 729.	2.3	1
1546	C ₃₆ and C ₃₅ E (E=N and B) Fullerenes as Potential Nanovehicles for Neuroprotective Drugs: A Comparative DFT Study. <i>ChemistrySelect</i> , 2021, 6, 4844-4858.	1.5	5

#	ARTICLE	IF	CITATIONS
1547	Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study. <i>Neurological Sciences</i> , 2022, 43, 357-364.	1.9	14
1548	Parkinson's Disease and Gene Therapy. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 60-63.	0.2	0
1549	Complicity of α -synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease. <i>Archives of Pharmacal Research</i> , 2021, 44, 564-573.	6.3	1
1550	Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson's Disease Models. <i>Biomolecules and Therapeutics</i> , 2022, 30, 90-97.	2.4	6
1551	The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play. <i>British Journal of Pharmacology</i> , 2022, 179, 1478-1495.	5.4	34
1552	Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP. <i>Neurobiology of Disease</i> , 2021, 153, 105313.	4.4	8
1553	Opicapone for the treatment of Parkinson's disease: a review. <i>International Journal of Neuroscience</i> , 2023, 133, 532-543.	1.6	3
1554	Treating Parkinson's disease by astrocyte reprogramming: Progress and challenges. <i>Science Advances</i> , 2021, 7, .	10.3	27
1555	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
1556	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. <i>Frontiers in Neurology</i> , 2021, 12, 678373.	2.4	14
1557	Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study. <i>Brain and Behavior</i> , 2021, 11, e2228.	2.2	8
1558	Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 661973.	2.0	13
1559	Irritable bowel syndrome and subsequent risk of Parkinson's disease: a nationwide population-based matched-cohort study. <i>Journal of Neurology</i> , 2022, 269, 1404-1412.	3.6	9
1560	Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats. <i>Brain Research</i> , 2021, 1762, 147442.	2.2	5
1561	Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1010.	1.8	5
1562	Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 274-279.	2.3	16
1563	Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited. <i>Neuroscience</i> , 2021, 467, 201-217.	2.3	12
1564	The Effects of Yoga on Patients with Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. <i>Behavioural Neurology</i> , 2021, 2021, 1-11.	2.1	19

#	ARTICLE	IF	CITATIONS
1565	Directed Brain Connectivity Identifies Widespread Functional Network Abnormalities in Parkinson's Disease. Cerebral Cortex, 2022, 32, 593-607.	2.9	8
1566	Does Personality Change Follow Deep Brain Stimulation in Parkinson's Disease Patients?. Frontiers in Psychology, 2021, 12, 643277.	2.1	5
1567	Abnormal Vision-Based Displacement Perception in Parkinson's Disease. Frontiers in Neuroscience, 2021, 15, 676469.	2.8	1
1568	Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease. Toxins, 2021, 13, 505.	3.4	9
1569	Chronic Respiratory Diseases and Neurodegenerative Disorders: A Primer for the Practicing Clinician. Medical Principles and Practice, 2021, 30, 501-507.	2.4	5
1570	Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review Protocol. Biomedicine Hub, 2021, 6, 64-68.	1.2	1
1571	Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease. Scientific Reports, 2021, 11, 15268.	3.3	15
1572	Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. Journal of Parkinson's Disease, 2021, 11, 1091-1115.	2.8	10
1573	The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease. Life, 2021, 11, 804.	2.4	10
1574	Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-((2,4-dichlorophenyl)methyl)-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach. Chemistry and Biodiversity, 2021, 18, e2100204.	2.1	2
1575	Qualitative Deficits in Verbal Fluency in Parkinson's Disease with Mild Cognitive Impairment: A Clinical and Neuroimaging Study. Journal of Parkinson's Disease, 2021, 11, 2005-2016.	2.8	2
1576	Predicting Wearing-Off of Parkinson's Disease Patients Using a Wrist-Worn Fitness Tracker and a Smartphone: A Case Study. Applied Sciences (Switzerland), 2021, 11, 7354.	2.5	7
1577	TEAR FILM EVALUATION IN CASES OF PARKINSON'S DISEASE. , 2021, , 22-24.		0
1578	Nonmotor symptoms and quality of life in Parkinson's disease with different motor subtypes. Zeitschrift Fur Gerontologie Und Geriatrie, 2022, 55, 496-501.	1.8	4
1579	Respiratory Disorders in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 993-1010.	2.8	9
1580	The Trajectory of Motor Deterioration to Death in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 670567.	2.4	4
1582	Association between β 2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis. Medicina (Lithuania), 2021, 57, 1006.	2.0	10
1583	Measuring anxiety in Lewy Body Disease – which scale to choose?. Clinical Parkinsonism & Related Disorders, 2021, 5, 100110.	0.9	0

#	ARTICLE	IF	CITATIONS
1584	Does Quantitative Electroencephalography Refine Preoperative Cognitive Assessment in Parkinsonâ€™s Disease Patients Treated with Deep Brain Stimulation? A Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 1-8.	1.5	0
1585	Psychometric features of brief pain inventory for Parkinsonâ€™s disease during medication states. Disability and Rehabilitation, 2021, , 1-6.	1.8	0
1586	The contribution of cognitive behavioural factors to social anxiety in Parkinsonâ€™s disease. Behavioural and Cognitive Psychotherapy, 2022, 50, 57-73.	1.2	1
1587	Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys. Cerebral Cortex, 2022, 32, 1804-1822.	2.9	8
1588	Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 753210.	3.4	8
1589	Application of AI for Analysis of Parkinsonâ€™s Disease. International Journal of Soft Computing and Engineering, 2021, 11, 33-39.	0.8	1
1590	Is there a special relationship between complex I activity and nigral neuronal loss in Parkinsonâ€™s disease? A critical reappraisal. Brain Research, 2021, 1767, 147434.	2.2	25
1591	Editorial Comment: Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 1057-1060.	1.5	0
1592	Interactions between interoception and perspective-taking: Current state of research and future directions. Neuroscience and Biobehavioral Reviews, 2021, 130, 252-262.	6.1	15
1593	Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. International Journal of Pharmaceutics: X, 2021, 3, 100087.	1.6	19
1594	Investigating cognitive neuroscience concepts using connectomic DBS. , 2022, , 483-504.		0
1595	Effect of Modified Wumei Wan on Non-Motor Symptoms of Parkinsonâ€™s Disease. Traditional Chinese Medicine, 2021, 10, 193-199.	0.2	0
1596	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
1597	Tau in the Pathophysiology of Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2021, 71, 2179-2191.	2.3	47
1598	Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinsonâ€™s disease. , 2021, 1, .		10
1602	The Hypocretin System and Sleepiness in Parkinsonâ€™s Disease. , 2011, , 347-356.		1
1603	Rotenone as Preclinical Model Compound in Parkinson Disease. , 2014, , 995-1012.		3
1604	Motor and Perceptual Timing in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2014, 829, 265-290.	1.6	40

#	ARTICLE	IF	CITATIONS
1605	Targeted Toxicants to Dopaminergic Neuronal Cell Death. <i>Methods in Molecular Biology</i> , 2015, 1254, 239-252.	0.9	7
1606	Dopamine Replacement Therapy in Parkinson's Disease: Past, Present and Future. , 2009, , 1-26.		1
1607	Sleep and Quality of Life in Parkinson's Disease. , 2008, , 175-185.		4
1610	Non-motor Symptoms in Parkinson's Disease. , 2020, , 109-118.		1
1611	Effects of Physical Activity on Walking in Individuals with Parkinson's Disease. , 2017, , 177-193.		1
1612	Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.		6
1614	Nonmotor Symptoms in Amyotrophic Lateral Sclerosis: A Systematic Review. <i>International Review of Neurobiology</i> , 2017, 134, 1409-1441.	2.0	37
1615	CHAPTER 1. Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets. <i>RSC Drug Discovery Series</i> , 2013, , 3-25.	0.3	1
1616	Immune-associated biomarkers for early diagnosis of Parkinson's disease based on hematological lncRNA-mRNA co-expression. <i>Bioscience Reports</i> , 2020, 40, .	2.4	11
1617	Sleep Supports Memory and Learning: Implications for Clinical Practice in Speech-Language Pathology. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 577-585.	1.8	10
1618	Systematic Audiological Assessment of Auditory Functioning in Patients With Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2019, 62, 4564-4577.	1.6	10
1619	Machine learning and deep learning for clinical data and PET/SPECT imaging in Parkinson's disease: a review. <i>IET Image Processing</i> , 2020, 14, 4013-4026.	2.5	21
1620	Positron emission tomography in Parkinson's disease: insights into impulsivity. <i>International Review of Psychiatry</i> , 2017, 29, 618-627.	2.8	4
1621	A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 937-945.	1.8	7
1627	Feasibility, appropriateness, meaningfulness and effectiveness of nursing interventions on the well-being of people with Parkinson's disease and their caregivers living in the community: a mixed-methods systematic review protocol. <i>JBHI Database of Systematic Reviews and Implementation Reports</i> , 2015, 13, 14-29.	1.7	4
1628	Effects of Simulated Horseback Riding on Balance, Postural Sway, and Quality of Life in Older Adults With Parkinson's Disease. <i>Adapted Physical Activity Quarterly</i> , 2019, 36, 413-430.	0.8	8
1629	Parkinson Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 896-918.	0.8	34
1630	The role of dance therapy in the rehabilitation of Parkinson disease patients. <i>Balneo Research Journal</i> , 2019, 10, 300-304.	0.4	2

#	ARTICLE	IF	CITATIONS
1631	C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α -Synuclein in a Yeast Model of Parkinson's Disease. PLoS Genetics, 2016, 12, e1006098.	3.5	49
1632	Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine. PLoS ONE, 2010, 5, e9260.	2.5	57
1633	Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms. PLoS ONE, 2010, 5, e12728.	2.5	355
1634	The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study. PLoS ONE, 2012, 7, e40166.	2.5	33
1635	Malnutrition in a Sample of Community-Dwelling People with Parkinson's Disease. PLoS ONE, 2013, 8, e53290.	2.5	62
1636	Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic Function. PLoS ONE, 2013, 8, e60378.	2.5	72
1637	Cognitive Dysfunction Precedes the Onset of Motor Symptoms in the MitoPark Mouse Model of Parkinson's Disease. PLoS ONE, 2013, 8, e71341.	2.5	47
1638	The Relationship between Thermoregulation and REM Sleep Behaviour Disorder in Parkinson's Disease. PLoS ONE, 2013, 8, e72661.	2.5	54
1639	Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs. PLoS ONE, 2013, 8, e80705.	2.5	157
1640	Abnormal Pulmonary Function and Respiratory Muscle Strength Findings in Chinese Patients with Parkinson's Disease and Multiple System Atrophy—Comparison with Normal Elderly. PLoS ONE, 2014, 9, e116123.	2.5	51
1641	Neural Substrates of Motor and Non-Motor Symptoms in Parkinson's Disease: A Resting fMRI Study. PLoS ONE, 2015, 10, e0125455.	2.5	20
1642	Identifying the Basal Ganglia Network Model Markers for Medication-Induced Impulsivity in Parkinson's Disease Patients. PLoS ONE, 2015, 10, e0127542.	2.5	20
1643	Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia. PLoS ONE, 2017, 12, e0175797.	2.5	12
1644	An fMRI study into emotional processing in Parkinson's disease: Does increased medial prefrontal activation compensate for striatal dysfunction?. PLoS ONE, 2017, 12, e0177085.	2.5	29
1645	Sensorimotor adaptation of voice fundamental frequency in Parkinson's disease. PLoS ONE, 2018, 13, e0191839.	2.5	61
1646	Increased risk of overactive bladder in patients with idiopathic Parkinson's disease: Insight from a nationwide population-based cohort study. PLoS ONE, 2018, 13, e0193783.	2.5	7
1647	Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies. , 2015, 6, 499.		14
1648	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?. , 2014, 5, 63-75.		33

#	ARTICLE	IF	CITATIONS
1649	NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2009, .	1.2	5
1650	The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 40-45.	1.2	2
1651	Validation of the Korean Version of the Scale for Outcomes in Parkinsonâ€™s Disease-Autonomic. Journal of Movement Disorders, 2017, 10, 29-34.	1.3	32
1652	Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinsonâ€™s Disease. Journal of Movement Disorders, 2018, 11, 30-34.	1.3	18
1653	Oro-Pharyngeal Dysphagia in Parkinsonâ€™s Disease and Related Movement Disorders. Journal of Movement Disorders, 2019, 12, 152-160.	1.3	41
1654	The Non-Motor Symptom Profile of Progressive Supranuclear Palsy. Journal of Movement Disorders, 2020, 13, 118-126.	1.3	15
1655	Emerging Concepts of Motor Reserve in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2020, 13, 171-184.	1.3	30
1656	Parkinsonâ€™s Disease: Etiology, Neuropathology, and Pathogenesis. , 0, , 3-26.		140
1657	The Differential Diagnosis of Parkinsonâ€™s Disease. , 0, , 109-128.		20
1658	Instrumentos de avaliaÃ§Ã£o clÃnica para disfagia orofarÃngea na doenÃa de Parkinson: revisÃ£o sistemÃtica. Audiology: Communication Research, 2017, 22, .	0.1	4
1661	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinsonâ€™s disease: a Complete Review. , 2017, 1, 001-026.		8
1662	Redressing the Balance in Parkinsonâ€™s Disease Management with a Greater Focus on Non-motor Symptoms and Care-giver Health. European Neurological Review, 2009, 4, 31.	0.5	3
1663	Non-motor Symptoms in Parkinsonâ€™s Disease. European Neurological Review, 2012, 7, 35.	0.5	3
1664	SNCA overexpression disturbs hippocampal gene expression trajectories in midlife. Aging, 2018, 10, 4024-4041.	3.1	10
1665	Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice. Aging, 2019, 11, 5008-5034.	3.1	22
1666	Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinsonâ€™s disease through AKT/mTOR pathway. Aging, 2020, 12, 9515-9533.	3.1	35
1667	MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Oncotarget, 2017, 8, 15-28.	1.8	52
1668	Differentiated cells derived from fetal neural stem cells improve motor deficits in a rat model of Parkinson's disease. Translational Neuroscience and Clinics, 2015, 1, 75-85.	0.1	1

#	ARTICLE	IF	CITATIONS
1669	Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinsonâ€™s disease. <i>Acta Neurobiologiae Experimentalis</i> , 2017, 77, 106-112.	0.7	14
1670	Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders. <i>Current Neuropharmacology</i> , 2017, 15, 800-814.	2.9	28
1671	Computer-aided Drug Design Applied to Parkinson Targets. <i>Current Neuropharmacology</i> , 2018, 16, 865-880.	2.9	17
1672	In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinsonâ€™s Disease. <i>Current Neuropharmacology</i> , 2018, 16, 786-848.	2.9	18
1673	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. <i>Current Neuropharmacology</i> , 2019, 17, 563-579.	2.9	48
1674	Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2019, 19, 57-66.	1.1	10
1675	Motor and Non-Motor Features of Parkinsonâ€™s Disease â€“ A Review of Clinical and Experimental Studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 439-449.	1.4	60
1676	Psychopharmacology for Patients with Parkinsonâ€™s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center. <i>Current Psychopharmacology</i> , 2019, 8, 41-54.	0.3	3
1677	Web-Based Telemonitoring and Delivery of Caregiver Support for Patients With Parkinson Disease After Deep Brain Stimulation: Protocol. <i>JMIR Research Protocols</i> , 2015, 4, e30.	1.0	9
1678	Catechol-o-methyltransferase inhibitor tolcapone improves learning and memory in naïve but not in haloperidol challenged rats. <i>Iranian Journal of Basic Medical Sciences</i> , 2019, 22, 695-702.	1.0	2
1679	Machine Learning and Similarity Network Approaches to Support Automatic Classification of Parkinsonâ€™s Diseases Using Accelerometer-based Gait Analysis. , 2019, , .		31
1680	Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. <i>Dialogues in Clinical Neuroscience</i> , 2016, 18, 99-107.	3.7	15
1681	Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. <i>Behavioural Neurology</i> , 2013, 27, 479-93.	2.1	52
1682	Side of onset in Parkinson's disease and alterations in religiosity: novel behavioral phenotypes. <i>Behavioural Neurology</i> , 2011, 24, 133-41.	2.1	7
1683	Functional neuroanatomy and behavioural correlates of the basal ganglia: evidence from lesion studies. <i>Behavioural Neurology</i> , 2013, 26, 219-23.	2.1	16
1684	Serum Uric Acid Levels and Non-Motor Symptoms in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1003-1010.	2.8	17
1685	Specialist rehabilitation for people with Parkinsonâ€™s disease in the community: a randomised controlled trial. <i>Health Services and Delivery Research</i> , 2014, 2, 1-376.	1.4	9
1686	Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Psychiatrists, and Psychiatrists. <i>Journal of Korean Medical Science</i> , 2020, 35, e230.	2.5	8

#	ARTICLE	IF	CITATIONS
1687	Effect of Cognitive Disability and Ambulation Status on Functioning in Moderate-to-Advanced Parkinson Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1360.	2.4	11
1688	Urodynamic analysis and treatment of male Parkinson's disease patients with voiding dysfunction. <i>Chinese Medical Journal</i> , 2014, 127, 878-881.	2.3	1
1689	Parkinsonâ€™s Disease, the Inflammatory Pathway and Anti-Inflammatory Drugs: An Overview. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2010, 10, 49-58.	0.0	3
1690	Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy. <i>Neural Regeneration Research</i> , 2017, 12, 549.	3.0	160
1691	Locus coeruleus-norepinephrine: basic functions and insights into Parkinsonâ€™s disease. <i>Neural Regeneration Research</i> , 2020, 15, 1006.	3.0	53
1692	Prevalence of non-motor symptoms in Parkinson's disease and its impact on quality of life in tertiary care center in India. <i>Annals of Indian Academy of Neurology</i> , 2020, 23, 270.	0.5	7
1693	Rehabilitation in Parkinsonâ€™s disease: Current status and future directions. <i>Annals of Movement Disorders</i> , 2020, 3, 79.	0.3	4
1694	Sweating and other thermoregulatory abnormalities in Parkinsonâ€™s disease: A review. <i>Annals of Movement Disorders</i> , 2019, 2, 39.	0.3	5
1695	Non-motor symptoms of Parkinsonâ€™s disease: its prevalence across various stages and its correlation with the severity of the disease and quality of life. <i>Annals of Movement Disorders</i> , 2019, 2, 102.	0.3	3
1696	Sleep Disturbance in Parkinsonâ€™s Disease Varies with Age of Onset and Family History. <i>Advances in Parkinson S Disease</i> , 2016, 05, 103-117.	0.2	1
1697	Tear Osmolarity, Break-up Time and Schirmerâ€™s Scores in Parkinsonâ€™s Disease. <i>Türk Oftalmoloji Dergisi</i> , 2015, 45, 142-145.	0.9	16
1698	Fabrication of Chitosan-gold Nanocomposites Combined with Optical Fiber as SERS Substrates to Detect Dopamine Molecules. <i>Bulletin of the Korean Chemical Society</i> , 2014, 35, 25-29.	1.9	19
1699	Parkinsonâ€™s Disease Patient Rehabilitation Using Gaming Platforms: Lessons Learnt. <i>International Journal of Biomedical Engineering and Science</i> , 2015, 2, 1-12.	1.0	8
1700	Total Knee Arthroplasty and Parkinson Disease: Enhancing Outcomes and Avoiding Complications. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2010, 18, 687-694.	2.5	37
1701	Mathematical Models: Interactions Between Serotonin and Dopamine in Parkinsonâ€™s Disease. , 0, , .		3
1702	The Evaluation Of Quality Of Life Of Relatives Caring For Patients With Parkinsonâ€™s Disease. <i>Dicle Medical Journal</i> , 2018, 45, 201-208.	0.6	2
1703	Sudden unexpected death in Parkinson's disease (SUDPAR): a review of publications since the decade of the brain. <i>Clinics</i> , 2017, 72, 649-651.	1.5	41
1704	Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinsonâ€™s disease. <i>PeerJ</i> , 2018, 6, e5539.	2.0	14

#	ARTICLE	IF	CITATIONS
1705	A Case study of Soyangin patient with early-stage Parkinson's disease diagnosed as Upper wasting-thirst pattern. Journal of Sasang Constitutional Medicine, 2015, 27, 178-188.	0.1	3
1706	Analyze The Effect of Dual Task Hand Activities In Parkinsons Patients. IOSR Journal of Nursing and Health Science, 2014, 3, 57-66.	0.1	2
1707	Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinsonâ€™s disease. Journal of Neurosurgery, 2020, , 1-8.	1.6	5
1708	Lower calcium levels in hair of Parkinsonâ€™s disease patients are associated with presence of sleeping disturbances. Nutritional Neuroscience, 2021, , 1-11.	3.1	0
1709	The Impact of Sex on the Neurocognitive Functions of Patients with Parkinsonâ€™s Disease. Brain Sciences, 2021, 11, 1331.	2.3	4
1710	Parkinson's disease: the nutrition perspective. Proceedings of the Nutrition Society, 2022, 81, 12-26.	1.0	9
1711	Exploring the benefits and barriers to Nordic walking in people with Parkinson's disease: a feasibility study. British Journal of Neuroscience Nursing, 2021, 17, 193-202.	0.2	1
1712	The subjective experience of family caregivers of people living with Parkinsonâ€™s disease: a meta-ethnography of qualitative literature. Aging Clinical and Experimental Research, 2022, 34, 959-970.	2.9	5
1713	Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review. Frontiers in Neurology, 2021, 12, 722892.	2.4	4
1714	Decreased frontotemporal connectivity in patients with parkinsonâ€™s disease experiencing face pareidolia. Npj Parkinson's Disease, 2021, 7, 90.	5.3	9
1715	Predicting Parkinsonâ€™s: Using Neural Networks to Evaluate the Genetic Risk Factors Behind the Disease. Journal of Student Research, 2021, 10, .	0.1	0
1716	The LC-NE system as a potential target for neuromodulation to ameliorate non-motor symptoms in Parkinson's disease. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102901.	2.8	5
1717	Dynamic Network Connectivity Reveals Markers of Response to Deep Brain Stimulation in Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2021, 15, 729677.	2.0	10
1718	Off Time Independently Affects Quality of Life in Advanced Parkinsonâ€™s Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinsonâ€™s Disease (JAQPAD) Study. Parkinson's Disease, 2021, 2021, 1-9.	1.1	3
1720	Nonmotor Problems in Parkinson Disease. , 2007, , 193-204.		1
1723	9.1 Exploring the Myths about Parkinsonâ€™s Disease. , 2009, , 421-433.		0
1726	Applications of fMRI to Neurodegenerative Disease. , 2011, , 639-670.		0
1727	Assessing Non-Motor Symptoms: An Overview of Scales and Questionnaires. , 2011, , 27-35.		0

#	ARTICLE	IF	CITATIONS
1729	Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia. Revista Medica De Chile, 2011, 139, 1032-1038.	0.2	0
1730	CFS Biomarkers in Parkinson's Disease. , 0, , .		0
1731	Developing an MRI-Based Biomarker for Early Diagnosis of Parkinson's Disease. , 0, , .		1
1732	Non-motor signs and symptoms in Parkinson's disease. Health, 2012, 04, 1133-1137.	0.3	0
1735	Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson's disease. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2012, .	1.2	2
1736	Parkinson's disease and body mass index: too much or too little?. Arquivos De Neuro-Psiquiatria, 2012, 70, 837-838.	0.8	0
1737	Basal ganglia disorders. , 2013, , 601-630.		5
1738	The Twin Hypotheses. Lecture Notes in Computer Science, 2013, , 430-463.	1.3	2
1740	Disease modification. , 2013, , 358-372.		0
1741	Sleep dysfunction. , 2013, , 120-143.		0
1742	Dopaminergic Neurons in Parkinson's Disease. , 2014, , 753-788.		5
1743	Yokukansan Ameliorates Psychiatric Problems in Parkinson's Disease. Juntendo Medical Journal, 2014, 60, 529-535.	0.1	0
1744	Correlation of the Neuropsychological Screening Battery (NSB) and Neuroanatomy for the Parkinson's Disease with Mild Cognitive Impairment by Using the Analysis of Cerebral Cortex Thickness in the Brain MRI. Journal of the Korean Society of Radiology, 2014, 8, 163-170.	0.0	0
1745	Correlation between the Seoul Neuropsychological Screening Battery of the Parkinson's Disease Patient with Mild Cognitive Impairment and Change of the Cerebral Ventricle Volume in the Brain MRI. Journal of the Korean Society of Radiology, 2014, 8, 231-240.	0.0	0
1746	Applications of fMRI to Neurodegenerative Disease. , 2015, , 465-504.		0
1747	Pain in Parkinson Patients. , 2015, , 209-219.		0
1751	Rhythmic Dopamine: New Emerging Role of The Pleasure Molecule. Neurotransmitter (Houston, Tex), 0, , .	1.2	0
1752	Sleep in Neurodegenerative Diseases. , 2015, , 271-283.		3

#	ARTICLE	IF	CITATIONS
1753	Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 183-205.	0.4	0
1754	Facial Emotion Recognition and Discrimination Deficit in Idiopathic Parkinson Patients. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2015, 21, 16-21.	0.3	1
1755	NEUROCOGNITIVE AND PSYCHOPHYSIOLOGICAL AND STUDY OF PATIENTS OF PARKINSONISM & PARKINSONâ€™S DISEASE IN CENTRAL INDIA. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 10374-10382.	0.1	0
1757	The Causes of Constipation. , 2016, , 53-74.		0
1758	Motivational Deficits in Parkinsonâ€™s Disease: Role of the Dopaminergic System and Deep-Brain Stimulation of the Subthalamic Nucleus. Innovations in Cognitive Neuroscience, 2016, , 363-388.	0.3	0
1759	Continuous Apomorphine Infusion in Patients with Advanced Parkinsonâ€™s Disease with Varying Degrees of Functional Impairment. Journal of Behavioral and Brain Science, 2016, 06, 393-403.	0.5	0
1760	Contribution of Musculoskeletal Disorders to Chronic Lumbago in Parkinsonâ€™s Disease. Advances in Parkinson S Disease, 2016, 05, 61-66.	0.2	1
1761	Translational Science of Psychosis in Parkinsons Disease. Clinical Depression, 2017, 01, .	0.1	0
1763	The Non-motor Parkinsonâ€™s Disease. , 2017, , 117-127.		0
1764	Enrichment of a Kinect-based Physiotherapy and Assessment Platform for Parkinsonâ€™s disease Patients. Advances in Image and Video Processing, 2017, 5, .	0.0	0
1765	Depression and other nonmotor manifestations of Parkinsonâ€™s disease. Klinicheskaia Meditsina, 2017, 95, 419-424.	0.1	2
1767	Treatment strategies in advanced Parkinson's disease: Review of the literature. Cumhuriyet Medical Journal, 2017, 39, 509-517.	0.1	0
1768	Male Sexual Disorders in Patients with Parkinson Disease: Treatment with Natural Remedies. Advances in Tissue Engineering & Regenerative Medicine Open Access, 2017, 3, .	0.1	1
1769	Central Pain in Parkinsonâ€™s Disease: A Case Report. Case Reports in Clinical Medicine, 2018, 07, 297-305.	0.2	0
1770	A Neuro-computational Model of Pallidal vs. Subthalamic Deep Brain Stimulation Effect on Synchronization at Tremor Frequency in Parkinsonâ€™s Disease. Springer Series in Cognitive and Neural Systems, 2019, , 3-12.	0.1	1
1771	Non-motor Symptoms of Parkinsonâ€™s Diseaseâ€”Considerations for Subclinical and Atypical Seizures. US Neurology, 2019, 15, 91.	0.2	0
1772	Psychiatric morbidity, cognitive dysfunction and quality of life in drug-naïve patients with Parkinson's disease: A comparative study. Industrial Psychiatry, 2019, 28, 13.	0.8	2
1774	Frequency of Comorbid Musculoskeletal Problems in Patients with Parkinsonâ€™s Disease: What and When?. Neuroscience and Medicine, 2019, 10, 331-338.	0.2	0

#	ARTICLE	IF	CITATIONS
1775	IN VIVO STUDY OF THE ACTION MECHANISM OF THE RAPITALAM PHARMACEUTICAL SUBSTANCE. Kuban Scientific Medical Bulletin, 2019, 26, 18-27.	0.4	0
1778	Parkinsonism and Related Disorders. , 0, , .		0
1779	Transcranial brain sonography for Parkinsonian syndromes. Journal of Neurosurgical Sciences, 2019, 63, 441-449.	0.6	2
1781	Parkinsonism and other extrapyramidal diseases. , 2020, , 5946-5956.		0
1782	Research Progress on Acupuncture Treatment of Motor and Nonmotor Symptoms in Parkinson's Disease. Traditional Chinese Medicine, 2020, 09, 136-144.	0.2	1
1783	Salivary Biomarkers in Neurologic Diseases. , 2020, , 121-152.		0
1786	Classical Model of 6-Hydroxydopamine-Induced Parkinsonism in Rats Is Characterized by Unilateral Lesion of Brain Mesolimbic System. Neurochemical Journal, 2020, 14, 303-309.	0.5	0
1787	Basal Ganglia Local Field Potentials as a Potential Biomarker for Sleep Disturbance in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 765203.	2.4	13
1788	Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1 ^{-/-} rat model of Parkinson disease. Behavioural Brain Research, 2022, 418, 113642.	2.2	13
1789	Nursing, Psychological Intervention and Self-Management after Deep Brain Stimulation in Parkinson's Disease. Journal of Behavioral and Brain Science, 2020, 10, 517-530.	0.5	1
1790	Template-Oriented Multi-task Sparse Low-Rank Learning for Parkinson's Diseases Diagnosis. Lecture Notes in Computer Science, 2020, , 178-187.	1.3	2
1791	Recent Advances in Nanocarrier-Based Brain-Targeted Drug Delivery for Effective Treatment of Central Nervous System Disorders. , 2020, , 187-203.		0
1793	Decision-Making and Impulse-Control Disorders in Parkinson's Disease. Neurological Sciences and Neurophysiology, 2020, 37, 11-17.	0.3	0
1794	Facial emotion recognition in Parkinson's disease: methodological, clinical, and pathophysiological factors. , 2020, , 91-106.		0
1795	Non-motor symptoms in cervical dystonia: A concept in evolution. Annals of Indian Academy of Neurology, 2020, 23, 428.	0.5	2
1796	Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology, and therapy. , 2020, , 139-155.		0
1797	Störungen der Basalganglienfunktion. , 2020, , 179-203.		0
1798	Sleep disturbances in Parkinson's disease. , 2020, , 139-155.		0

#	ARTICLE	IF	CITATIONS
1799	Neurodegenerative disorders in older people. , 2020, , 601-611.		0
1800	A Glance into Regional Parkinsonâ€™s Disease Characteristics: What Differs from Northwest to Southeast of Turkey?. Neuroscience and Medicine, 2020, 11, 63-73.	0.2	0
1801	Obesity may increase the prevalence of Parkinsonâ€™s Disease (PD) while PD may reduce obesity index in patients. Journal of Neuroscience and Neurological Disorders, 2020, 4, 024-028.	0.3	0
1802	Deep Learning Based Diagnosis of Parkinson's Disease Using CNN. International Journal of Scientific Research in Computer Science Engineering and Information Technology, 2020, , 351-355.	0.3	2
1803	An Update on the Critical Role of Î±-Synuclein in Parkinsonâ€™s Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Molecular Neurobiology, 2022, 59, 620-642.	4.0	21
1806	Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1541-1549.	2.8	4
1807	The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders. Movement Disorders, 2020, 35, 2150-2155.	3.9	5
1808	Dermatological Manifestations of Parkinson's Disease: Clues for Diagnosis. Cureus, 2020, 12, e10836.	0.5	1
1810	Parkinson's disease without tremor masquerading as mechanical back pain; a case report. Journal of the Canadian Chiropractic Association, 2008, 52, 185-92.	0.2	4
1811	Continuous levodopa for advanced Parkinson's disease. Neuropsychiatric Disease and Treatment, 2007, 3, 335-48.	2.2	22
1812	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evidence, 2010, 5, 1-10.	4.7	7
1814	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. American Journal of Neurodegenerative Disease, 2012, 1, 160-7.	0.1	24
1815	Restless "lower back" in a patient with Parkinson's disease. Tremor and Other Hyperkinetic Movements, 2013, 3, .	2.0	4
1816	Evaluation of non-motor symptoms in Parkinson's Disease: An underestimated necessity. Hippokratia, 2013, 17, 214-9.	0.3	26
1817	A cross-sectional study investigating clinical predictors and physical experiences of pain in Parkinson's disease. Functional Neurology, 2013, 28, 297-304.	1.3	15
1819	Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iranian Journal of Neurology, 2015, 14, 86-93.	0.5	12
1820	Serum leptin levels in Iranian patients with Parkinson's disease. Iranian Journal of Neurology, 2018, 17, 71-77.	0.5	2
1821	Looking Beyond the Obvious: Non-Motor Parkinsonism. Innovations in Clinical Neuroscience, 2018, 15, 11-13.	0.1	0

#	ARTICLE	IF	CITATIONS
1822	Assessment of Neurodegeneration by Optical Coherence Tomography and Mini-Mental Test in Parkinson's Disease. <i>Annals of Indian Academy of Neurology</i> , 2019, 22, 212-216.	0.5	4
1824	Melatonin as first-line treatment for sleep disorders in Parkinson's disease?. <i>Progress in Neurology and Psychiatry</i> , 2021, 25, 29-32.	0.9	0
1825	A New Approach to the Differential Diagnosis of Patients with Parkinson's Disease and Essential Tremor. <i>Neuroscience and Behavioral Physiology</i> , 2021, 51, 1059-1065.	0.4	0
1826	Respiratory disorders of Parkinson's disease. <i>Journal of Neurophysiology</i> , 2022, 127, 1-15.	1.8	11
1827	Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 82-92.	1.2	4
1828	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. <i>Life</i> , 2021, 11, 1239.	2.4	18
1829	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12198.	4.1	6
1830	Assembly of α -synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α -synuclein seeds. <i>Acta Neuropathologica Communications</i> , 2021, 9, 189.	5.2	10
1831	The role of frailty in Parkinson's disease: a cross-sectional study. <i>Journal of Neurology</i> , 2022, 269, 3006-3014.	3.6	7
1832	Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity. <i>PLoS ONE</i> , 2021, 16, e0258928.	2.5	17
1833	Different Associated Factors of Subjective Cognitive Complaints in Patients With Early- and Late-Onset Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 749471.	2.4	5
1834	The effect of Non-Motor symptoms on Health-Related quality of life in patients with young onset Parkinson's Disease: A single center Vietnamese Cross-Sectional study. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100118.	0.9	4
1835	Can Corticomuscular Coherence Differentiate between REM Sleep Behavior Disorder with or without Parkinsonism?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5585.	2.4	3
1836	Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0259935.	2.5	3
1837	Selenium reduces nociceptive response in acute 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity. <i>IBRO Neuroscience Reports</i> , 2022, 12, 1-11.	1.6	3
1838	Can We Use Consumer-Wearable Activity Tracker Fitbit in Parkinson Disease?. <i>Advances in Parkinson S Disease</i> , 2021, 10, 15-23.	0.2	1
1839	Clinical milestones in Parkinson's disease: Past, present, and future. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120082.	0.6	10
1840	Understanding Wearing-Off Symptoms in Parkinson's Disease Patients using Wrist-Worn Fitness Tracker and a Smartphone. <i>Procedia Computer Science</i> , 2022, 196, 684-691.	2.0	2

#	ARTICLE	IF	CITATIONS
1841	Etiologies of insomnia in Parkinson's disease – Lessons from human studies and animal models. <i>Experimental Neurology</i> , 2022, 350, 113976.	4.1	16
1842	Modeling dopamine dysfunction in autism spectrum disorder: From invertebrates to vertebrates. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 133, 104494.	6.1	10
1843	Shared Human Leukocyte Antigen (HLA) Coverage in dementia and Parkinson's disease. <i>Journal of Neurology and Neuromedicine</i> , 2020, 5, 45-54.	0.9	9
1844	Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease. <i>Communications Biology</i> , 2022, 5, 49.	4.4	10
1845	Effectiveness of Interventions for Dysphagia in Parkinson Disease: A Systematic Review. <i>American Journal of Speech-Language Pathology</i> , 2022, 31, 463-485.	1.8	15
1846	Neuropsychiatric Symptoms in Parkinson's Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. <i>Brain Sciences</i> , 2022, 12, 89.	2.3	17
1847	Sleep and circadian rhythms in Parkinson's disease and preclinical models. <i>Molecular Neurodegeneration</i> , 2022, 17, 2.	10.8	32
1848	Management of Psychotic Symptoms in a Patient With Parkinson's Disease Maintained on Levodopa-Carbidopa Intestinal Gel by Paliperidone Long-Acting Injection: A Case Report. <i>Cureus</i> , 2022, 14, e21491.	0.5	0
1849	Oral health-related quality of life in patients with Parkinson's disease. <i>Journal of Oral Rehabilitation</i> , 2022, 49, 398-406.	3.0	10
1850	Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics. <i>Journal of Personalized Medicine</i> , 2022, 12, 144.	2.5	14
1851	Effects of Baduanjin Exercise on Rehabilitation of Patients With Mild to Moderate Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 827180.	2.8	4
1852	Anxiety predicts impulsive-compulsive behaviours in Parkinson's disease: Clinical relevance and theoretical implications. <i>Journal of Psychiatric Research</i> , 2022, 148, 220-229.	3.1	2
1853	Beta band modulation by dopamine D2 receptors in the primary motor cortex and pedunculopontine nucleus in a rat model of Parkinson's disease. <i>Brain Research Bulletin</i> , 2022, 181, 121-128.	3.0	3
1855	Sudden unexpected death in Parkinson's disease: Insights from clinical practice. <i>Clinics</i> , 2022, 77, 100001.	1.5	5
1856	Dance training and performance in patients with Parkinson disease: Effects on motor functions and patients' well-being. <i>Science and Sports</i> , 2022, 37, 45-50.	0.5	2
1857	Beneficial Effects of Spirulina Consumption on Brain Health. <i>Nutrients</i> , 2022, 14, 676.	4.1	23
1858	Akkermansia muciniphila induces mitochondrial calcium overload and α -synuclein aggregation in an enteroendocrine cell line. <i>IScience</i> , 2022, 25, 103908.	4.1	35
1859	Autonomic and Depression Symptoms in Parkinson's Disease: Clinical Evidence for Overlapping Physiology. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1059-1067.	2.8	8

#	ARTICLE	IF	CITATIONS
1860	Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 479-489.	3.9	27
1861	Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches. <i>Genes and Diseases</i> , 2023, 10, 786-798.	3.4	4
1862	Predicting Parkinsonâ€™s Disease Progression: Evaluation of Ensemble Methods in Machine Learning. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-17.	1.9	26
1863	The effects of neurosteroid allopregnanolone on synaptic dysfunction in the hippocampus in experimental parkinsonism rats: An electrophysiological and molecular study. <i>Neuropeptides</i> , 2022, 92, 102229.	2.2	8
1864	Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinsonâ€™s Disease. <i>Cells</i> , 2021, 10, 3547.	4.1	28
1865	Preface. <i>Progress in Brain Research</i> , 2022, 269, xxi-xxvi.	1.4	0
1867	Treatment Satisfaction and Its Influencing Factors in Parkinsonâ€™s Disease: A Web-Based Survey of Patients and Physicians in Clinical Practice in Japan. <i>Parkinson's Disease</i> , 2022, 2022, 1-13.	1.1	1
1869	Internet of Things Technologies and Machine Learning Methods for Parkinsonâ€™s Disease Diagnosis, Monitoring and Management: A Systematic Review. <i>Sensors</i> , 2022, 22, 1799.	3.8	33
1870	Phenomenology of Atypical Anxiety Disorders in Parkinson's Disease: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 1026-1050.	1.2	3
1871	Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinsonâ€™s Disease. <i>Medicinal Chemistry</i> , 2022, 18, 757-771.	1.5	3
1872	Homocysteine and Dementia in Parkinson Disease. , 0, , .		0
1873	Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2022, 16, 836605.	2.8	17
1874	Chicago sky blue 6B inhibits Î±-synuclein aggregation and propagation. <i>Molecular Brain</i> , 2022, 15, 27.	2.6	2
1875	Neuroimaging Studies in Non-Motor Parkinsonâ€™s Disease Symptoms. , 2022, , 46-61.		0
1876	Brain Connectivity and Graph Theory Analysis in Alzheimerâ€™s and Parkinsonâ€™s Disease: The Contribution of Electrophysiological Techniques. <i>Brain Sciences</i> , 2022, 12, 402.	2.3	18
1877	Combination of Stem Cells with Chinese Herbs for Secondary Depression in Neurodegenerative Diseases Based on Traditional Chinese Medicine Theories. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-17.	1.2	0
1878	Gastrointestinal involvement in Parkinsonâ€™s disease: pathophysiology, diagnosis, and management. <i>Npj Parkinson's Disease</i> , 2022, 8, 31.	5.3	53
1880	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3349.	4.1	34

#	ARTICLE	IF	CITATIONS
1881	Sleep Disturbances in Parkinsonâ€™s Disease. , 2022, , 167-177.		1
1882	Recent Investigations on the Functional Role of Cerebellar Neural Networks in Motor Functions & Nonmotor Functions -Neurodegeneration. Current Neuropharmacology, 2022, 20, 1865-1878.	2.9	3
1883	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq0 0.8 BT / Overlock 10 T	0.8	0
1884	Chapter 5 â€œ Parkinson's disease â€œ A role of non-enzymatic posttranslational modifications in disease onset and progression?â€™ Molecular Aspects of Medicine, 2022, 86, 101096.	6.4	8
1885	Turning markers into targets â€œ scoping neural circuits for motor neurofeedback training in Parkinsonâ€™s disease. , 2022, 1, 1-27.		1
1886	Subthalamic and pallidal stimulation in Parkinson's disease induce distinct brain topological reconstruction. Neurolmage, 2022, 255, 119196.	4.2	2
1887	EEG-based emotion charting for Parkinson's disease patients using Convolutional Recurrent Neural Networks and cross dataset learning. Computers in Biology and Medicine, 2022, 144, 105327.	7.0	21
1888	Immune responses in the Parkinson's disease brain. Neurobiology of Disease, 2022, 168, 105700.	4.4	30
1889	Evaluation of Recurrent Neural Network Models for Parkinson's Disease Classification Using Drawing Data. , 2021, 2021, 1702-1706.		2
1890	The Cold Hand Sign in Multiple System Atrophy: Frequency-Associated Factors and Its Impact on Survival. Frontiers in Aging Neuroscience, 2021, 13, 767211.	3.4	4
1891	Sexual Dysfunction Among Egyptian Idiopathic Parkinsonâ€™s Disease Patients. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 816-822.	2.3	5
1892	The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinsonâ€™s Disease. Journal of Geriatric Psychiatry and Neurology, 2021, , 089198872110600.	2.3	0
1893	CHAPTER 1. Etiology and Pathogenesis of Parkinsonâ€™s Disease. Issues in Toxicology, 0, , 1-26.	0.1	3
1894	Assessment of neurodegeneration by optical coherence tomography and miniâ€™mental test in Parkinson's disease. Annals of Indian Academy of Neurology, 2019, 22, 212.	0.5	5
1895	Proof of Concept in Artificial-Intelligence-Based Wearable Gait Monitoring for Parkinsonâ€™s Disease Management Optimization. Biosensors, 2022, 12, 189.	4.7	14
1896	Deep brain stimulation for Parkinsonâ€™s Disease: A Review and Future Outlook. Biomedical Engineering Letters, 2022, 12, 303-316.	4.1	6
1897	Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date. Pharmaceutics, 2022, 14, 836.	4.5	18
1898	Physical Activity and Its Diurnal Fluctuations Vary by Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease: An Exploratory Study. Healthcare (Switzerland), 2022, 10, 749.	2.0	2

#	ARTICLE	IF	CITATIONS
1899	Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT. Journal of Parkinson's Disease, 2022, 12, 1591-1604.	2.8	4
1900	Parkinson's Disease Detection from Resting-State EEG Signals Using Common Spatial Pattern, Entropy, and Machine Learning Techniques. Diagnostics, 2022, 12, 1033.	2.6	22
1901	Parkinson's disease, temporomandibular disorder pain and bruxism and its clinical consequences: a protocol of a single-centre observational outpatient study. BMJ Open, 2022, 12, e052329.	1.9	5
1902	Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study. Movement Disorders, 2022, 37, 1444-1453.	3.9	11
1929	Dopamine D3 Receptors: A Potential Target to Treat Motivational Deficits in Parkinson's Disease. Current Topics in Behavioral Neurosciences, 2022, , 109-132.	1.7	4
1932	From saliva to SNP: non-invasive, point-of-care genotyping for precision medicine applications using recombinase polymerase amplification and giant magnetoresistive nanosensors. Lab on A Chip, 2022, 22, 2131-2144.	6.0	13
1933	Tau accelerates α -synuclein aggregation and spreading in Parkinson's disease. Brain, 2022, 145, 3454-3471.	7.6	36
1935	Exploring Perceptions of Cross-Sectoral Data Sharing with People with Parkinson's. , 2022, , .		2
1936	The prodromal phase of hereditary spastic paraplegia type 4: the preSPG4 cohort study. Brain, 2023, 146, 1093-1102.	7.6	6
1937	High rates of blood transfusion associated with Parkinson's disease. Neurological Sciences, 2022, , .	1.9	0
1938	Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease. Journal of Patient Safety, 2022, Publish Ahead of Print, .	1.7	2
1939	The Anti-Parkinson Potential of Ginkgo biloba-Supplement Mitigates Cortico-Cerebellar Degeneration and Neuropathobiological Alterations via Inflammatory and Apoptotic Mediators in Mice. Neurochemical Research, 2022, , .	3.3	3
1940	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. Parkinsonism and Related Disorders, 2022, 99, 51-57.	2.2	5
1941	Cost-effectiveness analysis of the Parkinson's KinetiGraph and clinical assessment in the management of Parkinson's disease. Journal of Medical Economics, 2022, 25, 774-782.	2.1	5
1942	A cross-sectional study of Parkinson's disease and the prodromal phase in community-dwelling older adults in eastern Japan. Clinical Parkinsonism & Related Disorders, 2022, 7, 100147.	0.9	2
1943	Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1479-1495.	2.8	2
1944	Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease. Movement Disorders, 2022, 37, 1535-1541.	3.9	12
1945	Treatment paradigms in Parkinson's Disease and Covid-19. International Review of Neurobiology, 2022, , .	2.0	1

#	ARTICLE	IF	CITATIONS
1946	Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	3.7	12
1947	Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	6
1948	A Pilot Randomized Controlled Trial Investigating MBSR for Parkinson's Disease Patients and Their Caregiving Partners: Effects on Distress, Social support, Cortisol, and Inflammation. <i>Mindfulness</i> , 2022, 13, 1271-1280.	2.8	0
1949	A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 170, 105777.	4.4	3
1951	Symptômes non moteurs dans la maladie de Parkinson. , 2022, , 267-276.		0
1952	Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review. <i>Sensors</i> , 2022, 22, 4551.	3.8	4
1953	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. <i>Neuroepidemiology</i> , 2022, 56, 309-318.	2.3	13
1954	New Understanding on the Pathophysiology and Treatment of Constipation in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	10
1956	Spotlight on non-motor symptoms and Covid-19. <i>International Review of Neurobiology</i> , 2022, , .	2.0	0
1957	Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson's in an international setting. <i>BMJ Open</i> , 2022, 12, e049530.	1.9	2
1959	Nutrition and Gut-Brain Pathways Impacting the Onset of Parkinson's Disease. <i>Nutrients</i> , 2022, 14, 2781.	4.1	3
1960	Therapeutic Insights on Ferroptosis in Parkinson's disease. <i>European Journal of Pharmacology</i> , 2022, 930, 175133.	3.5	28
1961	Characterization of Non-Motor Fluctuations Using the Movement Disorder Society <sc>Non-Motor</sc> Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 932-940.	1.5	5
1962	Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease. <i>Brain and Behavior</i> , 2022, 12, .	2.2	6
1963	A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1841-1861.	2.8	6
1964	Gene-Based Therapeutics for Parkinson's Disease. <i>Biomedicines</i> , 2022, 10, 1790.	3.2	3
1965	Nutrition impact symptoms and the risk of malnutrition in people with Parkinson's disease: A cross-sectional study. <i>Journal of Human Nutrition and Dietetics</i> , 2023, 36, 40-50.	2.5	2
1966	Does Executive Function Influence Walking in Acutely Hospitalized Patients With Advanced Parkinson's Disease: A Quantitative Analysis. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	2

#	ARTICLE	IF	CITATIONS
1968	Parkinson Hastalığında Yutma Bozukluklarına Yaklaşım. Muğla Sıtkı Koşman Üniversitesi Tıp Dergisi, 2022, 9, 189-203.	0.4	3
1969	Identifying and validating subtypes of Parkinson's disease based on multimodal MRI data via hierarchical clustering analysis. Frontiers in Human Neuroscience, 0, 16, .	2.0	4
1970	Management of Sleep Disturbances in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 2029-2058.	2.8	15
1971	Polysomnographic Predictors of Sleep, Motor, and Cognitive Dysfunction Progression in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2022, 22, 657-674.	4.2	5
1972	The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex. Cells, 2022, 11, 2628.	4.1	3
1973	Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
1974	Longitudinal Studies of Sleep Disturbances in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2022, 22, 635-655.	4.2	2
1975	Cognitive testing in late-stage Parkinson's disease: A critical appraisal of available instruments. Applied Neuropsychology Adult, 2024, 31, 191-202.	1.2	1
1976	Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up. Journal of Parkinson's Disease, 2022, 12, 2071-2083.	2.8	7
1978	Can we really "read" art to see the changing brain? A review and empirical assessment of clinical case reports and published artworks for systematic evidence of quality and style changes linked to damage or neurodegenerative disease. Physics of Life Reviews, 2022, 43, 32-95.	2.8	17
1979	Screening for non-motor symptoms in Egyptian patients with Parkinson's disease. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	1.0	2
1980	Cerebral control of swallowing: An update on neurobehavioral evidence. Journal of the Neurological Sciences, 2022, 442, 120434.	0.6	9
1981	Loss of cannabinoid receptor 2 promotes α -Synuclein-induced microglial synaptic pruning in nucleus accumbens by modulating the pCREB-c-Fos signaling pathway and complement system. Experimental Neurology, 2023, 359, 114230.	4.1	3
1982	Delay discounting in Parkinson's disease: A systematic review and meta-analysis. Behavioural Brain Research, 2023, 436, 114101.	2.2	5
1983	Mind-Body Exercises for Non-motor Symptoms of Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 0, 13, .	3.4	8
1984	Evaluation of non-motor symptoms in wilson disease using the parkinson's disease nonmotor symptoms questionnaire: A pilot cross-sectional study and critical assessment. Annals of Indian Academy of Neurology, 2022, 25, 1062.	0.5	1
1985	Interplay of alpha-synuclein pathology and gut microbiome in Parkinson's disease. , 2022, , 159-178.		1
1986	Sleep disorders in patients with Parkinson's disease during COVID-19 pandemic: A case-Control study. Annals of Indian Academy of Neurology, 2022, 25, 394.	0.5	1

#	ARTICLE	IF	CITATIONS
1987	Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	5
1988	Validation of the <scp>OPTIMIPARK</scp> Questionnaire: A tool to optimize treatment in Parkinson's disease.. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	0
1989	Inhibition of Spinal 5-HT ₃ Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinsonâ€™s Disease. <i>Molecular Neurobiology</i> , 2022, 59, 7253-7264.	4.0	6
1991	ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism. <i>Neurotherapeutics</i> , 2022, 19, 1966-1975.	4.4	3
1992	Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinsonâ€™s Disease: Beyond the Primary Mechanism of Action. <i>Current Neuropharmacology</i> , 2023, 21, 1214-1223.	2.9	3
1993	Which type of mindâ€™body exercise is most effective in improving functional performance and quality of life in patients with Parkinson's disease? A systematic review with network meta-analysis. <i>Acta Neurologica Belgica</i> , 2022, 122, 1433-1446.	1.1	7
1994	Adenosine A _{2A} receptor availability in patients with early- and moderate-stage Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 0, , .	3.6	3
1995	Like a Wave in Its Variable Shape, Breadth, and Depth: A Qualitative Interview Study of Experiences of Daytime Sleepiness in People with Parkinsonâ€™s Disease. <i>Parkinson's Disease</i> , 2022, 2022, 1-9.	1.1	0
1996	The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts. <i>Journal of Molecular Medicine</i> , 2022, 100, 1405-1425.	3.9	5
1997	Recent advances in dopamine D₂ receptor ligands in the treatment of neuropsychiatric disorders. <i>Medicinal Research Reviews</i> , 2023, 43, 55-211.	10.5	8
1998	Beta amyloid deposition and cognitive decline in Parkinsonâ€™s disease: a study of the PPMI cohort. <i>Molecular Brain</i> , 2022, 15, .	2.6	9
1999	Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinsonâ€™s disease. <i>Psychopharmacology</i> , 2022, 239, 3633-3656.	3.1	1
2000	Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease. <i>Nanoscale Advances</i> , 2022, 4, 5233-5244.	4.6	12
2001	Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease. <i>NeuroImage: Clinical</i> , 2022, 36, 103231.	2.7	1
2002	Non-linear statistics technique to differ the patients with Parkinson disease from essential tremor through kinesthetic and olfactory data. <i>AIP Conference Proceedings</i> , 2022, , .	0.4	0
2003	Amyotrophic Lateral Sclerosisâ€™The Complex Phenotypeâ€™From an Epidemiological Perspective: A Focus on Extrapyramidal and Non-Motor Features. <i>Biomedicines</i> , 2022, 10, 2537.	3.2	5
2004	Omnidirectional leaky opto-electrical fiber for optogenetic control of neurons in cell replacement therapy. <i>Bioelectrochemistry</i> , 2023, 149, 108306.	4.6	1
2005	Emotional Sentence Processing in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 0, , 1-9.	1.6	1

#	ARTICLE	IF	CITATIONS
2006	Management of psychiatric and cognitive complications in Parkinson's disease. <i>BMJ</i> , The, 0, , e068718.	6.0	11
2007	The inter-relationship between various non-motor symptoms and with habitual physical activity in Parkinsonism: a scoping review protocol. <i>Physical Therapy Reviews</i> , 2022, 27, 444-452.	0.8	0
2008	Perceptions of people with Parkinson's and their caregivers of falling and falls-related healthcare services- a qualitative study. <i>PLoS ONE</i> , 2022, 17, e0276588.	2.5	1
2009	Sexual needs and sexual function of patients with Parkinson's disease. <i>Neurological Sciences</i> , 0, , .	1.9	6
2010	Dental care utilization among persons with Parkinson's disease in Denmark. <i>Community Dentistry and Oral Epidemiology</i> , 0, , .	1.9	1
2011	Guidelines for Therapeutic Management of Parkinson's Disease in China. , 2022, , 3079-3098.		0
2012	Are static posturography-assisted biofeedback exercises effective in Parkinson's disease?. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 935-943.	0.8	1
2013	Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms. <i>International Journal of Pharmaceutics</i> , 2022, , 122401.	5.2	0
2014	Impact of long-term care insurance on medical costs and utilization by patients with Parkinson's disease. <i>Social Science and Medicine</i> , 2023, 317, 115563.	3.8	0
2015	Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases. <i>OpenNano</i> , 2023, 9, 100111.	4.8	4
2016	Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California. <i>Science of the Total Environment</i> , 2023, 864, 160851.	8.0	6
2017	Non-Motor symptoms burden in early stages of parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2023, 26, 39.	0.5	0
2018	Depression and Parkinson's disease: a Chicken-Egg story. <i>AIMS Neuroscience</i> , 2022, 9, 479-490.	2.3	2
2019	Should patients with Parkinson's disease only visit a neurologist's office? - a narrative review of neuropsychiatric disorders among people with Parkinson's disease. <i>Current Problems of Psychiatry</i> , 2022, 23, 220-236.	0.2	0
2020	Longitudinal assessment of motor function following the unilateral intrastriatal 6-hydroxydopamine lesion model in mice. <i>Frontiers in Behavioral Neuroscience</i> , 0, 16, .	2.0	1
2021	Non-motor manifestation of Parkinson's disease: a cross-sectional study in a teaching hospital in Jordan. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	1.0	4
2022	Constipation in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2023, 86, 34-44.	1.4	7
2024	Understanding the dopaminergic pathway relative to men's sexual dysfunction in patients with Parkinson's disease: a narrative review with implications for future research. <i>International Journal of Impotence Research</i> , 0, , .	1.8	3

#	ARTICLE	IF	CITATIONS
2025	Exploring factors that influence HRQoL for people living with Parkinsonâ€™s in one region of Ireland:ÂA cross-sectional study. BMC Geriatrics, 2022, 22, .	2.7	0
2026	Comparison of Associations between MIND and Mediterranean Diet Scores with Patient-Reported Outcomes in Parkinsonâ€™s Disease. Nutrients, 2022, 14, 5185.	4.1	5
2027	Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia. Biomolecules, 2023, 13, 26.	4.0	6
2028	Dysphagia treatments in Parkinson's disease: A systematic review and metaâ€analysis. Neurogastroenterology and Motility, 2023, 35, .	3.0	6
2029	Premotor, nonmotor and motor symptoms of Parkinson's Disease: A new clinical state of the art. Ageing Research Reviews, 2023, 84, 101834.	10.9	18
2030	The role of exercise in Parkinsonâ€™s Disease. Journal of King Abdulaziz University, Islamic Economics, 2023, 28, 4-12.	1.1	1
2031	Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinsonâ€™s Disease. Journal of Movement Disorders, 2023, 16, 22-41.	1.3	8
2032	Human mini-brains for reconstituting central nervous system disorders. Lab on A Chip, 2023, 23, 964-981.	6.0	3
2033	Cordycepin improved the cognitive function through regulating adenosine A2A receptors in MPTP induced Parkinson's disease mice model. Phytomedicine, 2023, 110, 154649.	5.3	2
2034	Depressive symptoms and axial motor disorders in individuals with Parkinson's disease: a cross-sectional study. Arquivos De Neuro-Psiquiatria, 2022, 80, 1126-1133.	0.8	0
2035	A Microfluidic System for Investigating Anticipatory Medication Effects on Dopamine Homeostasis in Dopaminergic Cells. Analytical Chemistry, 2023, 95, 3153-3159.	6.5	2
2036	Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinsonâ€™s Disease: An Exploratory Study. Journal of Personalized Medicine, 2023, 13, 242.	2.5	1
2037	The dilemma between milestones of progression versus clinical scales in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 169-185.	1.8	0
2038	Nitric Oxide in Parkinsonâ€™s Disease: Insights into Research and Therapeutics. , 2023, , 327-347.		0
2040	Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?. Parkinsonism and Related Disorders, 2023, , 105394.	2.2	0
2041	Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders. Chemico-Biological Interactions, 2023, 373, 110375.	4.0	1
2042	The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2023, 66, 2282-2307.	6.4	7
2043	Role of Ceramides and Sphingolipids in Parkinson's Disease. Journal of Molecular Biology, 2023, 435, 168000.	4.2	4

#	ARTICLE	IF	CITATIONS
2044	Identification of a Gait Pattern for Detecting Mild Cognitive Impairment in Parkinson's Disease. Sensors, 2023, 23, 1985.	3.8	2
2045	Translational molecular imaging and drug development in Parkinson's disease. Molecular Neurodegeneration, 2023, 18, .	10.8	11
2046	Longitudinal analysis of the Non-Motor Symptoms Scale in Parkinson's Disease (NMSS): An exploratory network analysis approach. Frontiers in Neurology, 0, 14, .	2.4	2
2047	Clinical Significance of Apathy in Parkinson's Disease. European Medical Journal Neurology, 0, , 56-63.	0.0	7
2048	Pain and Parkinson's disease: Current mechanism and management updates. European Journal of Pain, 2023, 27, 553-567.	2.8	2
2049	Beyond shallow feelings of complex affect: Non-motor correlates of subjective emotional experience in Parkinson's disease. PLoS ONE, 2023, 18, e0281959.	2.5	2
2050	Pathophysiology of non-motor signs in Parkinson's disease: some recent updating with brief presentation. , 0, , 24-46.		0
2051	Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility. Npj Parkinson's Disease, 2023, 9, .	5.3	1
2052	Effects of Popping For Parkinson's dance class on the mood of people with Parkinson's disease. International Journal of Therapy and Rehabilitation, 2023, 30, 1-12.	0.3	0
2053	Circadian Rhythmicity in Aging and Parkinson's Disease. Healthy Ageing and Longevity, 2023, , 237-255.	0.2	0
2054	Potassium Channels in Parkinson's Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment. Pharmacological Reviews, 2023, 75, 758-788.	16.0	12
2055	Pharmacological and Behavioral Interventions for Fatigue in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. Journal of Geriatric Psychiatry and Neurology, 0, , 089198872311632.	2.3	0
2056	Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinson's Disease: A Basic and Clinical Approach. Brain Sciences, 2023, 13, 508.	2.3	6
2057	Detection of rare genetic variations in the promoter regions of the ATG16L gene in Parkinson's patients. Neuroscience Letters, 2023, 804, 137195.	2.1	1
2058	Cognitive Impairment in Neurodegenerative Movement Disorders. Seminars in Neurology, 2023, 43, 081-094.	1.4	0
2059	Pink1 ^{-/-} Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease. Dysphagia, 0, , .	1.8	2
2060	Investigation of the relationship between lumbar spine MRI findings and pain in patients who received and did not receive Parkinson's treatment. The European Research Journal, 0, , 1-10.	0.3	0
2061	Therapeutic Group Singing for Individuals with Parkinson's Disease: A Conceptual Framework. Music Therapy Perspectives, 2023, 41, 178-186.	0.5	2

#	ARTICLE	IF	CITATIONS
2062	Robot-assisted investigation of sensorimotor control in Parkinson's disease. Scientific Reports, 2023, 13, .	3.3	1
2063	Parkinsonâ€™s Disease Diagnosis Using Laplacian Score, Gaussian Process Regression and Self-Organizing Maps. Brain Sciences, 2023, 13, 543.	2.3	1
2065	The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies. Frontiers in Neurology, 0, 14, .	2.4	2
2066	Examining the frequency of dysphagia and the predictive factors of dysphagia that require attention in patients with Parkinson's disease. Annals of Clinical and Experimental Neurology, 2023, 17, 14-19.	0.4	0
2067	Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cellular and Molecular Neurobiology, 2023, 43, 2627-2642.	3.3	4
2068	The Impact of Nonmotor Symptoms on Health-Related Quality of Life in Parkinsonâ€™s Disease: A Network Analysis Approach. Journal of Clinical Medicine, 2023, 12, 2573.	2.4	5
2069	Comparative Study of Machine Learning Models for Early Detection of Parkinsonâ€™s. Lecture Notes in Electrical Engineering, 2023, , 51-69.	0.4	0
2070	Dysphagia Requiring Medical Attention in Parkinsonâ€™s Disease: A Korean Population-Based Study. Journal of Korean Medical Science, 2023, 38, .	2.5	0
2071	Illness perceptions in pre-operative Parkinsonâ€™s disease patients. Journal of Neural Transmission, 2023, 130, 647-654.	2.8	0
2072	Revisiting Alpha-Synuclein Pathways to Inflammation. International Journal of Molecular Sciences, 2023, 24, 7137.	4.1	6
2073	Menstrual blood-derived endometrial stem cells alleviate neuroinflammation by modulating M1/M2 polarization in cell and rat Parkinsonâ€™s disease models. Stem Cell Research and Therapy, 2023, 14, .	5.5	3
2074	Impact of non-motor fluctuations on QOL in patients with Parkinsonâ€™s disease. Frontiers in Neurology, 0, 14, .	2.4	0
2075	Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of Î±-Synuclein in Parkinsonâ€™s Disease. Biomedicines, 2023, 11, 1187.	3.2	5
2078	Cortical and Subcortical Changes in MEG Activity Reflect Parkinsonâ€™s Progression over a Period of 7Years. Brain Topography, 0, , .	1.8	0
2079	Dimensions of apathy in Parkinson's disease. Brain and Behavior, 2023, 13, .	2.2	2
2082	Role of multimodal advanced biomarkers as potential predictors of cognitive and psychiatric aspects of Parkinson's disease. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023, 59, .	1.0	0
2084	Chaudhuriâ€™s Dashboard of Vitals in Parkinsonâ€™s syndrome: an unmet need underpinned by real life clinical tests. Frontiers in Neurology, 0, 14, .	2.4	4
2085	The effect of Forced Exercise on Striatal and Serum Serotonin Levels in a Parkinson's Mouse Model. European Journal of Therapeutics, 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
2086	The bladder as a readout in neuroscience research. , 2023, , 81-101.		0
2087	Hybrid Transcranial Magnetic Stimulation and Deep Brain Stimulation in the Presence of an Implantable Pulse Generator. IEEE Transactions on Magnetics, 2023, 59, 1-5.	2.1	0
2088	Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease. Neurology, 2023, 101, .	1.1	0
2089	Neurological Phenotypes in Mouse Models of Mitochondrial Disease and Relevance to Human Neuropathology. International Journal of Molecular Sciences, 2023, 24, 9698.	4.1	0
2090	New trends in advanced parkinson disease stage therapy. Ceska A Slovenska Farmacie, 2022, 71, 37-44.	0.2	0
2091	Non-pharmacological Approaches Based on Mind-Body Medicine to Enhancement of Cognitive and Brain Reserve in Humans. Contemporary Clinical Neuroscience, 2023, , 151-175.	0.3	0
2092	The contribution of executive control dysfunction to freezing of gait in Parkinsonâ€™s disease. Clinical Neurophysiology, 2023, 152, 75-89.	1.5	2
2093	Impact of deep brain stimulation (DBS) on olfaction in Parkinson's disease: Clinical features and functional hypotheses. Revue Neurologique, 2023, , .	1.5	0
2094	Validation of the Non-Motor Symptoms Scale for Parkinsonâ€™s Disease of Persian Version. Parkinson's Disease, 2023, 2023, 1-9.	1.1	0
2096	Parkinsonâ€™s Disease Stigma Questionnaire (PDStigmaQuest): Development and Pilot Study of a Questionnaire for Stigma in Patients with Idiopathic Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2023, , 1-11.	2.8	0
2097	Pain in Parkinson disease: mechanistic substrates, main classification systems, and how to make sense out of them. Pain, 2023, Publish Ahead of Print, .	4.2	1
2098	Salivary Gland Uptake on ¹⁸ F-FP-CIT PET as a New Biomarker in Patients With Parkinsonism. Korean Journal of Radiology, 2023, 24, 690.	3.4	0
2099	Neurological update: non-motor symptoms in atypical parkinsonian syndromes. Journal of Neurology, 2023, 270, 4558-4578.	3.6	1
2100	The Role of the Serotonergic System of the Brain in the Pathogenesis of Parkinsonâ€™s Disease. Neurochemical Journal, 2023, 17, 30-41.	0.5	0
2101	Metabolic Disturbances in the Gut-brain Axis of a Mouse Model of MPTP-induced Parkinsonism Evaluated by Nuclear Magnetic Resonance. Neuroscience, 2023, 526, 21-34.	2.3	0
2102	Smartphone-based detection of levodopa in human sweat using 3D printed sensors. Analytica Chimica Acta, 2023, 1273, 341546.	5.4	2
2103	The Effect of Different Types of Exercise on Sleep Quality and Architecture in Parkinson Disease: A Single-Blinded Randomized Clinical Trial Protocol. Physical Therapy, 2024, 104, .	2.4	0
2104	Non-motor symptoms in amyotrophic lateral sclerosis: lessons from Parkinsonâ€™s disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 562-571.	1.7	1

#	ARTICLE	IF	CITATIONS
2105	Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease. Food and Chemical Toxicology, 2023, 178, 113904.	3.6	2
2106	Experimental models of gut-first Parkinson's disease: A systematic review. Neurogastroenterology and Motility, 2023, 35, .	3.0	2
2107	Translation, cultural adaptation and validation of the Arabic version of the king's Parkinson's disease pain scale. Disability and Rehabilitation, 0, , 1-6.	1.8	0
2108	Visual Velocity Perception Dysfunction in Parkinson's Disease. Behavioural Brain Research, 2023, , 114490.	2.2	0
2109	Potential role of acupuncture in the treatment of Parkinson's disease: A narrative review. Integrative Medicine Research, 2023, 12, 100954.	1.8	0
2110	Chemical library design, QSAR modeling and molecular dynamics simulations of naturally occurring coumarins as dual inhibitors of MAO-B and AChE. Journal of Biomolecular Structure and Dynamics, 2024, 42, 1629-1646.	3.5	6
2111	Elucidation of the mechanisms of exercise-induced hypoalgesia and pain prolongation due to physical stress and the restriction of movement. Neurobiology of Pain (Cambridge, Mass), 2023, 14, 100133.	2.5	0
2112	Applications of fMRI to Neurodegenerative Disease. , 2023, , 819-860.		0
2113	Neuroprotective effects of flavonoids. , 2023, , 133-200.		1
2114	The Enigmatic CA2: Exploring the Understudied Region of the Hippocampus and Its Involvement in Parkinson's Disease. Biomedicines, 2023, 11, 1996.	3.2	1
2115	Probing the molecular mechanisms of α -synuclein inhibitors unveils promising natural candidates through machine-learning QSAR, pharmacophore modeling, and molecular dynamics simulations. Molecular Diversity, 0, , .	3.9	0
2116	All's well that ends well: an early-phase study testing lower end-session exercise intensity to promote physical activity in patients with Parkinson's disease. Movement and Sports Sciences - Science Et Motricite, 2024, , 17-31.	0.3	0
2117	Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease. Neurobiology of Disease, 2023, 185, 106237.	4.4	2
2118	Fully immersive virtual reality exergames with dual-task components for patients with Parkinson's disease: a feasibility study. Journal of NeuroEngineering and Rehabilitation, 2023, 20, .	4.6	4
2119	Non-Motor Symptoms in Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 25-45.	0.1	2
2120	Clinical and Experimental Evidence of Cirrhosis-Related Parkinsonism. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 102-119.	0.1	2
2122	Clinical and Non-Clinical Cardiovascular Disease Associated Pathologies in Parkinson's Disease. International Journal of Molecular Sciences, 2023, 24, 12601.	4.1	0
2123	Constipation in Parkinson's Disease. Seminars in Neurology, 0, , .	1.4	1

#	ARTICLE	IF	CITATIONS
2124	Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities. <i>Biomolecules</i> , 2023, 13, 1250.	4.0	2
2126	Rehabilitation for non-motor symptoms for patients with Parkinson's disease from an α -synuclein perspective: a narrative review. , 0, , 235-257.		0
2127	Effects of Popping For Parkinson's dance class on the mood of people with Parkinson's disease. <i>British Journal of Neuroscience Nursing</i> , 2023, 19, 130-138.	0.2	0
2128	Communal interaction of glycation and gut microbes in diabetes mellitus, Alzheimer's disease, and Parkinson's disease pathogenesis. <i>Medicinal Research Reviews</i> , 0, , .	10.5	1
2129	Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways. <i>Journal of Biomedical Science</i> , 2023, 30, .	7.0	4
2130	Distinct changes in global brain synchronization in different motor subtypes of Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
2131	Gastrointestinal Dysfunction in Neurological and Neurodegenerative Disorders. <i>Seminars in Neurology</i> , 2023, 43, 634-644.	1.4	1
2132	Machine learning models for diagnosis and prognosis of Parkinson's disease using brain imaging: general overview, main challenges, and future directions. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	3.4	4
2133	A comparison of the effects of occupation-based interventions with and without responsibility feedback and conventional interventions on participation in people with idiopathic Parkinson's disease: study protocol for a randomized controlled trial. <i>Trials</i> , 2023, 24, .	1.6	0
2134	Diagnostic Biomarkers of Parkinson's Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 64-80.	0.1	0
2135	Mitochondrial Dysfunction in Dopaminergic Neurons Derived from Patients with LRRK2- and SNCA-Associated Genetic Forms of Parkinson's Disease. <i>Current Issues in Molecular Biology</i> , 2023, 45, 8395-8411.	2.4	0
2136	Role of Stem Cells and Derived Exosomes as a Novel Therapeutic Agent against Alzheimer's and Parkinson's Disease. , 2023, , 231-258.		0
2137	Hybrid Transcranial Magnetic Stimulation and Deep Brain Stimulation in the Presence of an Implantable Pulse Generator. , 2023, , .		0
2138	The Involvement of Neuroinflammation in the Onset and Progression of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14582.	4.1	6
2139	Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women. <i>Movement Disorders</i> , 2023, 38, 1606-1614.	3.9	0
2140	Parkinson's Disease and Other Movement Disorders. , 2023, , 1-24.		0
2141	Psychosis in Parkinson's Disease and Current Management Trends- an Updated Review of Literature. <i>Journal of Neuroscience and Neurological Disorders</i> , 2023, 7, 027-057.	0.3	0
2142	Obstructive sleep apnea in Parkinson's disease: A prevalent, clinically relevant and treatable feature. <i>Parkinsonism and Related Disorders</i> , 2023, 115, 105790.	2.2	0

#	ARTICLE	IF	CITATIONS
2143	Stem Cells Vs Exosomes: Promising Therapeutic Approach and Biomarkers Agent against Neurodegenerative Disorders. , 2023, , 169-191.		0
2145	Aquaporin 4 beyond a water channel; participation in motor, sensory, cognitive and psychological performances, a comprehensive review. Physiology and Behavior, 2023, 271, 114353.	2.1	0
2146	Effects of deep brain stimulation on quantitative sleep electroencephalogram during non-rapid eye movement in Parkinsonâ€™s disease. Frontiers in Human Neuroscience, 0, 17, .	2.0	0
2147	Brain olfactoryâ€™related atrophy in isolated rapid eye movement sleep behavior disorder. Annals of Clinical and Translational Neurology, 2023, 10, 2192-2207.	3.7	0
2148	Striatal and thalamic automatic segmentation, morphology, and clinical correlates in Parkinsonism: Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Psychiatry Research - Neuroimaging, 2023, 335, 111719.	1.8	0
2150	Noradrenergic alterations in Parkinsonâ€™s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Brain, 0, , .	7.6	2
2151	Neuroimaging and serum biomarkers of neurodegeneration and neuroplasticity in Parkinsonâ€™s disease patients treated by intermittent theta-burst stimulation over the bilateral primary motor area: a randomized, double-blind, sham-controlled, crossover trial study. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
2152	Naturaleza del input y procesamiento de la sÃlaba en palabras en la enfermedad de Parkinson. Revista De Investigacion En Logopedia, 2023, 13, e83660.	0.4	0
2153	Involvement of A13 dopaminergic neurons in prehensile movements but not reward in the rat. Current Biology, 2023, , .	3.9	0
2154	A computerized assessment tool for the upper extremities motor performance in individuals with Parkinson's disease. Biomedical Signal Processing and Control, 2024, 87, 105547.	5.7	1
2155	Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2023, 2023, 1-11.	1.1	0
2157	Breaking ground: nursing-led approach to alleviating constipation in Parkinsonâ€™s disease. BMC Geriatrics, 2023, 23, .	2.7	1
2158	Depressive Symptoms and the Subsequent Risk of Parkinson's Disease: A Nationwide Cohort Study. American Journal of Geriatric Psychiatry, 2024, 32, 339-348.	1.2	0
2159	Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience. Scientific Reports, 2023, 13, .	3.3	0
2160	Mitochondrial dysfunction in Parkinsonâ€™s disease â€“ a key disease hallmark with therapeutic potential. Molecular Neurodegeneration, 2023, 18, .	10.8	10
2161	Emotion in action: When emotions meet motor circuits. Neuroscience and Biobehavioral Reviews, 2023, 155, 105475.	6.1	0
2162	Machine Learning Based Early Prediction of Parkinson's Disease for Sustainable Healthcare. Communications in Computer and Information Science, 2023, , 92-101.	0.5	0
2163	Information and Communication Technology for Managing Social Isolation and Loneliness among People Living with Parkinsonâ€™s Disease: A Qualitative Study of Barriers and Facilitators (Preprint). Journal of Medical Internet Research, 0, , .	4.3	0

#	ARTICLE	IF	CITATIONS
2164	Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinsonâ€™s disease. International Review of Neurobiology, 2024, , 1-58.	2.0	1
2165	Comparative Genetic Analysis of the Promoters of the ATG16L1 and ATG5 Genes Associated with Sporadic Parkinsonâ€™s Disease. Genes, 2023, 14, 2171.	2.4	0
2166	PIEZO mediates a protective mechanism for nematode Caenorhabditis elegans in response to nanoplastics caused dopaminergic neurotoxicity at environmentally relevant concentrations. Ecotoxicology and Environmental Safety, 2024, 269, 115738.	6.0	1
2167	Non-motor symptoms in motor neuron disease: prevalence, assessment and impact. Brain Communications, 2023, 6, .	3.3	0
2168	Unveiling the Mind: A Comprehensive Review of Psychiatric Disorders in Parkinsonâ€™s Disease. ARS Medica Tomitana, 2023, 29, 36-45.	0.1	0
2169	Parkinsonian Tremor Detection with Compact Convolutional Transformer from Bispectrum Representation of tri-Axial Accelerometer Signals*. , 2023, , .		0
2170	Alterations in descending brain-spinal pathways regulating colorectal motility in a rat model of Parkinsonâ€™s disease. American Journal of Physiology - Renal Physiology, 2024, 326, G195-G204.	3.4	0
2171	Delivering the diagnosis of Parkinson's disease- setting the stage with hope and compassion. Parkinsonism and Related Disorders, 2024, 118, 105926.	2.2	2
2172	Trends and hotspots in non-motor symptoms of Parkinsonâ€™s disease: a 10-year bibliometric analysis. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0
2173	Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2024, 14, 297-312.	2.8	1
2174	The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinsonâ€™s Disease: A Promising Therapeutic Approach. International Journal of Molecular Sciences, 2024, 25, 1071.	4.1	0
2175	Rehabilitation interventions for oropharyngeal dysphagia in people with Parkinson's disease. The Cochrane Library, 2024, 2024, .	2.8	0
2176	Development of a Smart Wireless Multisensor Platform for an Optogenetic Brain Implant. Sensors, 2024, 24, 575.	3.8	0
2177	ON/OFF non-motor evaluation: a new way to evaluate non-motor fluctuations in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2023-332551.	1.9	0
2178	Assessment of Mitochondrial Gene Activity in Dopaminergic Neuron Cultures Derived from Induced Pluripotent Stem Cells Obtained from Parkinson's Disease Patients. Annals of Clinical and Experimental Neurology, 2024, 17, 58-63.	0.4	0
2179	Different risks of early-onset and late-onset Parkinson disease in individuals with mental illness. Npj Parkinson's Disease, 2024, 10, .	5.3	0
2181	Î±-Synuclein reduces acetylserotonin O-methyltransferase mediated melatonin biosynthesis by microtubule-associated protein 1 light chain 3 beta-related degradation pathway. Cellular and Molecular Life Sciences, 2024, 81, .	5.4	0
2182	Genetics in Parkinsonâ€™s disease, state-of-the-art and future perspectives. British Medical Bulletin, 2024, 149, 60-71.	6.9	0

#	ARTICLE	IF	CITATIONS
2183	REPRINTED WITH PERMISSION OF IASP “PAIN 164 (2023) 2425–2434: Pain in Parkinson disease: mechanistic substrates, main classification systems, and how to make sense out of them. <i>BMC</i> , 2024, 24, 19-30.	0.1	0
2184	A comparative study: prediction of parkinson’s disease using machine learning, deep learning and nature inspired algorithm. <i>Multimedia Tools and Applications</i> , 0, , .	3.9	0
2185	Multidisciplinary rehabilitation for Parkinson’s disease. <i>The Cochrane Library</i> , 2024, 2024, .	2.8	0
2186	The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. <i>Lancet Regional Health - Europe</i> , The, 2024, 39, 100870.	5.6	0
2187	Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease. <i>Psychogeriatrics</i> , 2024, 24, 415-425.	1.2	0
2188	Deep Learning Approaches in the Early Diagnosis of Parkinson's Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2024, , 128-149.	0.1	0
2189	Parkinson’s Disease and Other Movement Disorders. , 2024, , 1073-1096.		0
2190	Aqueous extract of <i>Swietenia macrophylla</i> leaf exerts an anti-inflammatory effect in a murine model of Parkinson’s disease induced by 6-OHDA. <i>Frontiers in Neuroscience</i> , 0, 18, .	2.8	0
2191	The anterior cingulate cortex controls the hyperactivity in subthalamic neurons in male mice with comorbid chronic pain and depression. <i>PLoS Biology</i> , 2024, 22, e3002518.	5.6	0
2192	Synaptic loss and its association with symptom severity in Parkinson’s disease. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.3	0
2193	Effects of Paraquat, Dextran Sulfate Sodium, and Irradiation on Behavioral and Cognitive Performance and the Gut Microbiome in A53T and A53T-L444P Mice. <i>Genes</i> , 2024, 15, 282.	2.4	0
2194	Impact of Parkinsonism comorbid depression on cognitive functions. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2024, 60, .	1.0	0
2195	Apnea behavior in early- and late-stage mouse models of Parkinson's disease: Cineradiographic analysis of spontaneous breathing, acute stress, and swallowing. <i>Respiratory Physiology and Neurobiology</i> , 2024, 323, 104239.	1.6	0
2196	Investigating the Shared Genetic Etiology Between Parkinson’s Disease and Depression. <i>Journal of Parkinson's Disease</i> , 2024, 14, 483-493.	2.8	0
2197	Self-perceived stigma in Parkinson’s Disease in an online sample: Comparison with in-person sample, role of anxiety, and relative utility of four measures of stigma perception. <i>Applied Neuropsychology Adult</i> , 0, , 1-10.	1.2	0
2198	Efficacy and safety of primary and repeated therapy courses of Parkinson’s disease with autologous mesenchymal stromal cells in the long-term period. <i>Proceedings of the National Academy of Sciences of Belarus, Medical Series</i> , 2024, 21, 68-78.	0.1	0
2199	Towards a biological diagnosis of PD. <i>Parkinsonism and Related Disorders</i> , 2024, 122, 106078.	2.2	0
2200	Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
2201	Prescribing medications for Parkinson's disease. Journal of Prescribing Practice, 2024, 6, 124-128.	0.1	0
2202	Neuropathogenesis-on-chips for neurodegenerative diseases. Nature Communications, 2024, 15, .	12.8	0